{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "9ea68f8d",
   "metadata": {},
   "outputs": [],
   "source": [
    "import scripts.data_ingestion as di\n",
    "import scripts.utilities as ut\n",
    "from pathlib import Path"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "80e40695",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(WindowsPath('C:/Users/Public/Documents/MARIO/test_files'),\n",
       " WindowsPath('C:/Users/Public/Documents/MARIO/test_outs'))"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test_infiles = Path(r\"C:\\Users\\Public\\Documents\\MARIO\\test_files\")\n",
    "test_outfiles = Path(r\"C:\\Users\\Public\\Documents\\MARIO\\test_outs\")\n",
    "test_infiles, test_outfiles"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "9c9b8927",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Output folder exists\n",
      "Extracting title from the file name and authors from the first page and setting them as meta data\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 2/2 [00:06<00:00,  3.02s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Updating metadata completed\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "ut.set_title_author(test_infiles, test_outfiles)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "7ff8ad94",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Reading files from directory <bound method Kernel.raw_input of <ipykernel.ipkernel.IPythonKernel object at 0x00000156AB799BE0>>\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Working on <DirEntry 'Introduction to evidence synthesis for decision making.pdf'>: : 3doc [02:15, 45.22s/doc]                                    "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Read 3 documents\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "docs_path = di.read_documents(test_outfiles)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "95a0e295",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Reading files\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Loading docs:   0%|          | 0/2 [00:00<?, ?doc/s]The plugin langchain_docling will not be loaded because Docling is being executed with allow_external_plugins=false.\n",
      "The plugin langchain_docling will not be loaded because Docling is being executed with allow_external_plugins=false.\n",
      "\u001b[32m[INFO] 2026-02-09 12:50:29,711 [RapidOCR] base.py:22: Using engine_name: onnxruntime\u001b[0m\n",
      "\u001b[32m[INFO] 2026-02-09 12:50:29,742 [RapidOCR] download_file.py:60: File exists and is valid: C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_PP-OCRv4_det_infer.onnx\u001b[0m\n",
      "\u001b[32m[INFO] 2026-02-09 12:50:29,743 [RapidOCR] main.py:53: Using C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_PP-OCRv4_det_infer.onnx\u001b[0m\n",
      "\u001b[32m[INFO] 2026-02-09 12:50:29,840 [RapidOCR] base.py:22: Using engine_name: onnxruntime\u001b[0m\n",
      "\u001b[32m[INFO] 2026-02-09 12:50:29,862 [RapidOCR] download_file.py:60: File exists and is valid: C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_ppocr_mobile_v2.0_cls_infer.onnx\u001b[0m\n",
      "\u001b[32m[INFO] 2026-02-09 12:50:29,864 [RapidOCR] main.py:53: Using C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_ppocr_mobile_v2.0_cls_infer.onnx\u001b[0m\n",
      "\u001b[32m[INFO] 2026-02-09 12:50:29,942 [RapidOCR] base.py:22: Using engine_name: onnxruntime\u001b[0m\n",
      "\u001b[32m[INFO] 2026-02-09 12:50:29,979 [RapidOCR] download_file.py:60: File exists and is valid: C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_PP-OCRv4_rec_infer.onnx\u001b[0m\n",
      "\u001b[32m[INFO] 2026-02-09 12:50:29,980 [RapidOCR] main.py:53: Using C:\\Users\\Public\\Documents\\MARIO\\MAR\\Lib\\site-packages\\rapidocr\\models\\ch_PP-OCRv4_rec_infer.onnx\u001b[0m\n",
      "The plugin langchain_docling will not be loaded because Docling is being executed with allow_external_plugins=false.\n",
      "The plugin langchain_docling will not be loaded because Docling is being executed with allow_external_plugins=false.\n",
      "Loading docs: 100%|██████████| 2/2 [02:28<00:00, 74.23s/doc] "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Read 2 documents\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "paths = [test_outfiles / i for i in os.scandir(test_outfiles)]\n",
    "docs_list = di.read_documents(paths)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "02044618",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(list, tuple, docling.datamodel.document.ConversionResult, str)"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(docs_list), type(docs_list[0]), type(docs_list[0][0]), type(docs_list[0][1]) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "95aa20df",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Extracting data: 100%|██████████| 2/2 [00:00<00:00, 32.83doc/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Extracted markdown saved to C:\\Users\\Public\\Documents\\MARIO\\test_outs and images saved to C:\\Users\\Public\\Documents\\MARIO\\test_files\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "di.extract_markdown_images(docs_list, test_outfiles, test_infiles)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "6c21b802",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Loading docs: 2doc [00:00, 240.75doc/s]\n",
      "Loading docs: 3doc [00:00, 3253.92doc/s]\n"
     ]
    }
   ],
   "source": [
    "from langchain_text_splitters import MarkdownHeaderTextSplitter\n",
    "\n",
    "headers_to_split_on = [\n",
    "    (\"#\", \"Header 1\"),\n",
    "    (\"##\", \"Header 2\"),\n",
    "    (\"###\", \"Header 3\"),\n",
    "]\n",
    "\n",
    "splitter = MarkdownHeaderTextSplitter(headers_to_split_on=headers_to_split_on)\n",
    "\n",
    "mkd_docs, img_docs, imgs = di.load_data(test_outfiles, test_infiles, splitter)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "2b34d336",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'type': 'image', 'image': 'Introduction to evidence synthesis for decision making_image_1', 'document': 'Introduction to evidence synthesis for decision making', 'doc_type': 'TSD', 'page_no': '12', 'caption': 'Figure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in bold.  Treatment X has  been  added  to  the  synthesis  set  because  it  links  treatment  C  to  the  rest  of  the network (dashed lines).'}, page_content='Figure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in bold.  Treatment X has  been  added  to  the  synthesis  set  because  it  links  treatment  C  to  the  rest  of  the network (dashed lines).'),\n",
       " Document(metadata={'type': 'image', 'image': 'Introduction to evidence synthesis for decision making_image_2', 'document': 'Introduction to evidence synthesis for decision making', 'doc_type': 'TSD', 'page_no': '16', 'caption': 'Figure 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments X and Y.'}, page_content='Figure 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments X and Y.'),\n",
       " Document(metadata={'type': 'image', 'image': 'Introduction to evidence synthesis for decision making_image_3', 'document': 'Introduction to evidence synthesis for decision making', 'doc_type': 'TSD', 'page_no': '19', 'caption': 'Figure  3  Parkinson  network:  each  edge  represents  a  treatment,  connecting  lines  indicate  pairs  of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers of trials making that comparison.'}, page_content='Figure  3  Parkinson  network:  each  edge  represents  a  treatment,  connecting  lines  indicate  pairs  of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers of trials making that comparison.')]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "img_docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "2100e38b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Introduction to evidence synthesis for decision making_image_1': 'iVBORw0KGgoAAAANSUhEUgAAAIAAAACFCAIAAAAckWcvAAAPGElEQVR4nO2de1AT1x7HTxIDSIgiQmAQfCPiC7E+oYpKBVEBEYnPIbUDWC3TGVs7Yx1trbTQGae1Vp0WgwwRgiNWUajUB1hhCILEkRJpgNIAIWAg5EUCCZvH3tG9Q7notT42ye4mn79Ccvacw/nueezZ8/v9SDAMAwf/CwRBQ0NDTk5OJBIJAGA0GslksouLC7AAYyyRKd6Ry+W3bt0qKirSarVUKjUwMLC/v7+np8fHxychIWHjxo1oFgY7eA6TydTX1xceHg4AGDt2bGVlpVQqTUtLAwC4urqePHnSZDLBKEFGU0yiQCaT3dzcJk6ciAgwbtw4b2/vzz77LCAgYHBw8OzZs52dnaiVhVZGBAN+xvBnAACNRnN3dwcAyGQypVKJVkEOAf4FEonk7OwMAPj7779FIhEAYMWKFVOnTgUoYb8CtLa2nj17tre39+XJDAZDRUVFfn7+/v37KRRKWlpaVlYW0hVQwR5XQWKxmM1m83i8FStWODk5vTyx2Wzu6uoaGBiQyWQwDJvNZqVSOXnyZNRqA9sTjY2Nn3/++Zo1a44cOdLR0fGSlDqdLj4+HgDg4eHR0NAAw7BAIAgMDAQATJo0qaKiAq0q2csQ9Ndffx08eDAtLc3FxYXNZqenp7/6XWwymQAA8+bNi4uLAwB0dXUVFhaiVTHiD0H19fUXLlyor6+PiIgoKCjw8fF546zc3NyQD0NDQ2hVj8gCCASCrKwsoVAYFRXF4XD8/f1f/VoqlYrsQwyvgtRqdWVlJfIstmnTJtRqCRORBw8e7Nu377333vvuu+/6+vpe93KFQnHnzp2ZM2ciTXTw4EEul7tp0yYajbZkyZL8/Hyz2YxWVUkE24yrq6vLysoSi8UxMTFMJtPb2/sNMlEqlUKhsLu7G/nTaDTCMEyhUHx8fIKCgry8vFCsMHEEqKys5HA4EokkPj5+x44d48ePB3gA93OA2Wyuqqpis9kKhSI+Pn7Lli0eHh4AP+BYALPZXFZWlpubq1art23blpCQQKPRAN7ApQBGo7G8vDw7OxuCICaTGRsbS6fTAT7BmQAQBN26dYvD4RgMht27d8fGxiJrRPyCGwEgCCotLc3NzaVQKLt27dqwYYOF3hFaGRysggYHB2/cuJGXl+fs7Pz+++9HRkZSqVRAFDAtgF6vLyoqys/Pp9PpLBZr3bp1Y8bgpsviW4D+/v7r168XFBRMmDAhOTk5PDycQqEAIoI5AbRabeEzGAzGnj171qxZAwgNhgSQy+VXrly5fPmyn59famrq8uXLke0wYoMJAVQqFZfLLSoqmjZt2p49e0JDQ4HdYGMBnjx5UlhYWFxcHBAQsHfv3pCQEGBn2EwAmUzG4XBKS0vnzp3LYrEWL14M7BIbCNDR0XHx4sXbt28vWLAgNTV1zpw5wI6xqgBdXV05OTl3795dvHhxUlLS/PnzrVY0ZrHSc01LS0tBQUFFRcXy5cuzs7NnzJhhnXKxj8V7gEgkys7Ovn///sqVK3ft2oWc7HBgjR4gEAjy8vLq6urWrFmTl5fn5+dnubLwi0V6gFAoPHfuXH19fWRk5I4dO1A8SWkvAjx8+NBkMi1duvR1s+Pz+RcuXHj8+HF0dDSLxWIwGCjV054EMJlMSUlJVCqVzWa/+sbvo0eP2Gx2U1NTbGwsk8n09fW1QG2JyPMnVerq6jw9Pb28vOrr61/lZEt1dXVKSkpERMSPP/6oVCrROjBjJ4yehGEYvnjxYl9fHwDg6tWrwcHBL1GupqaGzWZLJJItW7ZkZGR4enpa/oYhHKMEaW5uXr9+PXKyIygoSCKRvFC333//ncViRUZGstlsjUZjlXuFmIyeA06dOkWj0Wpqas6fP0+hUM6ePbt3796RCYRCYWZmplwuZzKZmzdvxsv5J+wyUo3Ozs6UlBS5XF5eXj527FgAwKpVq+Ry+cg0Z86cCQgIGPWlA3TsA27evDlr1iwPD49FixatWLECAFBbW1tVVTUyzbZt2+h0+tWrV61+qxCTfwRQqVS3b9/u6ek5c+YMl8udOHEimUweGhq6cOGCwWAYTubp6fnpp5+eOHFCIpHYqM6E4p9VEI/Hmzp16s6dO5/ODCRScHBwU1OTQCC4d+8en89HOgRCXFycwWBwdXW1UZ2JBTISQRCUlpbG4/FGDk/Hjh1D0nz88cco2oY7GMnTIQiCoMuXL5eWlpLJZAiCkEY3GAzDLwi5XC6Px0NMpYYxGo1SqXTUlw5el6cCtLS0VFZWLlq0qKysrKWlBflBJBK1trYmJiZu3bo1PDy8rKxMJpONvLK7u3vDhg0CgeC1y3SAym6oyWT65JNPdDrduXPn3iwHB29lKU+hUA4ePNjY2Mjn81Gtkn3xtu8DysvLp0yZMmzP5gCXB7PsGXQs5Xk8nkajQSUrewMdAXJychxTsS0FSElJyc3NbW9vRyU3uwIdAZYuXRoSEpKXl4dKbnYFapNwR0eHTqebPXs2KrnZD45VkI1B2V8Qn88XCoXo5klsUBagtLQ0LS1Nr9ejmy2BQVmADz/8UCaTcblcdLMlMCgLwGAwDhw4wOFw1Go1ujkTFfQnYb1e/8cff4SEhPyrQ0IHjlWQ7bGU18SGhgbHTGBLAdzc3H766SfHktRmAkyfPj0mJgbx9G6hIoiBBR237tu3D4IgsVhsuSIIgGUnYaVSOW7cOKL62UAFxyrIShgMBpFIpNVq3d3dp02bhpw6NJvNFjdT1el02dnZH3zwAR496qGCXq/ncrkXL16k0+lhYWF0Ov3JkycMBkMmk0VHR1vcc67ZbE5ISDh16hRsl7S1tW3cuJFCoSQlJXV1dRmNRgiCJBJJamqqs7Pz3bt3reG6uKKiYs6cOW1tbbCdoVKpYmNjAQChoaGjDvT39PRERkbeuXPHGu7rQ0NDw8LCqqurgZ3B4XBKSkoAAEwmc5Q7WQaDkZSU9NQIwzr3glKp1Gq1sD2hUChWrVqFxGF6YcAHlUrV399vpQAO7u7uNBrNaDQCYqHRaMrKyoZPNI+ks7OzqakJAECn019ovjh+/Hg6nW69CBoQBB06dIhIpjVisXjnzp3FxcUv/LW/v1+n0yFnOF/ie816AlCpVH9///T0dBSDcNkWV1fXAwcOfP/99y/ceKfT6YidnU6nGxgYsL0AJBIpOTmZRqP98MMPuH76e/z4cVFREWKttXbt2v/nytTf3z8gIAAZprq6uv5fblYN4kOj0Y4fPz40NPTCQRP7QBB0/vz5mJgYPp//r/eQh4fHzp07yWSyyWQaZeiIoNPpnhrf2WKBgEvMZvPx48e9vb1zc3Nf0WCrv78/MTERADBt2rTGxsaRP3V2dqanp0skEpvtBZlMJtxt0lVVVbm5uS1cuPDVL5HL5RkZGfn5+b6+vkeOHAkMDBwaGmpra+Pz+StXroyOjraNAFevXpVKpfv37weYZ3Bw8Oeff968efP06dPfOJNHjx5VVVVJJBIPD4/x48d7eXktX7580qRJT3+DbcGff/4ZFhbW0tICYxuhUBgREbFgwYIHDx6gkiEEQaMiMNkmkl5QUFB0dPTJkyfNZjPAKs3NzSwWy9fX98aNG0uWLEElz+HwZP8A2wiFQnH48GEse1oZHBwcZThtCRwvZEbT3Nz88OHDxMRE64SJsHEwTwiCXvKQYmWMRmNBQUFycrJarbbeCg22KWKxeOvWrVKpFMYA+fn569evr6mpsWahNh6CzGZzcnKyt7f3N998QybbuDsqFAoKhWJtF1SwrXn06NHMmTMfP35sk9I1Gs0XX3zx8OFDm5SOiYDO8+fP//LLL60fnQeG4dra2tjY2La2tteKdIsu9rsKkkqlW7dujYmJOXDggA0PcmNFALPZLBaLfX19rdAWyDaUXq/v7e199cDmFsL2QxCCVqv96KOPkFfYFqWwsPDw4cMAABcXF5u3PoYEoNPpERERmZmZKpXKQkWo1eqjR49+9dVXmIpUgxUBSCRSSkoKlUq1nMsDLpfb1NR07dq17du3A8yAlTkAgcfj9fb2xsfHAwugVqtpNBrWgiFiSwDUkUqlX3/99bp16+Li4gAmwcoQNBKBQNDd3Q3eDqPRWFxcHB8f/2aBEKwGtvojwu3btyUSycmTJ8FboFKpLl++fOjQIcze+/8Fxh5SqXT16tX3799/s8sHBgZgGDaZTBAEwZgHi0OQt7f37t2732A5ZDQaMzIyUlNT1Wo1mUzGR9xnGJPo9fqGhobXuqShoSEqKio4OPjOnTs48vOLxTkAAODs7Py6cfZqa2udnZ1LSkpsuLNGtGVoZ2dnb2/vO++885I0T094k8lubm6IPSzuzhphcQ4YRqvVHj16dJTL5JGIRKLt27f/8ssvSNPjrvWxLkBQUNDChQtPnTr1/OkVk8n066+/MpnMuXPnYn2h+XJgbNPS0vLuu++KRKJR3w8ODh4+fPjKlSswzsH0HACe3R8ymWzChAnDa0qZTObl5YXU3uavkd8erP8DJBKJwWAgrW80Gk+fPo24bCeRSARofYxuRTyPUqnMycmprq4eM2bMsWPHXFxcAFHAhwDkZ4b9UVFRLBbL2dkZEAiszwGEhwjDKK5xCGBjHALYGIcANsYhgI1xCGBj8CEAPGKtjGzMjfwG2ZYA+AQHD2LwswDeVVVVRqPR19c3PDw8KChILpeXlJS0trY6OTktW7YsIiICHy8g8dgDSCTSjBkzmpqa0tPTFQqFn58f4uulvb2dw+H4+PgEBgbitPXx0QMAAFOmTElNTS0pKYEgiE6nI69i2tvbL126FBYWBvAMPgQAAMybN8/f37+6utpgMEil0tOnT7NYLLy3Pp4E8PT0XLZs2W+//VZWVnbz5s24uLi1a9cC/IODOWCY8PDwvr6+zMzMDRs2rFu3DhACPAkQGBhIIpGmTJkSFRUFiAJuBJDL5ZcuXfLy8mpubracEYf1wYcACoUiIyMjNDQ0OTm5tbWVSGEJcCCARqM5ceJEcHAwk8lctmyZwWCoq6sDRAHrAmg0mm+//XbWrFlJSUkAgIULF/r4+JSXlw8NDQFCgF0BdDqdUChksVgSiWTbtm3ILpCTk5O7u3tpaem9e/cQr5x4B7vPATU1NdeuXYNheOLEiWKxePbs2Vqt9vr167Nnz548eXJJSQmVSl29ejXeD6f8BzcBaz6JOtiOAAAAAElFTkSuQmCC',\n",
       " 'Introduction to evidence synthesis for decision making_image_2': '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',\n",
       " 'Introduction to evidence synthesis for decision making_image_3': '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'}"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "imgs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "196abf23",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='May 2011 (last updated April 2012)  \\nSofia Dias 1 , Alex J Sutton 2 , Nicky J Welton 1 , AE Ades 1  \\n1 School  of  Social  and  Community  Medicine,  University  of  Bristol,  Canynge  Hall,  39 Whatley Road, Bristol BS8 2PS, UK  \\n2 Department  of  Health  Sciences,  University  of  Leicester,  2nd  Floor  Adrian  Building, University Road, Leicester LE1 7RH, UK  \\nDecision Support Unit, ScHARR, University of Sheffield, Regent Court, 30 Regent Street Sheffield, S1 4DA;  \\nTel (+44) (0)114 222 0734 E-mail dsuadmin@sheffield.ac.uk'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content=\"The Decision Support Unit (DSU) is a collaboration between the Universities of Sheffield, York and Leicester. We also have members at the University of Bristol, London School of Hygiene and Tropical Medicine and Brunel University.  \\nThe  DSU  is  commissioned  by  The  National  Institute  for  Health  and  Clinical  Excellence (NICE)  to  provide  a  research  and  training  resource  to  support  the  Institute's  Technology Appraisal Programme. Please see our website for further information www.nicedsu.org.uk\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='The NICE Guide to the Methods of Technology Appraisal i is a regularly updated document that provides an overview of the key principles and methods of health technology assessment and  appraisal  for  use  in  NICE  appraisals.  The  Methods  Guide  does  not  provide  detailed advice  on  how  to  implement  and  apply  the  methods  it  describes.  This  DSU  series  of Technical  Support  Documents  (TSDs)  is  intended  to  complement  the  Methods  Guide  by providing detailed information on how to implement specific methods.  \\nThe TSDs provide a review of the current state of the art in each topic area, and make clear recommendations  on  the  implementation  of  methods  and  reporting  standards  where  it  is appropriate to do so. They aim to provide assistance to all those involved in submitting or critiquing evidence as part  of  NICE  Technology  Appraisals,  whether manufacturers, assessment groups or any other stakeholder type.  \\nWe recognise that there are areas of uncertainty, controversy and rapid development. It is our intention that such areas are indicated in the TSDs. All TSDs are extensively peer reviewed prior to publication (the names of peer reviewers appear in the acknowledgements for each document).  Nevertheless,  the  responsibility  for  each  TSD  lies  with  the  authors  and  we welcome any constructive feedback on the content or suggestions for further guides.  \\nPlease be aware that whilst the DSU is funded by NICE, these documents do not constitute formal NICE guidance or policy.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='Director of DSU and TSD series editor.  \\ni National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal, 2008 (updated June 2008), London.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='Alex  Sutton  has  received  financial  reimbursement  when  working  as  an  advisor  on  the development of the Comprehensive Meta-Analysis software package.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='The DSU thanks Rachael Fleurence, Jeroen Jansen, Alec Miners, Jaime Peters, Mike Spencer and the team at NICE, led by Gabriel Rogers, for reviewing this document. The editor for the TSD series is Allan Wailoo.  \\nThe production of this document was funded by the National Institute for Health and Clinical Excellence  (NICE)  through  its  Decision  Support  Unit.  The  views,  and  any  errors  or omissions, expressed in this document are of the author only. NICE may take account of part or all of this document if it considers it appropriate, but it is not bound to do so.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='Dias, S., Sutton, A.J., Welton, N.J. &amp; Ades, A.E. NICE DSU Technical Support Document 6: Embedding evidence synthesis in probabilistic cost-effectiveness analysis: software choices. 2011; last updated April 2012; available from http://www.nicedsu.org.uk'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='This  document  sets  out  software  options  for  evidence  synthesis  that  are  compatible  with probabilistic  cost-effectiveness  analysis,  which  is  the  preferred  methodology  for  the  NICE reference case. Four possibilities are discussed:  \\n1. Evidence synthesis  by Bayesian posterior estimation, and posterior sampling. Other parameters  of  the  cost-effectiveness  models  can  be  incorporated  into  the  same software  platform.  Bayesian  Markov  chain  Monte  Carlo  simulation  methods  with WinBUGS software are the most popular choice.\\n2. Evidence synthesis by Bayesian posterior estimation. Posterior samples are exported to another package where the other parameters are generated and the costeffectiveness model evaluated.\\n3. Frequentist  methods  of  parameter  estimation  followed  by  forward  Monte  Carlo simulation  from  the  maximum  likelihood  estimates  and  their  variance-covariance matrix\\n4. Bootstrap re-sampling - a frequentist simulation approach to parameter estimation.  \\nWhen multiple parameters are estimated from the same synthesis model, we emphasise the need to choose a method that propagates the parameter correlation structure through the costeffectiveness  model.  A  table  is  provided  that  shows  the  possible  approaches  and  the restrictions on their use.  \\nSoftware packages for evidence synthesis are listed. Technical issues relating to software are covered in an Appendix. Finally we mention software suitable for transferring data between different software packages, and software that provides user-friendly interface for integrated software  platforms.  These  offer  investigators  a  flexible  way  of  examining  alternative scenarios.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='| 1. 2.                                                                                                                                                                                                                                                                                                   | INTRODUCTION....................................................................................................... EMBEDDING EVIDENCE SYNTHESIS IN PROBABILISTIC CEA....................                                                                                                               | 7 8                                                                                                                                                                                                                                                                                                     |\\n|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\\n|                                                                                                                                                                                                                                                                                                         | 2.1. BAYESIAN POSTERIOR SIMULATION: ONE-STAGE APPROACH.....................................                                                                                                                                                                                                             | 2.1. BAYESIAN POSTERIOR SIMULATION: ONE-STAGE APPROACH.....................................                                                                                                                                                                                                             |\\n| 2.2.                                                                                                                                                                                                                                                                                                    | BAYESIAN POSTERIOR SIMULATION: TWO-STAGE APPROACH ....................................                                                                                                                                                                                                                  | 9                                                                                                                                                                                                                                                                                                       |\\n| 2.3.                                                                                                                                                                                                                                                                                                    | FREQUENTIST ESTIMATION WITH MONTE CARLO SAMPLING.....................................                                                                                                                                                                                                                   | 9                                                                                                                                                                                                                                                                                                       |\\n| 2.3.1.                                                                                                                                                                                                                                                                                                  | 2.3.1.                                                                                                                                                                                                                                                                                                  | Stand-alone meta-analysis packages.............................................................. 10                                                                                                                                                                                                     |\\n| 2.3.2.                                                                                                                                                                                                                                                                                                  | 2.3.2.                                                                                                                                                                                                                                                                                                  | General statistical packages with support for meta-analysis .......................... 10                                                                                                                                                                                                               |\\n| 2.3.3.                                                                                                                                                                                                                                                                                                  | 2.3.3.                                                                                                                                                                                                                                                                                                  | Software for network meta-analysis................................................................ 10                                                                                                                                                                                                   |\\n| 2.3.4.                                                                                                                                                                                                                                                                                                  | 2.3.4.                                                                                                                                                                                                                                                                                                  | Parameterisation of treatment effects............................................................. 11                                                                                                                                                                                                   |\\n| 2.4. FREQUENTIST                                                                                                                                                                                                                                                                                        | 2.4. FREQUENTIST                                                                                                                                                                                                                                                                                        | ESTIMATION WITH BOOTSTRAPPING ................................................. 11                                                                                                                                                                                                                      |\\n| 2.5. SUMMARY OF METHODS AND RESTRICTIONS ON THEIR USE                                                                                                                                                                                                                                                   | 2.5. SUMMARY OF METHODS AND RESTRICTIONS ON THEIR USE                                                                                                                                                                                                                                                   | .................................. 12                                                                                                                                                                                                                                                                   |\\n| 3.                                                                                                                                                                                                                                                                                                      | USE OF MULTIPLE SOFTWARE PLATFORMS................................................ 12                                                                                                                                                                                                                   | USE OF MULTIPLE SOFTWARE PLATFORMS................................................ 12                                                                                                                                                                                                                   |\\n| 3.1. COMMUNICATION BETWEEN SOFTWARE                                                                                                                                                                                                                                                                     | 3.1. COMMUNICATION BETWEEN SOFTWARE                                                                                                                                                                                                                                                                     | PACKAGES................................................ 13                                                                                                                                                                                                                                             |\\n| 3.2. INTEGRATED USE OF SOFTWARE                                                                                                                                                                                                                                                                         | 3.2. INTEGRATED USE OF SOFTWARE                                                                                                                                                                                                                                                                         | PLATFORMS.......................................................... 13                                                                                                                                                                                                                                  |\\n| 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 | 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 | 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 |\\n| TABLES                                                                                                                                                                                                                                                                                                  | TABLES                                                                                                                                                                                                                                                                                                  | TABLES                                                                                                                                                                                                                                                                                                  |\\n| Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   | Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   | Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   |'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='CEA  \\ncost-effectiveness analysis  \\nFE  \\nFixed effects  \\nMC  \\nMonte Carlo  \\nMCMC  \\nMarkov chain Monte Carlo  \\nRE  \\nRandom effects  \\nVCV  \\nvariance-covariance'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content=\"Probabilistic  methods  in  decision  analysis  were  introduced  in  the  1980s. 1,2 Their  defining feature is that they allow for a full expression of the uncertainty in model parameters. There are two main reasons for advocating probabilistic methods in decision making. The first is that they can provide a form of sensitivity analysis which allows investigators to easily see the joint impact of the uncertainty in multiple parameters on the expected costs, benefits and on  decision  uncertainty.  For  this  reason  use  of  these  methods  is  often  called  probabilistic sensitivity  analysis.  A  second  reason  is  that,  faced  with  uncertainty  in  the  vector/matrix  of model parameters θ ,  decision makers generally choose the decision option, D ,  that delivers the highest expected net benefit. In other words, the decision maker selects decision D* , such that:  \\n$$D ^ { * } = M _ { \\\\partial } \\\\alpha E _ { \\\\theta } [ N B ( D , \\\\theta ) ]$$  \\nThis 'expectation' requires an integration of the net benefit function, ( , ) NB D θ over the joint distribution  of  parameters θ .  There  are  a  wide  range  of  methods  for  achieving  this integration, and the appropriate choice of method depends on the algebraic structure of the net benefit function. It must be emphasised that the expected Net Benefit is not the same as the Net Benefit at the expected value of the parameters, except in the cases where Net Benefit is  linear  in  all  its  parameters, and there  are  no  correlations  between  parameters.  This  is relatively rare, as most evidence synthesis is performed on log or logit scales, and many costeffectiveness  analysis  (CEA)  models  include  Markov  models,  which  are  notoriously  nonlinear. Further, modern methods of evidence synthesis tend to generate estimates of several parameters from a common dataset, in most cases leading to correlations between parameters. It  is  therefore  essential  that  software  solutions  are  adopted  that  ensure  that  the  complex uncertainty  structure  in  parameter  estimates  is  faithfully  propagated  through  the  decision model. 3 This  document provides guidance on the appropriate choice of  software to deliver probabilistic cost-effectiveness analysis in any situation.  \\nMonte Carlo (MC) simulation from the joint parameter distribution is not only the simplest way to evaluate the expected Net Benefit, but for any form of model it also delivers other crucial  tools  of  probabilistic  CEA  such  as:  plots  of  the  cost-effectiveness  plane,  costeffectiveness  acceptability  curves  and  estimates  of  the  probability  that  a  decision  is  costeffective. 4,5 MC  simulation  is  also  the  easiest  approach  to  Expected  Value  of  Information analysis. 6-8 Probabilistic  methods  have  been  recommended  in  a  range  of  leading  textbooks  \\nand tutorial papers, and are the preferred option for submissions to re-imbursement agencies such  as  the  National  Institute  of  Health  and  Clinical  Excellence  (NICE)  in  the  UK.  We therefore  recommend  MC  simulation-based  approaches  for all analyses,  even  for  strictly linear models.  \\nThe document confines  itself to the question of  which computational approaches  correctly preserve  the  properties  of  the  evidence  synthesis  within  a  probabilistic  cost-effectiveness analysis. No advice is given on the relative merits of cohort models compared to individual patient  simulation.  Indeed,  no  advice  is  given  in  this  document  on  how  to  choose the  best model, it is restricted to providing guidance on how to implement the model of choice.  \\nThis document is organised as follows. The main body of the document (Section 2) sets out the different analysis options. These include Bayesian Markov chain Monte Carlo (MCMC) methods  (2.1,  2.2),  and  frequentist  methods,  either  sampling  from  maximum  likelihood estimates  and  their  variance-covariance  (VCV)  matrices  (2.3),  or  bootstrapping  (2.4).  We then  provide  a  brief  summary  of  software  tools  that  can  be  used  to  help  interface  between different  software,  and  review  some  recent  developments  in  user-friendly  'front  ends',  to assist the integrated use  of multiple  software  platforms.  These  offer  ways in  which investigators can conduct scenario analyses, not just with individual parameters but also with different datasets  or different synthesis models  and  quickly  see  the impact  on  costeffectiveness results.\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content=\"When  estimation  of  the  synthesis  parameters  is  via  sampling  from  a  Bayesian  posterior distribution  of  the  relevant  parameters,  this  can  be  integrated  with  the  CEA  as  a  single process within a single programming package, in what has been referred to as 'Comprehensive Decision Analysis'. 9-11  \\nBayesian MCMC simulation, 12 using WinBUGS, 13 OpenBUGS 14 or other MCMC packages, provides the obvious example. The advantage of this approach is that it not only estimates a Bayesian posterior distribution, but that it is simulation-based, so that its outputs are perfectly compatible with the MC sampling approach that has become the standard modelling method in so many areas of science. Samples from the joint posterior distribution can be put directly through the decision analysis, so that Net Benefit and other outputs can be evaluated for each  \\nset of parameter samples, without requirements for assumptions about its distributional form. Distributions of additional parameters and costs can be readily incorporated.  \\nDevelopment of MCMC algorithms and sampling schemes is a specialised area of research. Although  users  need  not  have  a  detailed  knowledge  of  the  precise  working  of  MCMC software,  a  good  understanding  of  the  fundamentals  and  of  Bayesian  data  analysis  is essential.  For  completeness  it  is  worth  mentioning  that  a  broad  range  of non -MCMC simulation-based Bayesian updating schemes have also been proposed, including the Sample Importance  Re-sampling  algorithm, 15 Bayesian  Melding, 16,17 and  Bayesian  Monte  Carlo. 18 All these have the same properties as Bayesian MCMC in that they all feature both Bayesian estimation and sampling  from  joint posterior distributions.  The  latter two  were  specifically designed for evidence synthesis.\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='If investigators have a preferred software for CEA, either general software packages such as R, STATA, SAS, or spread-sheet or decision tree packages such as EXCEL or TreeAGE, a further option is to take the posterior samples from the Bayesian MCMC, or other posterior sampling scheme, and use them as input to the CEA package. This has the same technical properties  as  the  Bayesian  one-stage  approach  since  the  full  posterior  distribution is preserved. From WinBUGS, the CODA output, which lists all values generated from the full posterior  distribution,  can  be  exported  into  a  spreadsheet-based  program  such  as  EXCEL, using BUS - BUGS Utility for Spreadsheets. 19 When using the CODA output it is important that the correlations in the parameter estimates are preserved. This is done by ensuring that all parameter values are sampled from the same MCMC iteration . If the CODA output is in spreadsheet  format,  for  example  in  EXCEL,  this  would  correspond  to  sampling  all  the parameter values in one row, each time. The CODA output can also be converted to the freely available  statistical  software  R 20 for  convergence  diagnostics,  further  analysis  and  plotting using  add-on  packages  such  as  BOA  -  Bayesian  Output  Analysis  Program 21 or  CODA  Convergence Diagnostics and Output Analysis. 22'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='If evidence synthesis can be performed using frequentist software (which may use a variety of methods of estimation including, methods of moments, iterative weighted least-squares or  \\n(restricted) maximum likelihood ((RE)ML)), a two-stage approach is also possible. The first step is estimation, which produces parameter estimates and their variance-covariance (VCV) matrix. In the second step, these are used to populate a multivariate normal distribution which can be used for forward MC sampling (in the same or in a different package) along with the other CEA parameters. When single parameters are of interest, such as in simple pair-wise meta-analysis, this  may  be  the  simplest  option  as  only  one  variance  needs  to  be  estimated (there is no VCV matrix). In such situations it is particularly easy to find the treatment effect parameter  and  its  variance  using  either  specific  meta-analysis  software  or  implementing meta-analysis routines in standard statistical software packages. A systematic and comprehensive review of all  software options  capable of evidence synthesis  is beyond the scope  of  this  document,  but  noteworthy  options  are  described  below  and  more  detailed reviews and comparisons are available elsewhere. 23-26'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='Numerous packages have been developed over the years, but probably those which include the most extensive and up-to-date feature sets, are  \\n-  Comprehensive meta-analysis (commercial); 27\\n-  Meta-Analyst (free); 26\\n-  MIX, 28 which is an add-on to EXCEL (commercial and free versions available);\\n-  RevMan, 29 which is the official software of the Cochrane Collaboration (free).\\n-  EXCEL:  Simple meta-analysis can be carried out with a small amount of programming.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='While it would be possible to program most standard meta-analysis models in any reasonably powerful  statistics  package,  probably  the  most  extensive  freely  available  software  routines which  allow  meta-analysis  to  be  conducted  and  numerous  graphical  outputs  produced  are available for STATA 30 and for R, such as the meta 31 and rmeta 32 packages.  \\nAlthough  all  the  above  options  will  conduct  pair-wise  meta-analysis,  not  all  have  the capability to do meta-regression, 33 which may be a decisive factor in choosing between them.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content=\"Specific comments on frequentist software options for network meta-analysis can be found in TSD2. 34 For  indirect  comparison  networks,  separate  syntheses  can  be  carried  out  for  AB  \\ntrials, and AC trials. Then the estimates obtained and their variances can be entered into the simulation package used for CEA, and the relative cost-effectiveness of A, B and C readily determined  (covariances  are  not  involved).  Although  this  is  an  acceptable  approach  in principle,  the  Bayesian  MCMC  approach  to  indirect  comparisons  (see  TSD2 34 )  may  be preferable in cases where one or more of the pair-wise comparisons is represented by a very small number of trials. This is because, MCMC has the flexibility to allow 'shared variance' Random Effects (RE) models, while with conventional methods it may be necessary to have some estimates from RE models and others from Fixed Effects (FE) models, which seems a less natural solution.  \\nIn many cases the use of frequentist estimates and their VCV matrix with RE models is likely to  produce  parameter  distributions  with  a  little  less  uncertainty,  because  Bayesian  methods take uncertainty in variance parameters into account. The extent of the difference is unlikely to  be  critical,  although  investigators  should  always  check  that  posterior  distributions  of variance parameters are sensible.\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='Whatever software is used, model parameterisation requires care, as a number of apparently innocuous  variations  may  give  very  different  or  wrong  results.  To  date,  a  few  coding problems have come to light and these are set out in the Appendix.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content=\"The final option of estimation and then Bootstrapping, 35 has been used from time to time in cost-effectiveness analysis. 36 In  its  original  form,  bootstrapping is a technique in which one generates  a  series  of  'new'  datasets  by  repeatedly  re-sampling with  replacement from  the original data, each time producing a new set of parameters estimates. This stream of estimates can  then  be  treated  in  the  same  way  as  samples  from  Bayesian  posterior  distributions. However, this procedure is not always straightforward, particularly with small sample sizes and zero cells.  \\nThere are, nonetheless, a very wide range of variant bootstrap procedures which can mitigate these and other problems. In the parametric bootstrap, for example a model is fitted to the data by maximum likelihood and is then used to generate a series of datasets with the same size and structure as the original. The analysis procedure is applied to each of these datasets  \\nto generate a stream of parameter values. Data analysis based on resampling is a rich area with an extensive literature. Readers are referred to texts for further information. 35,37,38\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='Table 1 summarises the methods and the restrictions on their use. Readers are referred to the text for further explanation.  \\nTable 1 Summary of methods and their properties and restrictions  \\n| Estimation                                       | Output to CEA Sotware                              | Restrictions                                                             |\\n|--------------------------------------------------|----------------------------------------------------|--------------------------------------------------------------------------|\\n| BayesianMCMC                                     | None: CEA within MCMC Software                     | None                                                                     |\\n| BayesianMCMC                                     | MCMCchains exported                                | None                                                                     |\\n| BayesianMCMC                                     | Posterior means, variances, correlations           | None, but assumes multi- variate normality in posterior distribution     |\\n| BayesianMCMC                                     | Posterior means and variances                      | Only suitable if no correlation between parameters*                      |\\n| Estimation by non-Bayesian (frequentist) methods | Parameter estimates and Variance-Covariance matrix | None, but assumes multi- variate normality of treatment effect estimates |\\n| Estimation by non-Bayesian (frequentist) methods | Parameter estimates and their variances            | Only suitable if no correlation between parameters*                      |\\n| Estimation by non-Bayesian (frequentist) methods | Bootstrap resampling                               | None, but special methods are necessary for sparse data                  |'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content=\"In  recent  years  interfaces  have  become  available  that  let  different  software  applications communicate with each other. These facilities allow for the integration of the components of a  CEA  which  may  have  been  conducted  in  different  packages.  The  motivations  and advantages of an integrated approach across software applications are potentially multifaceted. Firstly, it allows multidisciplinary teams who have different software skills and preferences  to  produce  an  integrated  analysis.  For  example,  statisticians  may  wish  to  use general statistical software, whereas decision modellers may wish to use EXCEL or specific decision  modelling  software.  It  also  allows  the  best  software  for  each  component  of  the analysis to be used therefore producing an 'optimal' mix. For example, if a network metaanalysis  is  required,  WinBUGS  may  be  the  best  software  to  implement  this  in,  but  it  has  \\nlimited  graphical  capabilities.  Therefore,  it  may  be  desirable  to  present  the  results  of  the synthesis  in  a  package  with  advanced  graphical  capability  such  as  R.  Furthermore,  the original dataset may have been prepared in spreadsheet software such as EXCEL. Although use of multiple pieces of software to conduct different components of the analysis is common historically, few have been integrated.  \\nSection 3.1 gives details of how to allow communication between different platforms, with the  primary  aim  of  transferring  data  between  them.  Section  3.2  explains  how  different software can be used to fully integrate data input, analysis and the display of results using multiple packages, into a single step.\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='To facilitate communication, transparency and future data updates, it is good practice to keep all data collected for the analysis, including all annotations and details of any corrections, in a single file, for example an EXCEL workbook with multiple worksheets. If the analysis is to be carried out in WinBUGS, data columns can be copied directly from spreadsheet software into  WinBUGS and pasted  by  selecting Paste Special from  the  WinBUGS Edit menu and choosing  the Plain  text option.  Alternatively, XL2BUGS 39 is  an  EXCEL  add-in  which converts  EXCEL  data  into  WinBUGS  vector  format,  and BAUW 40 converts  data  in  text format into WinBUGS vector or matrix format.  \\nIf data is stored in R, R2WinBUGS 41 can be used to convert R objects into WinBUGS list data using the bugs.data function.  \\nSee http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/remote14.shtml for details.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content=\"Integrated  platforms  reduce  the  need  to  copy  data  and  intermediate  results  from  one screen/system  to  another,  and  thereby  reduce  the  risk  of  transcription  errors.  Further advantages of integrating the analysis (which also exist if the Bayesian one-stage approach is conducted since in that approach the analysis is integrated by definition) include facilitating the modification and updating of any aspect of the analysis, conducting sensitivity analyses and, more generally, promoting transparency. For example, if a new trial is reported that is to be  added  to  the  evidence  synthesis,  then  in  an  integrated  approach  the  CEA  would automatically  be  updated.  This  goes  some  way  to  ensuring  the  appropriate  uncertainty  is  \\npropagated through to the decision model. If part of this integrated approach is the inclusion of a user-friendly interface, then this can also make the exploration of the synthesis and CEA accessible to non-technical experts including clinical experts and even NICE decision makers themselves, allowing them to interrogate the analysis.  \\nTo  this  end,  a  Transparent  Interactive  Decision  Interrogator  (TIDI) 42 which  integrated syntheses conducted in WinBUGS with graphical displays and the decision model conducted in  R  and  a  'point  and  click'  interface  in  EXCEL  was  developed  for  a  recent  Single Technology  Appraisal  (STA)  at  NICE.  This  pilot  'proof  of  concept'  initiative  allowed members  of  the  appraisal  committee  to  request  re-runs  of  the  CEA  using  alternative parameter values in real time in the committee meetings.  \\nSeveral (freely available) code routines have been developed for commonly used packages in Health Technology Assessment which allow them to communicate with other packages and these can be utilised in the creation of integrated analyses. For example, RExcel , 43 an add-on to  EXCEL,  provides  communication  between  EXCEL  and  R  and R2WinBUGS is  one  of several packages which allow the controlling of WinBUGS through R. Thus, if both of these linking packages are used in combination, then WinBUGS can be controlled through EXCEL (via R), and a Visual Basic interface can be written in EXCEL to facilitate this (which is the software  setup  used  in  the  TIDI  project  described  above).  Similar  control  of  WinBUGS through  STATA 44 and  several  other  packages  is  also  possible,  as  is  the  embedding  of OpenBUGS in R through rbugs 45 and the linking of many packages to each other.\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='1.   Critchfield,  G.C.,  Willard,  K.E.  Probabilistic  analysis  of  decision  trees  using  Monte Carlo simulation. Medical Decision Making 1986; 6(2):85-92.\\n2.   Doubilet,  P.,  Begg,  C.B.,  Weinstein,  M.C.,  Braun,  P.,  McNeil,  B.J.  Probabilistic sensitivity  analysis  using  Monte  Carlo  simulation:  A  practical  approach. Medical Decision Making: an International Journal of the Society for Medical Decision Making 1985; 5(2):157-177.\\n3.   Ades,  A.E.,  Claxton,  K.,  Sculpher,  M.  Evidence  synthesis,  parameter  correlation  and probabilistic sensitivity analysis. Health Economics 2005; 14:1-9.\\n4.   Claxton,  K.,  Sculpher,  M.,  McCabe,  C.,  Briggs,  A.,  Akehurst,  R.,  Buxton,  M.  et  al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics 2005; 14(4):339-347.\\n5.   National  Institute  for  health  and  Clinical  Excellence.  Guide  to  the  methods  of technology appraisal (updated 2008). 2008.\\n6.   Thompson, K.M., Evans, J.S. The value of improved national exposure information for perchloroethylene (perc): a case study for dry cleaners. Risk Analysis 1997; 17(2):253271.\\n7.   Claxton,  K.,  Posnett,  J.  An  economic  approach  to  clinical  trial  design  and  research priority setting. Health Economics 1996; 5(6):513-524.\\n8.   Felli, J.C., Hazen,  G.B.  Sensitivity analysis and  the expected  value  of perfect information. Medical Decision Making 1998; 18(1):95-109.\\n9.   Cooper,  N.J.,  Sutton,  A.J.,  Abrams,  K.R.,  Turner,  D.,  Wailoo,  A.  Comprehensive decision  analytical  modelling  in  economic  evaluation:  a  Bayesian  approach. Health Economics 2003; 13(3):203-226.\\n10.   Parmigiani, G., Samsa, G.P., Ancukiewicz, M., Lipscomb, J., Hasselblad, V., Matchar, D.B.  Assessing  uncertainty  in  cost-effectiveness  analyses:  Application  to  a  complex decision model. Medical Decision Making 1997; 17(4):390-401.\\n11.   Spiegelhalter, D.J., Myles, J.P., Jones, D.R., Abrams, K.R. Bayesian methods in health technology assessment: a review. Health Technology Assessment 2000; 4(38).\\n12.   Gilks, W.R., Richardson, S., Spiegelhalter, D.J. Markov chain Monte Carlo in practice. Chapman &amp; Hall/CRC, 1996.\\n13.   Lunn, D.J., Thomas, A., Best, N., Spiegelhalter, D. WinBUGS - a Bayesian modelling framework:  concepts,  structure,  and  extensibility. Statistics  and  Computing 2000; 10(4):325-337.\\n14.   Lunn,  D.,  Spiegelhalter,  D.,  Thomas,  A.,  Best,  N.  The  BUGS  project:  Evolution, critique and future directions. Statistics in Medicine 2009; 28(25):3049-3067.  \\n15.   Rubin,  D.B.  Using  the  SIR  algorithm  to  simulate  posterior  distributions. Bayesian Statistics 1988; 3:395-402.\\n16.   Raftery,  A.E.,  Givens,  G.H.,  Zeh,  J.E.  Inference  from  a  Deterministic  Population Dynamics Model for Bowhead Whales. Journal of the American Statistical Association 1995; 90(430):402-416.\\n17.   Poole, D., Raftery, A.E. Inference for Deterministic Simulation Models: The Bayesian Melding Approach. Journal of the American Statistical Association 2000; 95(452):1244-1255.\\n18.   Brand,  K.P.,  Small,  M.J.  Updating  uncertainty  in  an  integrated  risk  assessment: conceptual framework and methods. Risk Analysis 1995; 15(6):719-731.\\n19.   Hahn,  G.  BUGS  Utility for Spreadsheets. Version 1.0.1. 2001; available from http://faculty.salisbury.edu/~edhahn/bus.htm\\n20.   R Development Core Team. R: A Language and Environment for Statistical Computing. 2010. Vienna, Austria, R Foundation for Statistical Computing.\\n21.   Smith,  B.J. The  boa Package. Version 1.1.5. 2005; available from http://www.publichealth.uiowa.edu/boa/\\n22.   Plummer,  M.,  Best,  N.,  Cowles,  K.,  Vines,  K.  CODA:  Convergence  diagnosis  and output analysis for MCMC. R News 2006; 6(1):7-11.\\n23.   Bax,  L.,  Yu,  L.M.,  Ikeda,  N.,  Moons,  K.G.M.  A  systematic  comparison  of  software dedicated  to  meta-analysis  of  causal  studies. BMC  Medical  Research  Methodology 2007; 7(1):40.\\n24.   Sterne, J.A.C., Egger, M., Sutton, A.J. Meta-Analysis Software. In: Egger M., DaveySmith  G.,  Altman  D.G.,  eds. Systematic  Reviews  in  Health  Care:  Meta-analysis  in context . second edn ed. BMJ Books; London: 2001; 336-346.\\n25.   Sutton,  A.J.,  Lambert,  P.C.,  Hellmich,  M.A.G.,  Abrams,  K.R.,  Jones,  D.R.  Metaanalysis in practice: a critical review of available software. In: Stangl D.K., Berry D.A., eds. Meta-analysis  in  medicine  and  health  policy .  Marcel  Dekker;  New  York:  1998; 315-339.\\n26.   Wallace, B.C., Schmid, C.H., Lau, J., Trikalinos, T.A. Meta-Analyst: software for metaanalysis of binary, continuous and diagnostic data. BMC  Medical Research Methodology 2009; 9(1):80.\\n27.   Borenstein,  M.,  Hedges,  L.,  Higgins,  J.,  Rothstein,  H.  Comprehensive  meta-analysis version 2. 2005; available from http://www.meta-analysis.com/\\n28.   Bax, L., Yu, L.M., Ikeda, N., Tsuruta, H., Moons, K.G.M. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Medical Research Methodology 2006; 6(1):50.\\n29.   The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.0. 2008; available from http://ims.cochrane.org/revman  \\n30.   Sterne,  J.A.C.  Meta-analysis  in  Stata:  an  updated  collection  from  the  Stata  Journal. CRC PRESS, 2009.\\n31.   Schwarzer,  G.  meta:  Meta-Analysis  with  R.  Version  1.6-1.  2010;  available  from http://cran.r-project.org/web/packages/meta/\\n32.   Lumley, T. rmeta:Meta-analysis. 2009; available from http://cran.rproject.org/web/packages/rmeta/\\n33.   Thompson, S.G., Sharp, S.J. Explaining heterogeneity in meta analysis: a comparison of methods. Statistics in Medicine 1999; 18(20):2693-2708.\\n34.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  2:  A  generalised  linear  modelling  framework  for  pair-wise  and  network meta-analysis of randomised controlled trials. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n35.   Efron,  B.,  Tibshirani,  R.J.  An  introduction  to  the  bootstrap.  Chapman  &amp;  Hall,  New York; 1993.\\n36.   Lord,  J.,  Asante,  M.A.  Estimating  uncertainty  ranges  for  costs  by  the  bootstrap procedure  combined  with  probabilistic  sensitivity  analysis1. Health  Economics 1999; 8(4):323-333.\\n37.   Davison, A.C., Hinkley, D.V. Bootstrap methods and their application. Cambridge Univ Pr, 1997.\\n38.   Lunneborg,  C.E.  Data  analysis  by  resampling:  Concepts  and  applications.  Duxbury, 2000.\\n39.   Misra,  S.  XL2BUGS:  Excel  Add-In  to  convert  data  for  WinBUGS.  2011;  available from http://www.simon.rochester.edu/fac/misra/software.htm\\n40.   Zhang, Z., Wang, L. Use BAUW  to convert data. 2006; available from http://www.psychstat.org/us/article.php/52.htm\\n41.   Sturtz,  S.,  Ligges,  U.,  Gelman,  A.  R2WinBUGS:  A  package  for  running  WinBUGS from R. Journal of Statistical Software 2005; 12.\\n42.   Bujkiewicz, S., Jones, H.E., Lai, M.C.W., Cooper, N.J., Hawkins, N., Squires, H. et al. Development  of  a  Transparent  Interactive  Decision  Interrogator  to  facilitate  the decision making process in health care. Value in Health 2011; (in press).\\n43.   Heiberger,  R.M.,  Neuwirth,  E.  R through  Excel:  a  spreadsheet  interface  for  statistics, data analysis, and graphics. Springer-Verlag New York Inc, 2009.\\n44.   Thompson, J., Palmer, T., Moreno, S. Bayesian analysis in Stata using WinBUGS. The Stata Journal 2006; 6(4):530-549.\\n45.   Yan,  J.,  Prates,  M.  Package  rbugs:  Fusing  R  and  OpenBugs.  Version  0.4-9.  2011; available from http://cran.r-project.org/web/packages/rbugs/index.html  \\n46.   Higgins,  J.P.T.,  Whitehead,  A.  Borrowing  strength  from  external  trials  in  a  metaanalysis. Statistics in Medicine 1996; 15:2733-2749.\\n47.   Caldwell,  D.M.,  Ades,  A.E.,  Higgins,  J.P.T.  Simultaneous  comparison  of  multiple treatments: combining direct and indirect evidence. BMJ 2005; 331:897-900.\\n48.   Lu,  G.,  Ades,  A.  Assessing  evidence  consistency  in  mixed  treatment  comparisons. Journal of the American Statistical Association 2006; 101:447-459.\\n49.   Ades,  A.E.,  Sculpher,  M.,  Sutton,  A.,  Abrams,  K.,  Copper,  N.,  Welton,  N.J.  et  al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics, PharmacoEcon 2006; 24(1):1-19.\\n50.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  2:  A  generalised  linear  modelling  framework  for  pair-wise  and  network meta-analysis of randomised controlled trials. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n51.   Woolacott, N., Bravo Vergel, Y., Hawkins, N., Kainth, A., Khadjesari, Z., Misso, K. et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment 2006; 10(31).\\n52.   Woods, B.S., Hawkins, N., Scott, D.A. Network meta-analysis on the log-hazard scale, combining counts and hazard ratio statistics accounting for multi-arm trials: A tutorial. BMC Medical Research Methodology 2010; 10(54).\\n53.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  5:  Evidence  synthesis  in  the  baseline  natural  history  model.  2011;  last updated April 2012; available from http://www.nicedsu.org.uk'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content=\"Two ways of specifying network meta-analysis models have appeared in the literature. The main  area  of  difficulty  lies  in  the  precise  way  in  which  the  relative  effects  have  been parameterised, particularly in RE models. One way to write the model for binomial data is:  \\n$$r _ { i k } & \\\\sim \\\\binom { r _ { i } } { i _ { k } } \\\\\\\\ \\\\log ( p _ { i k } ) & = \\\\mu _ { i } & \\\\text {if } k = X \\\\\\\\ \\\\log ( p _ { i k } ) & = \\\\mu _ { i } + \\\\delta _ { i , X } & \\\\text {if } k = Y \\\\\\\\ \\\\delta _ { i , X Y } & \\\\sim N ( d _ { 1 Y } - d _ { 1 X } , \\\\sigma ^ { 2 } ) \\\\\\\\ \\\\mu _ { i } & \\\\sim N ( 0 , 1 0 ^ { 2 } ) \\\\\\\\ \\\\text {and} \\\\, \\\\text {treatment} \\\\, k \\\\, \\\\text { the numerators } \\\\, r _ { i } \\\\, \\\\text { are  have  binomial distributions with}$$  \\nHere,  for  trial i and  treatment k the  numerators rik are  have  binomial  distributions  with parameter pik and denominator nik . A logistic regression model says that, for a trial comparing treatments X and Y , the linear predictor consists of the 'baseline' term i  if the treatment is X ,  and  the  baseline plus a relative treatment effect , i i XY    if  the  treatment  is Y .  The key point is that the actual treatment that i  refers to can be any treatment (except the last one). The  trial-specific  relative  effects  are  from  distributions,  whose  means  can  be  expressed  in terms of the mean treatment effects relative to treatment 1 (through the consistency relations). The baseline terms are usually given vague priors. 46-50  \\nIn  (2)  it  is  clear  that  the  term i  refers  to  treatment X ,  but  it  is  also  clear  that  this  is  not necessarily treatment 1. In this formulation, one arm of a two arm trial informs a trial-specific 'baseline', while the other informs the baseline plus a treatment effect.  \\nAnother way of writing a network model that has appeared in certain submissions to NICE 51 contains this modification:  \\n$$\\\\log i ( p _ { i k } ) & = \\\\mu _ { i } + \\\\delta _ { i , 1 X } \\\\quad \\\\text {if } k = X \\\\\\\\ \\\\log i ( p _ { i k } ) & = \\\\mu _ { i } + \\\\delta _ { i , 1 Y } \\\\quad \\\\text {if } k = Y$$  \\nIn a general sense, this is the same model, except that here the i  terms represent Treatment 1 in every trial. In a trial that includes Treatment 1, this parameterisation is adequate, as ,1 i X  (the effect of X relative to itself) is zero. However, if any trial does not include treatment 1, then the model parameters cannot all be identified because there are three parameters to be estimated  from  only  two  arms.  Another  way  of  writing  an  MTC  model  that  has  appeared recently 52 has this same property. Models specified in this way should not be accepted unless  \\nthe  reference  treatment  is  the  same  treatment  in  every  trial,  and  therefore  appears  in  every trial.  \\nThe  instability  caused  by  this  parameterisation  can  be  avoided  if  a  model  is  placed  on  the baseline terms, i.e. 2 ~ ( , ) i m N m   rather than 2 ~ (0,100 ) i N  . However, this solution has a number of further difficulties and is not recommended (see TSD5 53 ).\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='April 2011 (last updated April 2012)  \\nSofia Dias 1 , Nicky J Welton 1 , Alex J Sutton 2 , AE Ades 1  \\n1 School  of  Social  and  Community  Medicine,  University  of  Bristol,  Canynge  Hall,  39 Whatley Road, Bristol BS8 2PS, UK  \\n2 Department  of  Health  Sciences,  University  of  Leicester,  2nd  Floor  Adrian  Building, University Road, Leicester LE1 7RH, UK  \\nDecision Support Unit, ScHARR, University of Sheffield, Regent Court, 30 Regent Street  \\nSheffield, S1 4DA Tel (+44) (0)114 222 0734  \\nE-mail dsuadmin@sheffield.ac.uk'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"The Decision Support Unit (DSU) is a collaboration between the Universities of Sheffield, York and Leicester. We also have members at the University of Bristol, London School of Hygiene and Tropical Medicine and Brunel University. The DSU is commissioned by The National  Institute  for  Health  and  Clinical  Excellence  (NICE)  to  provide  a  research  and training resource to support the Institute's Technology Appraisal Programme.  \\nPlease see our website for further information www.nicedsu.org.uk\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='The NICE Guide to the Methods of Technology Appraisal i is a regularly updated document that provides an overview of the key principles and methods of health technology assessment and  appraisal  for  use  in  NICE  appraisals.  The  Methods  Guide  does  not  provide  detailed advice  on  how  to  implement  and  apply  the  methods  it  describes.  This  DSU  series  of Technical  Support  Documents  (TSDs)  is  intended  to  complement  the  Methods  Guide  by providing detailed information on how to implement specific methods.  \\nThe TSDs provide a review of the current state of the art in each topic area, and make clear recommendations  on  the  implementation  of  methods  and  reporting  standards  where  it  is appropriate to do so. They aim to provide assistance to all those involved in submitting or critiquing evidence as part  of  NICE  Technology  Appraisals,  whether manufacturers, assessment groups or any other stakeholder type.  \\nWe recognise that there are areas of uncertainty, controversy and rapid development. It is our intention that such areas are indicated in the TSDs. All TSDs are extensively peer reviewed prior to publication (the names of peer reviewers appear in the acknowledgements for each document).  Nevertheless,  the  responsibility  for  each  TSD  lies  with  the  authors  and  we welcome any constructive feedback on the content or suggestions for further guides.  \\nPlease be aware that whilst the DSU is funded by NICE, these documents do not constitute formal NICE guidance or policy.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='Director of DSU and TSD series editor.  \\ni National  Institute  for  Health  and  Clinical  Excellence.  Guide  to  the  methods  of  technology  appraisal,  2008 (updated June 2008), London.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='The DSU thanks Julian Higgins, Alec Miners, Georgia Salanti, Mike Spencer and the team at NICE led by Janet Robertson for reviewing this document. The editor for the TSD series is Allan Wailoo.  \\nThe production of this document was funded by the National Institute for Health and Clinical Excellence  (NICE)  through  its  Decision  Support  Unit.  The  views,  and  any  errors  or omissions, expressed in this document are of the authors only. NICE may take account of part or all of this document if it considers it appropriate, but it is not bound to do so.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='Dias, S., Welton, N.J., Sutton, A.J., Ades, A.E. NICE DSU Technical Support Document 1: Introduction  to  evidence  synthesis  for  decision  making.  2011;  last  updated  April  2012; available from http://www.nicedsu.org.uk'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"This  document  serves  as  a  brief  introduction  and  orientation  to  the  series  of  Technical Support  Documents  on  Evidence  Synthesis.  It  describes  (Section  2)  the  overall  analytic approach to evidence synthesis, in terms of separate models for the 'baseline', that represents the  natural  history  in  the  specified  target  population  under  a  standard  comparator,  and  the model for the treatment effects relative to that standard. It then clarifies  the  impact  of  the decision  making  context  on  synthesis  methodology.  It  concludes  that,  in  order  for  the estimates of treatment effects to be appropriate for cost-effectiveness analysis and comparative  effectiveness  research  alike  (and  indeed  for  any  scientific  enquiry  into  the relative  efficacy  of  medical  interventions),  the  decision  maker  should  restrict  the  study inclusion criteria to a target patient population that has a relatively narrow definition. In the specific  context  of  cost-effectiveness  analysis,  the  document  then  refers  to  the  need  for synthesis methods that are compatible with the use of probabilistic methods.  \\nCriteria  for  inclusion  of  treatments  are  described  (Section  3),  distinguishing  between  the comparator set of treatments  in the decision analysis, and the comparator set of treatments used  in  synthesis.  Once  a  target  patient  population  has  been  defined,  a  suggested  trial inclusion  rule  that  avoids  potential  ambiguity  regarding  the  relevance  of  evidence  is  to include any trial that compares at least two treatments in the synthesis comparator set. We suggest  that  any  exceptions  to  this  should  require  special  justification.  Trials  with  small sample  sizes  or  trials  with  sample  size  motivated  for  particular  reasons  (such  as  'noninferiority  trials')  should  not  be  excluded  unless  specific  reasons  can  be  given.  Attention should  be  drawn  to  known  or  potential  effect  modifiers,  biases  in  the  trial  evidence,  or markers associated with risk of bias, as consideration should be given to the potential role of methods for addressing heterogeneity and bias. Some guidance is suggested on approaches that can be taken to disconnected evidence networks.  \\nSection 4 sets out some 'good practice' in presenting the evidence base for relative treatment effects, transparency and reproducibility of methods, presentation of results, and presentation of model critique and model selection. We encourage the use of network diagrams and tables to clarify exactly what comparative evidence is used in the relative efficacy synthesis, and the production of tables that show both the relative and the absolute effects of treatments that are taken forward for use in the cost-effectiveness analysis. Justification and explanation should  \\nbe  given  for  choice  of  statistical  model,  for  example  fixed  or  random  effects  synthesis. Sensitivity  analyses  should  be  used  to  explore  robustness  of  conclusions  to  variations  in assumptions, when the evidence is compatible with alternative interpretations or analyses. The document ends with a brief description of the other documents in the series.\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='| 1. INTRODUCTION.......................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1. INTRODUCTION.......................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 8                                                                                           |\\n|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|\\n| 2. OVERALL ANALYTIC APPROACH TO SYNTHESIS FOR COST EFFECTIVENESS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ANALYSIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ......................................................................................... 9 |\\n| 2.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | SEPARATE MODELS FOR BASELINE NATURALHISTORY AND FOR RELATIVE TREATMENT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                             |\\n| EFFECTS .............................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | EFFECTS .............................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 9                                                                                           |\\n| 2.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | THE DECISION-MAKINGCONTEXTAND METHODOLOGY FOR EVIDENCE SYNTHESIS......                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 9                                                                                           |\\n| 2.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | ANALYTIC METHODS COMPATIBLE WITH PROBABILISTIC COST-EFFECTIVENESS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                             |\\n| ANALYSIS.........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | ANALYSIS.........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11                                                                                          |\\n| 3. DATASET FOR EVIDENCE SYNTHESIS OF RELATIVE TREATMENT EFFECTS..........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 3. DATASET FOR EVIDENCE SYNTHESIS OF RELATIVE TREATMENT EFFECTS..........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 11                                                                                          |\\n| 3.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | COMPARATOR SETS FOR DECISIONAND FOR SYNTHESIS ...........................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12                                                                                          |\\n| 3.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | TRIAL INCLUSION AND EXCLUSION .........................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12                                                                                          |\\n| 3.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | EXTENSION OF THE SYNTHESIS COMPARATOR SET ...................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 14                                                                                          |\\n| 3.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | RECORDING OF TREATMENTEFFECTMODIFIERS ......................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15                                                                                          |\\n| 3.5.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | DEALING WITH DISCONNECTED NETWORKS.............................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 15                                                                                          |\\n| 4. PRESENTATION OF THE EVIDENCE AND THE RESULTS OF EVIDENCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 4. PRESENTATION OF THE EVIDENCE AND THE RESULTS OF EVIDENCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                             |\\n|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16                                                                                          |\\n| SYNTHESIS...................................................................................................................... 4.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | THE EVIDENCE BASE ..............................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 16                                                                                          |\\n| 4.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | DESCRIPTION OF SYNTHESIS METHODOLOGY...........................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 17                                                                                          |\\n| 4.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | PRESENTATION OF SYNTHESIS RESULTS ..................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 18                                                                                          |\\n| 4.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | MODELDIAGNOSIS AND SELECTION ........................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20                                                                                          |\\n| 5.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | USING THE TECHNICAL SUPPORT DOCUMENTS.........................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 20                                                                                          |\\n| 6.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | REFERENCES..........................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22                                                                                          |\\n| TABLES AND FIGURES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | TABLES AND FIGURES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | mean                                                                                        |\\n| Table 1 Certolizumab Pegol (CZP) for Rheumatoid Arthritis: 28 number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with Placebo, and mean disease duration (in years) for patients in each trial. Blank cells indicate that the treatment was not compared in that trial. All trial arms had Methotrexate in addition to the placebo or active treatment. .....17 Table 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5....................................18 Table 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the | Table 1 Certolizumab Pegol (CZP) for Rheumatoid Arthritis: 28 number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with Placebo, and mean disease duration (in years) for patients in each trial. Blank cells indicate that the treatment was not compared in that trial. All trial arms had Methotrexate in addition to the placebo or active treatment. .....17 Table 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5....................................18 Table 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the |                                                                                             |\\n| relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta- analysis and separate pairwise meta-analyses with fixed effects..............................................................19 Figure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in                                                                                                                                                                                                                                                                                                                                                                                                                                  | relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta- analysis and separate pairwise meta-analyses with fixed effects..............................................................19 Figure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                             |\\n| bold. Treatment X has been added to the synthesis set because it links treatment C to the rest of the network (dashed lines)...........................................................................................................................12 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | bold. Treatment X has been added to the synthesis set because it links treatment C to the rest of the network (dashed lines)...........................................................................................................................12 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                             |\\n| Figure one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments Xand Y................................................................................................................................16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Figure one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments Xand Y................................................................................................................................16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                             |\\n| Figure 3 Parkinson network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers trials making that comparison................................................................................................................19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Figure 3 Parkinson network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers trials making that comparison................................................................................................................19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | of                                                                                          |'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='CEA  \\nCost-effectiveness analysis  \\nCrI  \\nCredible interval  \\nDMARD  \\nDisease Modifying Anti-Rheumatics Drugs  \\nIPD  \\nIndividual patient data  \\nRCT  \\nRandomised controlled trial  \\nTSD  \\nTechnical Support Document'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"This  Technical  Support  Document  (TSD)  is  the  first  in  a  series  of  seven  documents  on evidence  synthesis  methods  in  decision  making.  These  are  intended  to  support  those presenting submissions to the National Institute for Health and Clinical Excellence (NICE). While the 2008 revision of the NICE Methods Guide 1 sets out what properties submissions should have,  the  evidence  synthesis  TSDs  show  how  the  required  analyses  can be implemented.  There  is  no  attempt  to  'prescribe'  the  form  that  analyses  must  take  or  the methods  that  must  be  used.  Any  methods  can  be  used,  as  long  as  they  have  the  required properties.  The  purpose  of  the  TSDs  is  to  further  explain  these  properties,  to  set  out  the implications for what kinds of analyses meet the requirements, and to describe some methods that can be used.  \\nThe series is intended primarily to address the issues of the relative and absolute efficacy of interventions.  Although oriented to the health technology appraisal process, they would  be equally  relevant  to  clinical  guideline  development,  or  to  comparisons  between  medical devices,  or  between  public  health  interventions.  The  series  does  not,  however,  cover questions arising in the synthesis of data on diagnostic test performance, or general synthesis of epidemiological data.  \\nThis  document  sets  the  scene  for  the  remaining  TSDs,  providing  a  general  outline  of  the overall  evidence  synthesis  process,  and  referring  forward  to  subsequent  TSDs  for  more detailed  information. We begin (Section 2) by describing the overall analytic approach, the distinction between a 'baseline' model, and the relative treatment effect usually informed by randomised  controlled  trial  (RCT)  evidence.  The  distinction  between  evidence  synthesis undertaken  specifically  for  decision  making  and  more  general  ideas  of  synthesis  as  a summary  of  what  appears  in  the  literature  is  also  explored.  Section  3  is  about  inclusion criteria for treatments and for trials. Here we suggest some simple rules that provide answers to questions such as: how far should an evidence network be extended? We also note the need to  address  potential  effect  modifiers  or  biases.  Section  4  deals  with  presentation  of  the evidence base, the synthesis methodology, the synthesis results, and the attention that must be given to model diagnosis and model choice. Finally, Section 5 provides a brief description of the  other  documents  in  the  series,  guiding  users  to  the  most  appropriate  document  for different analyses.\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"The  most  common  formula  that  is  followed  in  constructing  cost-effectiveness  analyses (CEAs)  is  to  divide  the  model  into  two  distinct  components:  a  'baseline'  natural  history model,  which  in  effect  represents  the  natural  history  of  patients  with  the  target  condition under  a  'standard'  comparator  treatment,  and  the  relative  treatment  effects.  The  natural history  for  the  'treatment  arms'  is  based  on  a  second  model  where  the  relative  treatment effects  are  appropriately  combined  with  the  baseline  model  to  generate  predicted  absolute effects for the non-standard treatments. The point in the natural history model at which the relative  effects  are  considered  to  act  depends  on  the  model.  In  models  for  Rheumatoid Arthritis, for example, the treatment effect generally acts on the probability that patients will stay  on  treatment  beyond  the  initial  3  to  6  months  trial  period. 2,3 In  models  of  smoking cessation, treatments are assumed to act on the probability of relapse within say 12 months. 4,5 A common, though not invariable feature of such natural history models is that, conditional on the initial response, the subsequent 'downstream' outcomes do not depend on treatment. Where  Markov  models  are  used,  treatment  effects  are  assumed  to  act  on  one  or  more transition probabilities.  \\nThe 2008 Methods Guide 1 requires that systematic literature search should be used to identify the data sources for both baseline, and relative treatment effects. TSD5 6 gives further details on methods for constructing the baseline model, while synthesis of relative effects is covered in TSD2. 7\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"The methods proposed throughout this series of documents are designed for decision making and, indeed, for probabilistic modelling (see below). It is important, however, to be clear that the decision making context impresses itself on evidence synthesis methodology in a way that goes far beyond the choice of analytic methods and software. A decision maker has to have in  \\nmind a well-defined decision problem . This will consist of a target population of individuals not only with a specific condition, but probably at a specific point in a disease progression pathway. Accompanying this there will be a set of comparator interventions. Each candidate intervention  has  to  consist  of  a  pre-specified  dosing  regimen  and/or  a  particular  mode  of delivery, possibly with concomitant treatments that must also be defined. There is latitude, of course, for dosing regimens that start at one level and may then be increased or decreased according to a pre-specified monitoring system. However, it has to be possible, at the end of the  CEA to ascribe a single cost and a single effect to each  intervention alternative. Costs may be variable, and if so they should be appropriately averaged. Effects may vary as well, and may need to be modelled. But, eventually, expected lifetime costs and effects must be calculable, if necessary under some set of clearly stated assumptions.  \\nAs  a  result  it  has  long  been  recognised  that  the  trial  inclusion  criteria  for  a  synthesis undertaken for decision making, whether based on CEA or on an efficacy analysis alone, 8 is likely  to  be  drawn  more  narrowly  than  for  syntheses  whose  objective  can  be  described, perhaps, as a summary of literature. Likewise, previous authors have distinguished between evidence synthesis as 'science' and evidence synthesis as 'summary', 9 and the common use of  random  effect  models  to  average  over  important  heterogeneity  has  attracted  particular criticism. 10 Expressing  a  similar  view,  the  Cochrane  Handbook 11 states:  'meta-analysis should only be considered when a group of studies is sufficiently homogeneous in terms of participants, interventions and outcomes to provide a meaningful summary'.  \\nNevertheless,  this  advice  is  not  always  followed.  For  example,  an  overview  of  reviews  of treatments for enuresis presented trials that involved young children who were being treated for the first time alongside trials of older children and adolescents who had failed on the firstline  treatments. 12 Similarly,  in  treatments  for  Rheumatoid  Arthritis,  one  cannot  assess  the relative efficacy of biologics by combining trials of biologics in patients who have failed on standard therapies, with trials of patients who have failed on biologics. 13 Summaries of effect sizes  in  these  cases  lack  validity  because  young  children  and  adolescents  with  enuresis,  or patients who are naïve to biologics and those who have failed on them, represent different clinical  populations  and  require  different  decisions,  informed  by  different  summaries  of treatment effects. The effect of the decision-making context, therefore, is often to markedly reduce the clinical heterogeneity of the trials assembled for synthesis.  \\nSynthesis of evidence from clinically heterogeneous populations, not only increases the risk of statistical heterogeneity and inconsistency, but often requires highly implausible assumptions, such as assuming that interventions are equally effective in a naïve population  \\nor in a population that has already failed on that intervention or has contra-indications to its use.  \\nThe focus of this series of TSDs is, therefore, to provide a formal underpinning of studies of relative  efficacy  in  specific  decision  contexts.  These  synthesis  methods  can  be  applied equally  well  within  CEA,  Comparative  Effectiveness  Research, 14 or  within  intermediate forms  of  analysis  that  attempt  to  weigh  the  benefits  of  treatments  against  harms. 15 What distinguishes the decision context from a literature summary rationale for synthesis appears to be the clinical heterogeneity and the degree to which it needs to be addressed. The methods we propose can be used outside what we have referred to as a decision making context, but certain  key  assumptions  (TSD2 7 )  may  not  hold.  Furthermore,  without  a  clearly  defined decision problem it is not clear how the results should be interpreted.\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='There are a wide range of methods for synthesising information on relative treatment effects. The  NICE  methods  guide 1 states  that  probabilistic  methods 16,17 are  preferred  for  costeffectiveness analyses. This puts some constraints, if not on the kinds of synthesis methods that must be used, then certainly on the way outputs from the synthesis are fed into the CEA. The  synthesis  methods  described  in  TSDs  2,  3  and  5  are  specifically  designed  to  be compatible with probabilistic CEA. A set of alternative approaches to incorporate the results from the synthesis into the CEA are described in TSD6. 18'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='Within the context of NICE Technology Appraisals or Guidelines, an initial scoping exercise will  have defined the target population(s)  for whom one or more decisions are to be made. The specification may refer, for example, to a stage of disease progression, a level of disease severity, previous treatments that have failed or that are contra-indicated for whatever reason, or  to  various  combinations  of  these.  The  wider  the  definition  of  the  target  population,  the greater  the  potential  for  clinical  and  statistical  heterogeneity,  as  discussed  in  Section  2, raising the possibility of different decisions in different groups of patients.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='An initial set of treatments that are to be compared will have been identified in the scoping exercise.  We will  call  this  the decision comparator set. Ideally,  this  should  include  all  the candidate  treatments  for  the  target  population  in  question.  If  it  is  not  possible  to  form  a connected network of comparisons of these treatments based on randomised data, it may be possible  to  introduce  further  treatments  so  that  a  connected  network  can  be  formed.  For example, in Figure 1 the treatments A and B have been compared in RCTs, but treatment C has  not  been  compared  to  either  A  or  B.  An  additional  treatment  X  has  been  introduced because  there  are  AX  and  CX  trials,  forming  a  connected  network.  Thus,  the synthesis comparator set consists of A, B, C, and X and is different from the decision comparator set A, B, C.  \\nOther ways to deal with disconnected networks are discussed in Section 3.5.  \\nFigure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in bold.  Treatment X has  been  added  to  the  synthesis  set  because  it  links  treatment  C  to  the  rest  of  the network (dashed lines).  \\n<!-- image -->'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"Once  the  target  population  and  the  synthesis  comparator  set  have  been  defined,  the  trial inclusion criteria are, in principle, relatively easy to implement. All trials on the target patient population that  compare  two  or  more  of  the  treatments  from  the  synthesis comparator  set should be included. This wording is constructed with the intent of producing an unambiguous definition that eliminates the risk of what could be perceived as 'gaming' with trial inclusion and exclusion criteria, that is, deliberately leaving out or including trials in order to obtain a particular result. It also clarifies that, even though the key comparisons might be considered  \\nto  be  those  involving  a  particular  active  treatment  and  one  or  more  standard  comparators, 'head-to-head' trials comparing similar active treatments must also be included. Note that if there was a three arm trial comparing A vs B vs Z, and treatment Z is not in the synthesis comparator set, the Z arm would be dropped as it adds no further information, but the A vs B comparison would be used, as long as it was on the same patient population. It is important to include all the trials that compare any of the treatments in the synthesis comparator set. This is  because  decisions  are  usually  based  on  an  incremental  CEA,  which  means  that,  for  any treatments  A,  B,  C,  trials  comparing  AB,  AC,  and  BC  must  all  be  considered  equally informative. Indeed,  in  this  context,  it  is  technically  impossible  to  distinguish  'direct'  and 'indirect'  evidence  -  direct  evidence  for  one  model  parameter  is  indirect  evidence  for another.  \\nIt  is  sometime  argued  that  trials  which  are  not  'double-blind',  or  trials  which  are  small should  be  excluded.  In  general,  no  trials  that  would  be  included  if  the  above  rules  were followed  should  be  excluded  without  a  clear  reason  being  given.  For  example,  one conceivable reason for excluding small trials might be on the basis that they were more likely to be biased, often termed 'small study bias', where trial size is used as a proxy for factors associating trial quality with increased effect size. However, in this case, it would be prudent to consider how sensitive the CEA would be to inclusion or exclusion of 'small' trials, and also what effect bias adjustment procedures might have (see TSD3 19 ). Another reason that is sometimes given for excluding a trial is on the basis that it was designed as a 'non-inferiority trial'.  This  is  not,  however, a  valid reason  for exclusion. The rationale  for the sample size calculations has no obvious connection to the size or direction of the effect estimate.  \\nAnother reason given for not including data is that outcomes are reported in a different way. We show in later documents 6,7,19 how different outcomes can in many cases be synthesized in a single coherent analysis, although this may not always be possible. However one frames the 'rules'  for  trial  inclusion  and  exclusion,  subjective  judgement  is  required  about  whether  a trial's target population does or does not match the target population for the present decision, or  there  may  be  doubts  on  whether  the  interventions  compared  are  sufficiently  similar  to those  defined  in  the  synthesis  comparator  set.  Investigators  may  wish  to  argue  that  the relative  treatment  effects  will  be  the  same  in  this  group  and  that  such  trials  should  be included, or that they are not, in which case they would be excluded. In such cases it may be possible  to  use  bias  or  covariate  adjustment  methods  (TSD3 19 ).  Alternatively,  some  of  the trial evidence could involve a mixture of patients, for example children and adults, while the target  population  for  decision  is  adults  alone.  Whether  or  not  such  evidence  should  be  \\nincluded depends on whether it can be used to inform the parameter of interest. Regression adjustment for the proportion of adults, for example, may be possible (see TSD3 19 ), but the comments on ecological  and  aggregation  biases  in  TSD3 19 (Section  1)  must  be  taken  into account.  Whenever  trial  inclusion  or  exclusion  is  debatable  or  depends  on  judgement, sensitivity analyses should be used to assess the impact on the decision.\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"It is  sometimes asked: how far should a network be extended? There is no specific need to extend the synthesis comparator set beyond the comparator set for decision making, unless such an extension is required to produce a connected network. Extending the network further does have potential advantages such as, for example, strengthening inference, 20 producing a more robust analysis which is less sensitive to specific sources of data, the ability to check consistency  more  thoroughly  (see  TSD4 21 ),  and  the  ability  to  identify  effect  modifiers  or carry out bias adjustment (see TSD3 19 ). Thus, while extension of the network is not ruled out, in  the  spirit  of  the  2008  Methods  Guide, 1 it  would  not  be  considered  as  the  'base-case' analysis.  Further,  counter-balancing  the  potential  advantages  outlined  above,  there  are  a number of potential dis advantages. These would include an increased danger of introducing effect modifiers as the more 'remotely' connected treatments are more likely to have been trialled  on  somewhat  different  patient  populations.  There  may  be  a  particular  danger  in extending the network to include treatments that were trialled earlier, particularly if - as is so often the case - date is associated with severity of condition.  \\nThe  situation  in  Figure  1,  where  a  new  treatment  is  introduced  to  connect  the  network, suggests an exception to the above. In this case, if the network could have been connected either by the addition of BY and CY trials, or by the addition of AX and CX trials, then it would seem logical that both X and Y should be added to the synthesis comparison set. Then, in accordance with the rules given for trial inclusion, X vs Y trials would need to be included as well.  \\nFinally,  another  reason for  extending  the  set  of  trials  beyond  the  set  of  immediate comparators  is  to  estimate  relationships  between  outcomes  and  use  this  to  fill  gaps  in  the evidence base. For example, a cost-effectiveness model for cancers may require information on  percent  responders,  on  time  to  tumour  progression,  and  time  to  death.  Some  of  this information may  not be reported within the synthesis comparator set. Under  these circumstances it may be possible to estimate the relationships from a wider set of trials, either  \\nin  the  same  statistical  analysis  (preferable)  or  separately,  and  then  apply  the  estimated relationship  to  the  treatments  where  it  is  missing.  This  approach  has  been  adopted  in advanced  breast  cancer 22 but  it  can  be  applied  in  any  situation  where  there  are  related multiple outcomes. Another example would be in treatments for influenza where trials may report one or more of time to end of fever, time to end of symptoms, time to return to work, and so on. 23,24 The advantage of these more complex forms of synthesis is that they provide more stable estimates where data are sparse, and allow investigators to produce estimates for less  commonly reported outcomes that are appropriately  'calibrated' to the available data. However, they require a range of assumptions, particularly regarding the constancy of certain relationships between outcomes, that need to be checked against expert clinical opinion, and wherever possible, empirically.\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='It is  important that investigators thoroughly research previous literature and consult clinical experts to assess whether there are known or likely treatment effect modifiers for any of the interventions in the comparator set for synthesis. The presence of effect modifiers in the trials should  be  recorded,  and  taken  into  consideration  during  the  synthesis,  as  they  may  have  a bearing  on  heterogeneity  and  bias  adjustment  (TSD3 19 )  or  inconsistency  in  networks (TSD4 21 ).'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"Although the focus of the TSDs is for situations where a connected evidence network can be constructed  from  randomised  evidence,  there  may  be  situations  like  the  one  depicted  in Figure 2 where the evidence forms two, or even more, disconnected elements. In these cases the methods described in TSD2 7 cannot be applied without further assumptions being made.  \\n<!-- image -->  \\nC  \\nFigure 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments X and Y.  \\nThese assumptions must take the form of a relative treatment effect linking the two networks. For example an assumption may be made about the relative efficacy of treatment X relative to A, of treatment Y relative to A, or of treatment X relative to B, and so on. From a technical point of view a distribution for such a treatment effect can readily be inserted into a synthesis (see  methods  for  shared  parameter  models  in  TSD2 7 )  and  expert  opinion  or  observational data  can  be  used  to  inform  the  treatment  effect. The  difficulty,  of  course,  lies  in  making  a convincing case for the central estimate of the 'missing' treatment effect and assigning it a variance that appropriately reflects the  increased  uncertainty attaching to a non-randomised comparison. The increased uncertainty will affect comparisons between, but not within, the two networks.\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='Where there are more than two treatments in the comparator set for synthesis, it is helpful to show  a  network  diagram  (such  as  Figure  1).  Software  for  automatically  drawing  such diagrams is available as stand-alone programs with multiple capabilities (e.g. Pajek 25 ) or as packages and routines developed for R 26 among other programs.  \\nFurther  refinements  in  network  diagrams  which  can  be  implemented  in  various  software include: adding the number of studies making that comparison to each connecting line (see Figure 3);  having  the  thickness  of  the  connecting  lines  reflect  the  number  of  trials  on  that  \\ncontrast  and  the  size  of  the  vertices  reflect  the  number  of  patients  included  in  that comparison. 27 A second useful presentation is a table of the sort shown as Table 1. This has a separate  row  for  each  trial,  with  columns  for  each  treatment  where  the  presence  of  data indicates which treatments have been compared in each trial arm. It is also convenient to add to  the  table  trial  level  covariate  values,  or  to  indicate  whether  individual  participant  data (IPD) are available. Another useful representation of the same data is given in TSD3. 19  \\nTable 1 Certolizumab Pegol (CZP) for Rheumatoid Arthritis: 28 number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with Placebo, and mean disease  duration  (in  years)  for  patients  in  each  trial.  Blank  cells  indicate  that  the  treatment  was  not compared in that trial. All trial arms had Methotrexate in addition to the placebo or active treatment.  \\n| Study Name     | Placebo   | CZP     | Adalimumab   | Etanercept   | Infliximab   | Rituximab   | Tocilizumab   |   Mean disease duration (years) |\\n|----------------|-----------|---------|--------------|--------------|--------------|-------------|---------------|---------------------------------|\\n| Kim 2007       | 9/63      |         | 28/65        |              |              |             |               |                           6.85  |\\n| DE019          | 19/200    |         | 81/207       |              |              |             |               |                          10.95  |\\n| ARMADA         | 5/62      |         | 37/67        |              |              |             |               |                          11.65  |\\n| RAPID 1        | 15/199    | 146/393 |              |              |              |             |               |                           6.15  |\\n| RAPID 2        | 4/127     | 80/246  |              |              |              |             |               |                           5.85  |\\n| START          | 33/363    |         |              |              | 110/360      |             |               |                           8.1   |\\n| ATTEST         | 22/110    |         |              |              | 61/165       |             |               |                           7.85  |\\n| Abe 2006*      | 0/47      |         |              |              | 15/49        |             |               |                           8.3   |\\n| Weinblatt 1999 | 1/30      |         |              | 23/59        |              |             |               |                          13     |\\n| Strand 2006    | 5/40      |         |              |              |              | 5/40        |               |                          11.25  |\\n| CHARISMA*      | 14/49     |         |              |              |              |             | 26/50         |                           0.915 |\\n| OPTION         | 22/204    |         |              |              |              |             | 90/205        |                           7.65  |  \\n* ACR50 at 3 months'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='In  the  interests  of  transparency,  reviewers  and  general  readers  must  be  provided  with sufficient information that would allow them to exactly reproduce the analyses, if they had access  to  the  data.  If  possible  journal  citations  for  the  precise  model  of  the  data  being assumed,  and/or  citation  of  the  source  of  software  code,  must  be  provided.  Otherwise  the statistical model for the synthesis should be set out fully in algebraic form. The software code used  for  the  synthesis  should  be  annotated  and  made  available,  along  with  the  data  used, although  in  some  situations confidentiality  requirements  may  prevent the  latter  from  being released.  \\nA clear discussion of the underlying statistical and clinical assumptions implied by the model, and  their  impact  on  the  final  decision  should  also  be  provided.  In  particular,  reasons  for  \\nchoosing  to  model  the  outcomes  on  a  particular  scale  (e.g.  odds  ratio,  hazard  ratio,  risk difference  etc)  and  the  assumptions  implied  in  any  transformation  from  the  relative  to  the absolute effects should be clearly presented (see TSD2 7 , Section 2).'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"Although the parameters required  by the  CEA tend to be the absolute treatment effects of each treatment, it  is  essential that both the relative treatment effects, which are the outputs from  the  evidence  synthesis,  and  the  absolute  effects  on  which  the  CEA  is  based  are presented.  It  is  important  for  those  reviewing  and  evaluating  submissions  that  there  is absolute clarity  and  transparency  about  exactly  what  relative  efficacies  between  treatments are being assumed, and exactly what absolute effects are going forward into the CEA. This can  be  achieved  in  a  number  of  ways.  Perhaps  the  simplest  method  is  a  table  of  the  mean treatment effect with 95% Credible Intervals (CrI), of every treatment relative to placebo, or to a standard comparator. Table 2 gives an example, of the relative and absolute mean offtime reduction in patients given four dopamine agonists and Placebo as adjunct therapy for Parkinson's disease. The treatment network is presented in Figure 3 (for further details see TSD2 7 , Example 5).  \\nTable 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the  mean off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5.  \\n|             |             | mean                                          | sd                                            | 95% CrI                                       |\\n|-------------|-------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|\\n| X           | Y           | Relative effects of treatment Y compared to X | Relative effects of treatment Y compared to X | Relative effects of treatment Y compared to X |\\n| Placebo     | Treatment 2 | -1.81                                         | 0.33                                          | (-2.46,-1.16)                                 |\\n| Placebo     | Treatment 3 | -0.47                                         | 0.49                                          | (-1.43,0.49)                                  |\\n| Placebo     | Treatment 4 | -0.52                                         | 0.48                                          | (-1.46,0.43)                                  |\\n| Placebo     | Treatment 5 | -0.82                                         | 0.52                                          | (-1.84,0.22)                                  |\\n|             |             | Absolute treatment effects                    | Absolute treatment effects                    | Absolute treatment effects                    |\\n| Placebo     | Placebo     | -0.73                                         | 0.22                                          | (-1.16,-0.30)                                 |\\n| Treatment 2 | Treatment 2 | -2.54                                         | 0.40                                          | (-3.32,-1.76)                                 |\\n| Treatment 3 | Treatment 3 | -1.21                                         | 0.53                                          | (-2.25,-0.15)                                 |\\n| Treatment 4 | Treatment 4 | -1.25                                         | 0.53                                          | (-2.28,-0.21)                                 |\\n| Treatment 5 | Treatment 5 | -1.55                                         | 0.57                                          | (-2.66,-0.43)                                 |  \\n<!-- image -->  \\nTreatment 3  \\nFigure  3  Parkinson  network:  each  edge  represents  a  treatment,  connecting  lines  indicate  pairs  of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers of trials making that comparison.  \\nAnother format (Table 3) allows investigators to contrast results of pair-wise meta-analyses with  the  results  of  a  network  synthesis.  Although  this  table  does  not  constitute  a  formal analysis of inconsistency in the network (see TSD4 21 ), if the direct estimates are very close to their  network counter-parts, there  may  be  no need to proceed with further consideration of inconsistency. Similarly, graphical displays such as forest plots which summarise the results in  the  tables  along  with  the  raw  effect  estimates  from  each  trial  informing  that  treatment comparison, can also be presented. TSD3 19 shows an example of these plots (Example 2 in the Appendix).  \\nTable 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta-analysis and separate pairwise meta-analyses with fixed effects.  \\n|             |             | Network Meta-analysis   | Network Meta-analysis   | Network Meta-analysis   | Pairwise Meta-analyses   | Pairwise Meta-analyses   | Pairwise Meta-analyses   |\\n|-------------|-------------|-------------------------|-------------------------|-------------------------|--------------------------|--------------------------|--------------------------|\\n| X           | Y           | mean                    | sd                      | 95% CrI                 | mean                     | sd                       | 95% CrI                  |\\n| Placebo     | Treatment 2 | -1.81                   | 0.33                    | (-2.46,-1.16)           | -1.83                    | 0.34                     | (-2.49,-1.17)            |\\n| Placebo     | Treatment 3 | -0.47                   | 0.49                    | (-1.43,0.49)            | -0.31                    | 0.67                     | (-1.62,1.00)             |\\n| Placebo     | Treatment 4 | -0.52                   | 0.48                    | (-1.46,0.43)            | -0.90                    | 0.69                     | (-2.26,0.46)             |\\n| Placebo     | Treatment 5 | -0.82                   | 0.52                    | (-1.84,0.22)            | -                        | -                        | -                        |\\n| Treatment 2 | Treatment 3 | 1.34                    | 0.54                    | (0.28,2.41)             | -                        | -                        | -                        |\\n| Treatment 2 | Treatment 4 | 1.29                    | 0.52                    | (0.27,2.32)             | 1.40                     | 0.70                     | (0.03,2.77)              |\\n| Treatment 2 | Treatment 5 | 0.99                    | 0.56                    | (-0.10,2.10)            | -                        | -                        | -                        |\\n| Treatment 3 | Treatment 4 | -0.04                   | 0.32                    | (-0.68,0.59)            | 0.00                     | 0.35                     | (-0.68,0.68)             |\\n| Treatment 3 | Treatment 5 | -0.34                   | 0.38                    | (-1.10,0.41)            | -                        | -                        | -                        |\\n| Treatment 4 | Treatment 5 | -0.30                   | 0.21                    | (-0.71,0.11)            | -0.30                    | 0.21                     | (-0.71,0.11)             |  \\nA number of authors tabulate the probability that each treatment is best, which is an output available  from  Bayesian or other simulation-based approaches. This should be treated with  \\ngreat caution, however, particularly when there are many treatment alternatives. A treatment whose mean effect ranks quite low may still have a high probability of being best if there is relatively more uncertainty in its mean effect. This is misleading because for a given set of expected  (mean)  treatment  effects,  greater  uncertainty  may  flatter  a  treatment.  Differences between  treatments  in  probability  of  being  best  of  less  than  90%  cannot  be  given  much credence. A more reliable indicator is a plot of the rankings of each treatment. When there are multiple  outcomes,  for  example  remission,  relapse,  discontinuation  due  to  side  effects, 'rankograms'  for  each  treatment,  which  plot  the  ranks  on  each  outcome,  can  be  very informative. Readers are referred to Cipriani et al. 29 , where these plots first appeared, and to Ades  et  al. 30 for  a  further  application.  Salanti  et  al. 31 suggest  a  number  of  graphical presentations of results that may be useful in different circumstances.\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"It is essential that the model that is chosen is compatible with the evidence. While questions of statistical  inference  are  less relevant  in decision  making, where a  'balance of evidence' approach, takes precedence over 'significance testing', the question of whether the model fits the data is still relevant. Decisions must be based on an internally coherent model, which is compatible with all the available evidence. Methods for assessing model fit are discussed in TSD2, 7 and  there  is  a  discussion  of  heterogeneity  and  outlier  detection  in  TSD3. 19 Where several synthesis models were examined, an explanation must be provided for the choice of model  that  is  put  forward  into  the  CEA.  Choice  of  fixed  or  random  effects  models  for synthesis of relative treatment effects is a common example (see TSD2 7 ). Where the evidence is  compatible  with  more  than  one  model,  a  sensitivity  analysis  can  be  used  to  establish whether or not the CEA results are sensitive to model choice.\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"TSD2 7 presents  a  general  framework  for  pairwise  and  network  meta-analysis  for  different data  types,  with  details  of  fixed  and  random  effects  models  for  different  outcome  types, assumptions and applications. It highlights the importance of using the appropriate model for the type of data available and shows how to combine data given in different formats.  \\nTSD3 19 considers  outlier  detection  and  covariate  and  bias  adjustment  in  detail. Models  for different  types  of  regression  in  both  pairwise  and  network  meta-analysis  are  given  with  a  \\ndiscussion  of  the  assumptions  and  risks  of  meta-regression,  as  well  as  its  implications  for decision-making.  \\nTSD4 21 defines  inconsistency  in  a  network  meta-analysis.  It  describes  how  to  detect  and locate inconsistency, its likely causes and steps that should be taken to avoid it.  \\nTSD5 6 provides  guidance  on  how  a  baseline  model  can  be  informed  and  built,  discusses sources of evidence which can be used to inform a baseline model, and provides examples of baseline models.  \\nTSDs 2, 3, 4 and 5 include an extensive set of worked examples of analyses using Bayesian Markov  chain  Monte  Carlo  methods  in  WinBUGS  and  provide  generic  code  applied  to illustrative  examples.  The  WinBUGS  code  is  also  available  for  download  as  WinBUGS system (.odc) files (users are advised to download these files instead of copying and pasting code from the TSDs).  \\nAlthough  the  models,  worked  examples  and  WinBUGS  code  in  TSDs  3,  4  and  5  are  for binary data, TSD2 shows how they can be changed to suit other types of data.  \\nTSD6 18 describes some of the software which can be used to implement the models described in TSDs 2 to 5 and to incorporate the results of the evidence synthesis into a decision model.  \\nFinally, TSD7 32 provides a reviewer's checklist. It focuses on a series of questions aimed at revealing the assumptions underlying the synthesis, the adequacy of the arguments in support of these assumptions, and aims to inform a decision on the need for further analyses.\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"1.   National  Institute  for  health  and  Clinical  Excellence.  Guide  to  the  methods  of technology appraisal (updated June 2008). 2008.\\n2.   Brennan,  A.,  Bansback,  N.,  Nixon,  R.,  Madan,  J.,  Harrison,  M.,  Watson,  K.  et  al. Modelling  the  cost  effectiveness  of  TNF-alpha  antagonists  in  the  management  of rheumatoid  arthritis:  results  from  the  British  Society  for  Rheumatology  Biologics Registry. Rheumatology 2007; 46:1345-1354.\\n3.   Woolacott, N.F., Bravo Vergel, Y., Hawkins, N., Kainth, A., Khadjesari, Z., Misso, K. et  al.  Etanercept  and  infliximab  for  the  treatment  of  psoriatic  arthritis:  a  systematic review and economic evaluation. Health Technology Assessment 2006; 10(31).\\n4.   Woolacott, N.F., Jones, L., Ford, C.A., Mather, L.C., Sowden, A.J., Song, F.J. et al. The clinical  effectiveness  and  cost-effectiveness  of  buproprion  and  nicotine  replacement therapy  for  smoking  cessation:  a  systematic  review  and  economic  evaluation. Health Technology Assessment 2002; 6(16):1-245.\\n5.   Wang, D., Connock, M., Barton, P., Fry-Smith, A., Aveyard, P., Moore, D. 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis. Health Technology Assessment 2008; 12(2).\\n6.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  5:  Evidence  synthesis  in  the  baseline  natural  history  model.  2011;  last updated April 2012; available from http://www.nicedsu.org.uk\\n7.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  2:  A  generalised  linear  modelling  framework  for  pair-wise  and  network meta-analysis of randomised controlled trials. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n8.   Eccles,  M.,  Freemantle,  N.,  Mason,  J.  Using  systematic  reviews  in  clinical  guideline development. In: Egger M., Davey Smith G., Altman D.G., eds. Systematic Reviews in Health Care: meta-analysis in context . Second ed. BMJ; London: 2001; 400-409.\\n9.   Rubin, D.B. A new perspective. In: Wachter K.W., Straf M.L., eds. The Future of Metaanalysis . Russell Sage Foundation; New York: 1990.\\n10.   Greenland,  S.  Invited  commentary:  A  critical  look  at  some  popular  meta-analytic methods. American Journal Of Epidemiology 1994; 140(3):290-296.\\n11.   Higgins, J.P.T., Green, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, Wiley, Chichester; 2008.\\n12.   Russell,  K.,  Kiddoo,  D.  The  Cochrane  library  and  nocturnal  enuresis:  an  umbrella review. Evidence-Based Child Health: a Cochrane Review Journal 2006; 1(1):5-8.  \\n13.   Wells,  G.A.,  Sultan,  S.A.,  Chen,  L.,  Khan,  M.,  Coyle,  D.  Indirect  Evidence:  Indirect Treatment Comparisons in Meta-Analysis. Cochrane Database of Systematic Reviews 2009. Ottawa, Canadian Agency for Drugs and Technologies in Health.\\n14.   Iglehart, J.K. Prioritizing comparative-effectiveness research - IOM recommendations. New England Journal of Medicine 2009; 361:325-328.\\n15.   Glasziou,  P.P.,  Irwig,  L.M.  An  evidence-based  approach  to  individualising  treatment. British Medical Journal 1995; 311:1356-1359.\\n16.   Doubilet,  P.,  Begg,  C.B.,  Weinstein,  M.C.,  Braun,  P.,  McNeill,  B.J.  Probabilistic sensitivity  analysis  using  Monte  Carlo  simulation:  a  practical  approach. Medical Decision Making 1985; 5:157-177.\\n17.   Critchfield,  G.C.,  Willard,  K.E.  Probabilistic  analysis  of  decision  trees  using  Monte Carlo simulation. Med Decis Making, MED 1986; 6:85-92.\\n18.   Dias,  S.,  Sutton,  A.J.,  Welton,  N.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document 6: Embedding evidence synthesis in probabilistic cost-effectiveness analysis: software choices. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n19.   Dias,  S.,  Sutton,  A.J.,  Welton,  N.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  3:  Heterogeneity:  subgroups,  meta-regression,  bias  and  bias-adjustment. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n20.   Cooper,  N.J.,  Peters,  J.,  Lai,  M.C.W.,  Juni,  P.,  Wandel,  S.,  Palmer,  S.  et  al.  How valuable  are  multiple  treatment  comparison  methods  in  evidence-based  health-care evaluation? Value in Health 2011; 14:371-380.\\n21.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Caldwell,  D.M.,  Lu,  G.,  Ades,  A.E.  NICE  DSU Technical  Support  Document  4:  Inconsistency  in  networks  of  evidence  based  on randomised controlled trials. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n22.   Welton,  N.J.,  Willis,  S.R.,  Ades,  A.E.  Synthesis  of  Survival  and  Disease  Progression Outcomes for Health Technology Assessment of Cancer Therapies. Research Synthesis Methods 2010; 1:239-257.\\n23.   Welton, N.J., Cooper, N.J., Ades, A.E., Lu, G., Sutton, A.J. Mixed  treatment comparison with multiple outcomes reported inconsistently across trials: evaluation of antivirals  for  treatment  of  influenza  A  and  B. Statistics  In  Medicine 2008;  27:56205639.\\n24.   Burch, J., Paulden, M., Conti, S., Stock, C., Corbette, M., Welton, N.J. et al. Antiviral drugs  for  the  treatment  of  influenza:  a  systematic  review  and  economic  evaluation. Health Technology Assesment 2010; 13(58):1-290.\\n25.   Batagelj,  V.,  Mrvar,  A.  Pajek  -  Program  for  Large  Network  Analysis. Connections 1998; 21(2):47-57.  \\n26.   R:  A  Language  and  Environment  for  Statistical  Computing  [  Windows.  Vienna, Austria: R Foundation for Statistical Computing; 2010.\\n27.   Salanti, G. Multiple-treatments meta-analysis of a network of interventions. http://www mtm uoi gr/ 2011;  Available from http://www.mtm.uoi.gr/\\n28.   National  Institute  for  health  and  Clinical  Excellence.  Certolizumab  pegol  for  the treatment  of  rheumatoid  arthritis.  2010;  TA186.    National  Institute  for  Health  and Clinical Excellence. NICE technology appraisal guidance.\\n29.   Cipriani, A., Furukawa, T.A., Salanti, G., Geddes, J.R., Higgins, J.P.T., Churchill, R. et al.  Comparative  efficacy  and  acceptability  of  12  new  generation  antidepressants:  a multiple-treatments meta-analysis. Lancet 2009; 373:746-758.\\n30.   Ades,  A.E.,  Mavranezouli,  I.,  Dias,  S.,  Welton,  N.J.,  Whittington,  C.,  Kendall,  T. Network meta-analysis with competing risk outcomes. Value in Health 2010; 13(8):976-983.\\n31.   Salanti, G., Ades, A.E., Ioannidis, J.P.A. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011; 64:163-171.\\n32.   Ades, A.E., Caldwell, D.M., Reken, S., Welton, N.J., Sutton, A.J., Dias, S. NICE DSU Technical  Support  Document  7:  Evidence  synthesis  of  treatment  efficacy  in  decision making: a reviewer's checklist. 2012; available from http://www.nicedsu.org.uk\")]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "mkd_docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "014666d4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from langchain_community.vectorstores import FAISS\n",
    "import faiss\n",
    "from langchain_openai import OpenAIEmbeddings, ChatOpenAI\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "ec4e1ebd",
   "metadata": {},
   "outputs": [],
   "source": [
    "embedding = OpenAIEmbeddings(model=\"text-embedding-3-small\")\n",
    "vdb = FAISS.from_documents(mkd_docs, embedding)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "4bb85fa2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "faiss.swigfaiss_avx2.IndexFlatL2"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(vdb.index)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "169e59f4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(id='2d3ec963-7c4f-4402-856a-721c00672ba3', metadata={'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"## NICE DSU TECHNICAL SUPPORT DOCUMENT 1: INTRODUCTION TO EVIDENCE SYNTHESIS FOR DECISION MAKING\\n\\n## REPORT BY THE DECISION SUPPORT UNIT\\n\\nApril 2011 (last updated April 2012)\\n\\nSofia Dias 1 , Nicky J Welton 1 , Alex J Sutton 2 , AE Ades 1\\n\\n1 School  of  Social  and  Community  Medicine,  University  of  Bristol,  Canynge  Hall,  39 Whatley Road, Bristol BS8 2PS, UK\\n\\n2 Department  of  Health  Sciences,  University  of  Leicester,  2nd  Floor  Adrian  Building, University Road, Leicester LE1 7RH, UK\\n\\nDecision Support Unit, ScHARR, University of Sheffield, Regent Court, 30 Regent Street\\n\\nSheffield, S1 4DA Tel (+44) (0)114 222 0734\\n\\nE-mail dsuadmin@sheffield.ac.uk\\n\\n## ABOUT THE DECISION SUPPORT UNIT\\n\\nThe Decision Support Unit (DSU) is a collaboration between the Universities of Sheffield, York and Leicester. We also have members at the University of Bristol, London School of Hygiene and Tropical Medicine and Brunel University. The DSU is commissioned by The National  Institute  for  Health  and  Clinical  Excellence  (NICE)  to  provide  a  research  and training resource to support the Institute's Technology Appraisal Programme.\\n\\nPlease see our website for further information www.nicedsu.org.uk\\n\\n## ABOUT THE TECHNICAL SUPPORT DOCUMENT SERIES\\n\\nThe NICE Guide to the Methods of Technology Appraisal i is a regularly updated document that provides an overview of the key principles and methods of health technology assessment and  appraisal  for  use  in  NICE  appraisals.  The  Methods  Guide  does  not  provide  detailed advice  on  how  to  implement  and  apply  the  methods  it  describes.  This  DSU  series  of Technical  Support  Documents  (TSDs)  is  intended  to  complement  the  Methods  Guide  by providing detailed information on how to implement specific methods.\\n\\nThe TSDs provide a review of the current state of the art in each topic area, and make clear recommendations  on  the  implementation  of  methods  and  reporting  standards  where  it  is appropriate to do so. They aim to provide assistance to all those involved in submitting or critiquing evidence as part  of  NICE  Technology  Appraisals,  whether manufacturers, assessment groups or any other stakeholder type.\\n\\nWe recognise that there are areas of uncertainty, controversy and rapid development. It is our intention that such areas are indicated in the TSDs. All TSDs are extensively peer reviewed prior to publication (the names of peer reviewers appear in the acknowledgements for each document).  Nevertheless,  the  responsibility  for  each  TSD  lies  with  the  authors  and  we welcome any constructive feedback on the content or suggestions for further guides.\\n\\nPlease be aware that whilst the DSU is funded by NICE, these documents do not constitute formal NICE guidance or policy.\\n\\n## Dr Allan Wailoo\\n\\nDirector of DSU and TSD series editor.\\n\\ni National  Institute  for  Health  and  Clinical  Excellence.  Guide  to  the  methods  of  technology  appraisal,  2008 (updated June 2008), London.\\n\\n## Acknowledgements\\n\\nThe DSU thanks Julian Higgins, Alec Miners, Georgia Salanti, Mike Spencer and the team at NICE led by Janet Robertson for reviewing this document. The editor for the TSD series is Allan Wailoo.\\n\\nThe production of this document was funded by the National Institute for Health and Clinical Excellence  (NICE)  through  its  Decision  Support  Unit.  The  views,  and  any  errors  or omissions, expressed in this document are of the authors only. NICE may take account of part or all of this document if it considers it appropriate, but it is not bound to do so.\\n\\n## This report should be referenced as follows:\\n\\nDias, S., Welton, N.J., Sutton, A.J., Ades, A.E. NICE DSU Technical Support Document 1: Introduction  to  evidence  synthesis  for  decision  making.  2011;  last  updated  April  2012; available from http://www.nicedsu.org.uk\\n\\n## EXECUTIVE SUMMARY\\n\\nThis  document  serves  as  a  brief  introduction  and  orientation  to  the  series  of  Technical Support  Documents  on  Evidence  Synthesis.  It  describes  (Section  2)  the  overall  analytic approach to evidence synthesis, in terms of separate models for the 'baseline', that represents the  natural  history  in  the  specified  target  population  under  a  standard  comparator,  and  the model for the treatment effects relative to that standard. It then clarifies  the  impact  of  the decision  making  context  on  synthesis  methodology.  It  concludes  that,  in  order  for  the estimates of treatment effects to be appropriate for cost-effectiveness analysis and comparative  effectiveness  research  alike  (and  indeed  for  any  scientific  enquiry  into  the relative  efficacy  of  medical  interventions),  the  decision  maker  should  restrict  the  study inclusion criteria to a target patient population that has a relatively narrow definition. In the specific  context  of  cost-effectiveness  analysis,  the  document  then  refers  to  the  need  for synthesis methods that are compatible with the use of probabilistic methods.\\n\\nCriteria  for  inclusion  of  treatments  are  described  (Section  3),  distinguishing  between  the comparator set of treatments  in the decision analysis, and the comparator set of treatments used  in  synthesis.  Once  a  target  patient  population  has  been  defined,  a  suggested  trial inclusion  rule  that  avoids  potential  ambiguity  regarding  the  relevance  of  evidence  is  to include any trial that compares at least two treatments in the synthesis comparator set. We suggest  that  any  exceptions  to  this  should  require  special  justification.  Trials  with  small sample  sizes  or  trials  with  sample  size  motivated  for  particular  reasons  (such  as  'noninferiority  trials')  should  not  be  excluded  unless  specific  reasons  can  be  given.  Attention should  be  drawn  to  known  or  potential  effect  modifiers,  biases  in  the  trial  evidence,  or markers associated with risk of bias, as consideration should be given to the potential role of methods for addressing heterogeneity and bias. Some guidance is suggested on approaches that can be taken to disconnected evidence networks.\\n\\nSection 4 sets out some 'good practice' in presenting the evidence base for relative treatment effects, transparency and reproducibility of methods, presentation of results, and presentation of model critique and model selection. We encourage the use of network diagrams and tables to clarify exactly what comparative evidence is used in the relative efficacy synthesis, and the production of tables that show both the relative and the absolute effects of treatments that are taken forward for use in the cost-effectiveness analysis. Justification and explanation should\\n\\nbe  given  for  choice  of  statistical  model,  for  example  fixed  or  random  effects  synthesis. Sensitivity  analyses  should  be  used  to  explore  robustness  of  conclusions  to  variations  in assumptions, when the evidence is compatible with alternative interpretations or analyses. The document ends with a brief description of the other documents in the series.\\n\\n## CONTENTS\\n\\n| 1. INTRODUCTION.......................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1. INTRODUCTION.......................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 8                                                                                           |\\n|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|\\n| 2. OVERALL ANALYTIC APPROACH TO SYNTHESIS FOR COST EFFECTIVENESS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ANALYSIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ......................................................................................... 9 |\\n| 2.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | SEPARATE MODELS FOR BASELINE NATURALHISTORY AND FOR RELATIVE TREATMENT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                             |\\n| EFFECTS .............................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | EFFECTS .............................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 9                                                                                           |\\n| 2.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | THE DECISION-MAKINGCONTEXTAND METHODOLOGY FOR EVIDENCE SYNTHESIS......                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 9                                                                                           |\\n| 2.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | ANALYTIC METHODS COMPATIBLE WITH PROBABILISTIC COST-EFFECTIVENESS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                             |\\n| ANALYSIS.........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | ANALYSIS.........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11                                                                                          |\\n| 3. DATASET FOR EVIDENCE SYNTHESIS OF RELATIVE TREATMENT EFFECTS..........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 3. DATASET FOR EVIDENCE SYNTHESIS OF RELATIVE TREATMENT EFFECTS..........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 11                                                                                          |\\n| 3.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | COMPARATOR SETS FOR DECISIONAND FOR SYNTHESIS ...........................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12                                                                                          |\\n| 3.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | TRIAL INCLUSION AND EXCLUSION .........................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12                                                                                          |\\n| 3.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | EXTENSION OF THE SYNTHESIS COMPARATOR SET ...................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 14                                                                                          |\\n| 3.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | RECORDING OF TREATMENTEFFECTMODIFIERS ......................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15                                                                                          |\\n| 3.5.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | DEALING WITH DISCONNECTED NETWORKS.............................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 15                                                                                          |\\n| 4. PRESENTATION OF THE EVIDENCE AND THE RESULTS OF EVIDENCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 4. PRESENTATION OF THE EVIDENCE AND THE RESULTS OF EVIDENCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                             |\\n|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16                                                                                          |\\n| SYNTHESIS...................................................................................................................... 4.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | THE EVIDENCE BASE ..............................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 16                                                                                          |\\n| 4.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | DESCRIPTION OF SYNTHESIS METHODOLOGY...........................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 17                                                                                          |\\n| 4.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | PRESENTATION OF SYNTHESIS RESULTS ..................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 18                                                                                          |\\n| 4.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | MODELDIAGNOSIS AND SELECTION ........................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20                                                                                          |\\n| 5.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | USING THE TECHNICAL SUPPORT DOCUMENTS.........................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 20                                                                                          |\\n| 6.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | REFERENCES..........................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22                                                                                          |\\n| TABLES AND FIGURES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | TABLES AND FIGURES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | mean                                                                                        |\\n| Table 1 Certolizumab Pegol (CZP) for Rheumatoid Arthritis: 28 number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with Placebo, and mean disease duration (in years) for patients in each trial. Blank cells indicate that the treatment was not compared in that trial. All trial arms had Methotrexate in addition to the placebo or active treatment. .....17 Table 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5....................................18 Table 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the | Table 1 Certolizumab Pegol (CZP) for Rheumatoid Arthritis: 28 number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with Placebo, and mean disease duration (in years) for patients in each trial. Blank cells indicate that the treatment was not compared in that trial. All trial arms had Methotrexate in addition to the placebo or active treatment. .....17 Table 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5....................................18 Table 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the |                                                                                             |\\n| relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta- analysis and separate pairwise meta-analyses with fixed effects..............................................................19 Figure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in                                                                                                                                                                                                                                                                                                                                                                                                                                  | relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta- analysis and separate pairwise meta-analyses with fixed effects..............................................................19 Figure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                             |\\n| bold. Treatment X has been added to the synthesis set because it links treatment C to the rest of the network (dashed lines)...........................................................................................................................12 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | bold. Treatment X has been added to the synthesis set because it links treatment C to the rest of the network (dashed lines)...........................................................................................................................12 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                             |\\n| Figure one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments Xand Y................................................................................................................................16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Figure one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments Xand Y................................................................................................................................16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                             |\\n| Figure 3 Parkinson network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers trials making that comparison................................................................................................................19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Figure 3 Parkinson network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers trials making that comparison................................................................................................................19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | of                                                                                          |\\n\\n## Abbreviations and definitions\\n\\nCEA\\n\\nCost-effectiveness analysis\\n\\nCrI\\n\\nCredible interval\\n\\nDMARD\\n\\nDisease Modifying Anti-Rheumatics Drugs\\n\\nIPD\\n\\nIndividual patient data\\n\\nRCT\\n\\nRandomised controlled trial\\n\\nTSD\\n\\nTechnical Support Document\\n\\n## 1. INTRODUCTION\\n\\nThis  Technical  Support  Document  (TSD)  is  the  first  in  a  series  of  seven  documents  on evidence  synthesis  methods  in  decision  making.  These  are  intended  to  support  those presenting submissions to the National Institute for Health and Clinical Excellence (NICE). While the 2008 revision of the NICE Methods Guide 1 sets out what properties submissions should have,  the  evidence  synthesis  TSDs  show  how  the  required  analyses  can be implemented.  There  is  no  attempt  to  'prescribe'  the  form  that  analyses  must  take  or  the methods  that  must  be  used.  Any  methods  can  be  used,  as  long  as  they  have  the  required properties.  The  purpose  of  the  TSDs  is  to  further  explain  these  properties,  to  set  out  the implications for what kinds of analyses meet the requirements, and to describe some methods that can be used.\\n\\nThe series is intended primarily to address the issues of the relative and absolute efficacy of interventions.  Although oriented to the health technology appraisal process, they would  be equally  relevant  to  clinical  guideline  development,  or  to  comparisons  between  medical devices,  or  between  public  health  interventions.  The  series  does  not,  however,  cover questions arising in the synthesis of data on diagnostic test performance, or general synthesis of epidemiological data.\\n\\nThis  document  sets  the  scene  for  the  remaining  TSDs,  providing  a  general  outline  of  the overall  evidence  synthesis  process,  and  referring  forward  to  subsequent  TSDs  for  more detailed  information. We begin (Section 2) by describing the overall analytic approach, the distinction between a 'baseline' model, and the relative treatment effect usually informed by randomised  controlled  trial  (RCT)  evidence.  The  distinction  between  evidence  synthesis undertaken  specifically  for  decision  making  and  more  general  ideas  of  synthesis  as  a summary  of  what  appears  in  the  literature  is  also  explored.  Section  3  is  about  inclusion criteria for treatments and for trials. Here we suggest some simple rules that provide answers to questions such as: how far should an evidence network be extended? We also note the need to  address  potential  effect  modifiers  or  biases.  Section  4  deals  with  presentation  of  the evidence base, the synthesis methodology, the synthesis results, and the attention that must be given to model diagnosis and model choice. Finally, Section 5 provides a brief description of the  other  documents  in  the  series,  guiding  users  to  the  most  appropriate  document  for different analyses.\\n\\n## 2. OVERALL ANALYTIC APPROACH TO SYNTHESIS FOR COST EFFECTIVENESS ANALYSIS\\n\\n## 2.1. SEPARATE MODELS FOR BASELINE NATURAL HISTORY AND FOR RELATIVE TREATMENT EFFECTS\\n\\nThe  most  common  formula  that  is  followed  in  constructing  cost-effectiveness  analyses (CEAs)  is  to  divide  the  model  into  two  distinct  components:  a  'baseline'  natural  history model,  which  in  effect  represents  the  natural  history  of  patients  with  the  target  condition under  a  'standard'  comparator  treatment,  and  the  relative  treatment  effects.  The  natural history  for  the  'treatment  arms'  is  based  on  a  second  model  where  the  relative  treatment effects  are  appropriately  combined  with  the  baseline  model  to  generate  predicted  absolute effects for the non-standard treatments. The point in the natural history model at which the relative  effects  are  considered  to  act  depends  on  the  model.  In  models  for  Rheumatoid Arthritis, for example, the treatment effect generally acts on the probability that patients will stay  on  treatment  beyond  the  initial  3  to  6  months  trial  period. 2,3 In  models  of  smoking cessation, treatments are assumed to act on the probability of relapse within say 12 months. 4,5 A common, though not invariable feature of such natural history models is that, conditional on the initial response, the subsequent 'downstream' outcomes do not depend on treatment. Where  Markov  models  are  used,  treatment  effects  are  assumed  to  act  on  one  or  more transition probabilities.\\n\\nThe 2008 Methods Guide 1 requires that systematic literature search should be used to identify the data sources for both baseline, and relative treatment effects. TSD5 6 gives further details on methods for constructing the baseline model, while synthesis of relative effects is covered in TSD2. 7\\n\\n## 2.2. THE  DECISION-MAKING  CONTEXT  AND  METHODOLOGY  FOR  EVIDENCE SYNTHESIS\\n\\nThe methods proposed throughout this series of documents are designed for decision making and, indeed, for probabilistic modelling (see below). It is important, however, to be clear that the decision making context impresses itself on evidence synthesis methodology in a way that goes far beyond the choice of analytic methods and software. A decision maker has to have in\\n\\nmind a well-defined decision problem . This will consist of a target population of individuals not only with a specific condition, but probably at a specific point in a disease progression pathway. Accompanying this there will be a set of comparator interventions. Each candidate intervention  has  to  consist  of  a  pre-specified  dosing  regimen  and/or  a  particular  mode  of delivery, possibly with concomitant treatments that must also be defined. There is latitude, of course, for dosing regimens that start at one level and may then be increased or decreased according to a pre-specified monitoring system. However, it has to be possible, at the end of the  CEA to ascribe a single cost and a single effect to each  intervention alternative. Costs may be variable, and if so they should be appropriately averaged. Effects may vary as well, and may need to be modelled. But, eventually, expected lifetime costs and effects must be calculable, if necessary under some set of clearly stated assumptions.\\n\\nAs  a  result  it  has  long  been  recognised  that  the  trial  inclusion  criteria  for  a  synthesis undertaken for decision making, whether based on CEA or on an efficacy analysis alone, 8 is likely  to  be  drawn  more  narrowly  than  for  syntheses  whose  objective  can  be  described, perhaps, as a summary of literature. Likewise, previous authors have distinguished between evidence synthesis as 'science' and evidence synthesis as 'summary', 9 and the common use of  random  effect  models  to  average  over  important  heterogeneity  has  attracted  particular criticism. 10 Expressing  a  similar  view,  the  Cochrane  Handbook 11 states:  'meta-analysis should only be considered when a group of studies is sufficiently homogeneous in terms of participants, interventions and outcomes to provide a meaningful summary'.\\n\\nNevertheless,  this  advice  is  not  always  followed.  For  example,  an  overview  of  reviews  of treatments for enuresis presented trials that involved young children who were being treated for the first time alongside trials of older children and adolescents who had failed on the firstline  treatments. 12 Similarly,  in  treatments  for  Rheumatoid  Arthritis,  one  cannot  assess  the relative efficacy of biologics by combining trials of biologics in patients who have failed on standard therapies, with trials of patients who have failed on biologics. 13 Summaries of effect sizes  in  these  cases  lack  validity  because  young  children  and  adolescents  with  enuresis,  or patients who are naïve to biologics and those who have failed on them, represent different clinical  populations  and  require  different  decisions,  informed  by  different  summaries  of treatment effects. The effect of the decision-making context, therefore, is often to markedly reduce the clinical heterogeneity of the trials assembled for synthesis.\\n\\nSynthesis of evidence from clinically heterogeneous populations, not only increases the risk of statistical heterogeneity and inconsistency, but often requires highly implausible assumptions, such as assuming that interventions are equally effective in a naïve population\\n\\nor in a population that has already failed on that intervention or has contra-indications to its use.\\n\\nThe focus of this series of TSDs is, therefore, to provide a formal underpinning of studies of relative  efficacy  in  specific  decision  contexts.  These  synthesis  methods  can  be  applied equally  well  within  CEA,  Comparative  Effectiveness  Research, 14 or  within  intermediate forms  of  analysis  that  attempt  to  weigh  the  benefits  of  treatments  against  harms. 15 What distinguishes the decision context from a literature summary rationale for synthesis appears to be the clinical heterogeneity and the degree to which it needs to be addressed. The methods we propose can be used outside what we have referred to as a decision making context, but certain  key  assumptions  (TSD2 7 )  may  not  hold.  Furthermore,  without  a  clearly  defined decision problem it is not clear how the results should be interpreted.\\n\\n## 2.3. ANALYTIC METHODS COMPATIBLE WITH PROBABILISTIC COSTEFFECTIVENESS ANALYSIS.\\n\\nThere are a wide range of methods for synthesising information on relative treatment effects. The  NICE  methods  guide 1 states  that  probabilistic  methods 16,17 are  preferred  for  costeffectiveness analyses. This puts some constraints, if not on the kinds of synthesis methods that must be used, then certainly on the way outputs from the synthesis are fed into the CEA. The  synthesis  methods  described  in  TSDs  2,  3  and  5  are  specifically  designed  to  be compatible with probabilistic CEA. A set of alternative approaches to incorporate the results from the synthesis into the CEA are described in TSD6. 18\\n\\n## 3. DATASET FOR EVIDENCE SYNTHESIS OF RELATIVE TREATMENT EFFECTS\\n\\nWithin the context of NICE Technology Appraisals or Guidelines, an initial scoping exercise will  have defined the target population(s)  for whom one or more decisions are to be made. The specification may refer, for example, to a stage of disease progression, a level of disease severity, previous treatments that have failed or that are contra-indicated for whatever reason, or  to  various  combinations  of  these.  The  wider  the  definition  of  the  target  population,  the greater  the  potential  for  clinical  and  statistical  heterogeneity,  as  discussed  in  Section  2, raising the possibility of different decisions in different groups of patients.\\n\\n## 3.1. COMPARATOR SETS FOR DECISION AND FOR SYNTHESIS\\n\\nAn initial set of treatments that are to be compared will have been identified in the scoping exercise.  We will  call  this  the decision comparator set. Ideally,  this  should  include  all  the candidate  treatments  for  the  target  population  in  question.  If  it  is  not  possible  to  form  a connected network of comparisons of these treatments based on randomised data, it may be possible  to  introduce  further  treatments  so  that  a  connected  network  can  be  formed.  For example, in Figure 1 the treatments A and B have been compared in RCTs, but treatment C has  not  been  compared  to  either  A  or  B.  An  additional  treatment  X  has  been  introduced because  there  are  AX  and  CX  trials,  forming  a  connected  network.  Thus,  the synthesis comparator set consists of A, B, C, and X and is different from the decision comparator set A, B, C.\\n\\nOther ways to deal with disconnected networks are discussed in Section 3.5.\\n\\nFigure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in bold.  Treatment X has  been  added  to  the  synthesis  set  because  it  links  treatment  C  to  the  rest  of  the network (dashed lines).\\n\\n<!-- image -->\\n\\n## 3.2. TRIAL INCLUSION AND EXCLUSION\\n\\nOnce  the  target  population  and  the  synthesis  comparator  set  have  been  defined,  the  trial inclusion criteria are, in principle, relatively easy to implement. All trials on the target patient population that  compare  two  or  more  of  the  treatments  from  the  synthesis comparator  set should be included. This wording is constructed with the intent of producing an unambiguous definition that eliminates the risk of what could be perceived as 'gaming' with trial inclusion and exclusion criteria, that is, deliberately leaving out or including trials in order to obtain a particular result. It also clarifies that, even though the key comparisons might be considered\\n\\nto  be  those  involving  a  particular  active  treatment  and  one  or  more  standard  comparators, 'head-to-head' trials comparing similar active treatments must also be included. Note that if there was a three arm trial comparing A vs B vs Z, and treatment Z is not in the synthesis comparator set, the Z arm would be dropped as it adds no further information, but the A vs B comparison would be used, as long as it was on the same patient population. It is important to include all the trials that compare any of the treatments in the synthesis comparator set. This is  because  decisions  are  usually  based  on  an  incremental  CEA,  which  means  that,  for  any treatments  A,  B,  C,  trials  comparing  AB,  AC,  and  BC  must  all  be  considered  equally informative. Indeed,  in  this  context,  it  is  technically  impossible  to  distinguish  'direct'  and 'indirect'  evidence  -  direct  evidence  for  one  model  parameter  is  indirect  evidence  for another.\\n\\nIt  is  sometime  argued  that  trials  which  are  not  'double-blind',  or  trials  which  are  small should  be  excluded.  In  general,  no  trials  that  would  be  included  if  the  above  rules  were followed  should  be  excluded  without  a  clear  reason  being  given.  For  example,  one conceivable reason for excluding small trials might be on the basis that they were more likely to be biased, often termed 'small study bias', where trial size is used as a proxy for factors associating trial quality with increased effect size. However, in this case, it would be prudent to consider how sensitive the CEA would be to inclusion or exclusion of 'small' trials, and also what effect bias adjustment procedures might have (see TSD3 19 ). Another reason that is sometimes given for excluding a trial is on the basis that it was designed as a 'non-inferiority trial'.  This  is  not,  however, a  valid reason  for exclusion. The rationale  for the sample size calculations has no obvious connection to the size or direction of the effect estimate.\\n\\nAnother reason given for not including data is that outcomes are reported in a different way. We show in later documents 6,7,19 how different outcomes can in many cases be synthesized in a single coherent analysis, although this may not always be possible. However one frames the 'rules'  for  trial  inclusion  and  exclusion,  subjective  judgement  is  required  about  whether  a trial's target population does or does not match the target population for the present decision, or  there  may  be  doubts  on  whether  the  interventions  compared  are  sufficiently  similar  to those  defined  in  the  synthesis  comparator  set.  Investigators  may  wish  to  argue  that  the relative  treatment  effects  will  be  the  same  in  this  group  and  that  such  trials  should  be included, or that they are not, in which case they would be excluded. In such cases it may be possible  to  use  bias  or  covariate  adjustment  methods  (TSD3 19 ).  Alternatively,  some  of  the trial evidence could involve a mixture of patients, for example children and adults, while the target  population  for  decision  is  adults  alone.  Whether  or  not  such  evidence  should  be\\n\\nincluded depends on whether it can be used to inform the parameter of interest. Regression adjustment for the proportion of adults, for example, may be possible (see TSD3 19 ), but the comments on ecological  and  aggregation  biases  in  TSD3 19 (Section  1)  must  be  taken  into account.  Whenever  trial  inclusion  or  exclusion  is  debatable  or  depends  on  judgement, sensitivity analyses should be used to assess the impact on the decision.\\n\\n## 3.3. EXTENSION OF THE SYNTHESIS COMPARATOR SET\\n\\nIt is  sometimes asked: how far should a network be extended? There is no specific need to extend the synthesis comparator set beyond the comparator set for decision making, unless such an extension is required to produce a connected network. Extending the network further does have potential advantages such as, for example, strengthening inference, 20 producing a more robust analysis which is less sensitive to specific sources of data, the ability to check consistency  more  thoroughly  (see  TSD4 21 ),  and  the  ability  to  identify  effect  modifiers  or carry out bias adjustment (see TSD3 19 ). Thus, while extension of the network is not ruled out, in  the  spirit  of  the  2008  Methods  Guide, 1 it  would  not  be  considered  as  the  'base-case' analysis.  Further,  counter-balancing  the  potential  advantages  outlined  above,  there  are  a number of potential dis advantages. These would include an increased danger of introducing effect modifiers as the more 'remotely' connected treatments are more likely to have been trialled  on  somewhat  different  patient  populations.  There  may  be  a  particular  danger  in extending the network to include treatments that were trialled earlier, particularly if - as is so often the case - date is associated with severity of condition.\\n\\nThe  situation  in  Figure  1,  where  a  new  treatment  is  introduced  to  connect  the  network, suggests an exception to the above. In this case, if the network could have been connected either by the addition of BY and CY trials, or by the addition of AX and CX trials, then it would seem logical that both X and Y should be added to the synthesis comparison set. Then, in accordance with the rules given for trial inclusion, X vs Y trials would need to be included as well.\\n\\nFinally,  another  reason for  extending  the  set  of  trials  beyond  the  set  of  immediate comparators  is  to  estimate  relationships  between  outcomes  and  use  this  to  fill  gaps  in  the evidence base. For example, a cost-effectiveness model for cancers may require information on  percent  responders,  on  time  to  tumour  progression,  and  time  to  death.  Some  of  this information may  not be reported within the synthesis comparator set. Under  these circumstances it may be possible to estimate the relationships from a wider set of trials, either\\n\\nin  the  same  statistical  analysis  (preferable)  or  separately,  and  then  apply  the  estimated relationship  to  the  treatments  where  it  is  missing.  This  approach  has  been  adopted  in advanced  breast  cancer 22 but  it  can  be  applied  in  any  situation  where  there  are  related multiple outcomes. Another example would be in treatments for influenza where trials may report one or more of time to end of fever, time to end of symptoms, time to return to work, and so on. 23,24 The advantage of these more complex forms of synthesis is that they provide more stable estimates where data are sparse, and allow investigators to produce estimates for less  commonly reported outcomes that are appropriately  'calibrated' to the available data. However, they require a range of assumptions, particularly regarding the constancy of certain relationships between outcomes, that need to be checked against expert clinical opinion, and wherever possible, empirically.\\n\\n## 3.4. RECORDING OF TREATMENT EFFECT MODIFIERS\\n\\nIt is  important that investigators thoroughly research previous literature and consult clinical experts to assess whether there are known or likely treatment effect modifiers for any of the interventions in the comparator set for synthesis. The presence of effect modifiers in the trials should  be  recorded,  and  taken  into  consideration  during  the  synthesis,  as  they  may  have  a bearing  on  heterogeneity  and  bias  adjustment  (TSD3 19 )  or  inconsistency  in  networks (TSD4 21 ).\\n\\n## 3.5. DEALING WITH DISCONNECTED NETWORKS\\n\\nAlthough the focus of the TSDs is for situations where a connected evidence network can be constructed  from  randomised  evidence,  there  may  be  situations  like  the  one  depicted  in Figure 2 where the evidence forms two, or even more, disconnected elements. In these cases the methods described in TSD2 7 cannot be applied without further assumptions being made.\\n\\n<!-- image -->\\n\\nC\\n\\nFigure 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments X and Y.\\n\\nThese assumptions must take the form of a relative treatment effect linking the two networks. For example an assumption may be made about the relative efficacy of treatment X relative to A, of treatment Y relative to A, or of treatment X relative to B, and so on. From a technical point of view a distribution for such a treatment effect can readily be inserted into a synthesis (see  methods  for  shared  parameter  models  in  TSD2 7 )  and  expert  opinion  or  observational data  can  be  used  to  inform  the  treatment  effect. The  difficulty,  of  course,  lies  in  making  a convincing case for the central estimate of the 'missing' treatment effect and assigning it a variance that appropriately reflects the  increased  uncertainty attaching to a non-randomised comparison. The increased uncertainty will affect comparisons between, but not within, the two networks.\\n\\n## 4. PRESENTATION OF THE EVIDENCE AND THE RESULTS OF EVIDENCE SYNTHESIS\\n\\n## 4.1. THE EVIDENCE BASE\\n\\nWhere there are more than two treatments in the comparator set for synthesis, it is helpful to show  a  network  diagram  (such  as  Figure  1).  Software  for  automatically  drawing  such diagrams is available as stand-alone programs with multiple capabilities (e.g. Pajek 25 ) or as packages and routines developed for R 26 among other programs.\\n\\nFurther  refinements  in  network  diagrams  which  can  be  implemented  in  various  software include: adding the number of studies making that comparison to each connecting line (see Figure 3);  having  the  thickness  of  the  connecting  lines  reflect  the  number  of  trials  on  that\\n\\ncontrast  and  the  size  of  the  vertices  reflect  the  number  of  patients  included  in  that comparison. 27 A second useful presentation is a table of the sort shown as Table 1. This has a separate  row  for  each  trial,  with  columns  for  each  treatment  where  the  presence  of  data indicates which treatments have been compared in each trial arm. It is also convenient to add to  the  table  trial  level  covariate  values,  or  to  indicate  whether  individual  participant  data (IPD) are available. Another useful representation of the same data is given in TSD3. 19\\n\\nTable 1 Certolizumab Pegol (CZP) for Rheumatoid Arthritis: 28 number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with Placebo, and mean disease  duration  (in  years)  for  patients  in  each  trial.  Blank  cells  indicate  that  the  treatment  was  not compared in that trial. All trial arms had Methotrexate in addition to the placebo or active treatment.\\n\\n| Study Name     | Placebo   | CZP     | Adalimumab   | Etanercept   | Infliximab   | Rituximab   | Tocilizumab   |   Mean disease duration (years) |\\n|----------------|-----------|---------|--------------|--------------|--------------|-------------|---------------|---------------------------------|\\n| Kim 2007       | 9/63      |         | 28/65        |              |              |             |               |                           6.85  |\\n| DE019          | 19/200    |         | 81/207       |              |              |             |               |                          10.95  |\\n| ARMADA         | 5/62      |         | 37/67        |              |              |             |               |                          11.65  |\\n| RAPID 1        | 15/199    | 146/393 |              |              |              |             |               |                           6.15  |\\n| RAPID 2        | 4/127     | 80/246  |              |              |              |             |               |                           5.85  |\\n| START          | 33/363    |         |              |              | 110/360      |             |               |                           8.1   |\\n| ATTEST         | 22/110    |         |              |              | 61/165       |             |               |                           7.85  |\\n| Abe 2006*      | 0/47      |         |              |              | 15/49        |             |               |                           8.3   |\\n| Weinblatt 1999 | 1/30      |         |              | 23/59        |              |             |               |                          13     |\\n| Strand 2006    | 5/40      |         |              |              |              | 5/40        |               |                          11.25  |\\n| CHARISMA*      | 14/49     |         |              |              |              |             | 26/50         |                           0.915 |\\n| OPTION         | 22/204    |         |              |              |              |             | 90/205        |                           7.65  |\\n\\n* ACR50 at 3 months\\n\\n## 4.2. DESCRIPTION OF SYNTHESIS METHODOLOGY\\n\\nIn  the  interests  of  transparency,  reviewers  and  general  readers  must  be  provided  with sufficient information that would allow them to exactly reproduce the analyses, if they had access  to  the  data.  If  possible  journal  citations  for  the  precise  model  of  the  data  being assumed,  and/or  citation  of  the  source  of  software  code,  must  be  provided.  Otherwise  the statistical model for the synthesis should be set out fully in algebraic form. The software code used  for  the  synthesis  should  be  annotated  and  made  available,  along  with  the  data  used, although  in  some  situations confidentiality  requirements  may  prevent the  latter  from  being released.\\n\\nA clear discussion of the underlying statistical and clinical assumptions implied by the model, and  their  impact  on  the  final  decision  should  also  be  provided.  In  particular,  reasons  for\\n\\nchoosing  to  model  the  outcomes  on  a  particular  scale  (e.g.  odds  ratio,  hazard  ratio,  risk difference  etc)  and  the  assumptions  implied  in  any  transformation  from  the  relative  to  the absolute effects should be clearly presented (see TSD2 7 , Section 2).\\n\\n## 4.3. PRESENTATION OF SYNTHESIS RESULTS\\n\\nAlthough the parameters required  by the  CEA tend to be the absolute treatment effects of each treatment, it  is  essential that both the relative treatment effects, which are the outputs from  the  evidence  synthesis,  and  the  absolute  effects  on  which  the  CEA  is  based  are presented.  It  is  important  for  those  reviewing  and  evaluating  submissions  that  there  is absolute clarity  and  transparency  about  exactly  what  relative  efficacies  between  treatments are being assumed, and exactly what absolute effects are going forward into the CEA. This can  be  achieved  in  a  number  of  ways.  Perhaps  the  simplest  method  is  a  table  of  the  mean treatment effect with 95% Credible Intervals (CrI), of every treatment relative to placebo, or to a standard comparator. Table 2 gives an example, of the relative and absolute mean offtime reduction in patients given four dopamine agonists and Placebo as adjunct therapy for Parkinson's disease. The treatment network is presented in Figure 3 (for further details see TSD2 7 , Example 5).\\n\\nTable 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the  mean off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5.\\n\\n|             |             | mean                                          | sd                                            | 95% CrI                                       |\\n|-------------|-------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|\\n| X           | Y           | Relative effects of treatment Y compared to X | Relative effects of treatment Y compared to X | Relative effects of treatment Y compared to X |\\n| Placebo     | Treatment 2 | -1.81                                         | 0.33                                          | (-2.46,-1.16)                                 |\\n| Placebo     | Treatment 3 | -0.47                                         | 0.49                                          | (-1.43,0.49)                                  |\\n| Placebo     | Treatment 4 | -0.52                                         | 0.48                                          | (-1.46,0.43)                                  |\\n| Placebo     | Treatment 5 | -0.82                                         | 0.52                                          | (-1.84,0.22)                                  |\\n|             |             | Absolute treatment effects                    | Absolute treatment effects                    | Absolute treatment effects                    |\\n| Placebo     | Placebo     | -0.73                                         | 0.22                                          | (-1.16,-0.30)                                 |\\n| Treatment 2 | Treatment 2 | -2.54                                         | 0.40                                          | (-3.32,-1.76)                                 |\\n| Treatment 3 | Treatment 3 | -1.21                                         | 0.53                                          | (-2.25,-0.15)                                 |\\n| Treatment 4 | Treatment 4 | -1.25                                         | 0.53                                          | (-2.28,-0.21)                                 |\\n| Treatment 5 | Treatment 5 | -1.55                                         | 0.57                                          | (-2.66,-0.43)                                 |\\n\\n<!-- image -->\\n\\nTreatment 3\\n\\nFigure  3  Parkinson  network:  each  edge  represents  a  treatment,  connecting  lines  indicate  pairs  of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers of trials making that comparison.\\n\\nAnother format (Table 3) allows investigators to contrast results of pair-wise meta-analyses with  the  results  of  a  network  synthesis.  Although  this  table  does  not  constitute  a  formal analysis of inconsistency in the network (see TSD4 21 ), if the direct estimates are very close to their  network counter-parts, there  may  be  no need to proceed with further consideration of inconsistency. Similarly, graphical displays such as forest plots which summarise the results in  the  tables  along  with  the  raw  effect  estimates  from  each  trial  informing  that  treatment comparison, can also be presented. TSD3 19 shows an example of these plots (Example 2 in the Appendix).\\n\\nTable 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta-analysis and separate pairwise meta-analyses with fixed effects.\\n\\n|             |             | Network Meta-analysis   | Network Meta-analysis   | Network Meta-analysis   | Pairwise Meta-analyses   | Pairwise Meta-analyses   | Pairwise Meta-analyses   |\\n|-------------|-------------|-------------------------|-------------------------|-------------------------|--------------------------|--------------------------|--------------------------|\\n| X           | Y           | mean                    | sd                      | 95% CrI                 | mean                     | sd                       | 95% CrI                  |\\n| Placebo     | Treatment 2 | -1.81                   | 0.33                    | (-2.46,-1.16)           | -1.83                    | 0.34                     | (-2.49,-1.17)            |\\n| Placebo     | Treatment 3 | -0.47                   | 0.49                    | (-1.43,0.49)            | -0.31                    | 0.67                     | (-1.62,1.00)             |\\n| Placebo     | Treatment 4 | -0.52                   | 0.48                    | (-1.46,0.43)            | -0.90                    | 0.69                     | (-2.26,0.46)             |\\n| Placebo     | Treatment 5 | -0.82                   | 0.52                    | (-1.84,0.22)            | -                        | -                        | -                        |\\n| Treatment 2 | Treatment 3 | 1.34                    | 0.54                    | (0.28,2.41)             | -                        | -                        | -                        |\\n| Treatment 2 | Treatment 4 | 1.29                    | 0.52                    | (0.27,2.32)             | 1.40                     | 0.70                     | (0.03,2.77)              |\\n| Treatment 2 | Treatment 5 | 0.99                    | 0.56                    | (-0.10,2.10)            | -                        | -                        | -                        |\\n| Treatment 3 | Treatment 4 | -0.04                   | 0.32                    | (-0.68,0.59)            | 0.00                     | 0.35                     | (-0.68,0.68)             |\\n| Treatment 3 | Treatment 5 | -0.34                   | 0.38                    | (-1.10,0.41)            | -                        | -                        | -                        |\\n| Treatment 4 | Treatment 5 | -0.30                   | 0.21                    | (-0.71,0.11)            | -0.30                    | 0.21                     | (-0.71,0.11)             |\\n\\nA number of authors tabulate the probability that each treatment is best, which is an output available  from  Bayesian or other simulation-based approaches. This should be treated with\\n\\ngreat caution, however, particularly when there are many treatment alternatives. A treatment whose mean effect ranks quite low may still have a high probability of being best if there is relatively more uncertainty in its mean effect. This is misleading because for a given set of expected  (mean)  treatment  effects,  greater  uncertainty  may  flatter  a  treatment.  Differences between  treatments  in  probability  of  being  best  of  less  than  90%  cannot  be  given  much credence. A more reliable indicator is a plot of the rankings of each treatment. When there are multiple  outcomes,  for  example  remission,  relapse,  discontinuation  due  to  side  effects, 'rankograms'  for  each  treatment,  which  plot  the  ranks  on  each  outcome,  can  be  very informative. Readers are referred to Cipriani et al. 29 , where these plots first appeared, and to Ades  et  al. 30 for  a  further  application.  Salanti  et  al. 31 suggest  a  number  of  graphical presentations of results that may be useful in different circumstances.\\n\\n## 4.4. MODEL DIAGNOSIS AND SELECTION\\n\\nIt is essential that the model that is chosen is compatible with the evidence. While questions of statistical  inference  are  less relevant  in decision  making, where a  'balance of evidence' approach, takes precedence over 'significance testing', the question of whether the model fits the data is still relevant. Decisions must be based on an internally coherent model, which is compatible with all the available evidence. Methods for assessing model fit are discussed in TSD2, 7 and  there  is  a  discussion  of  heterogeneity  and  outlier  detection  in  TSD3. 19 Where several synthesis models were examined, an explanation must be provided for the choice of model  that  is  put  forward  into  the  CEA.  Choice  of  fixed  or  random  effects  models  for synthesis of relative treatment effects is a common example (see TSD2 7 ). Where the evidence is  compatible  with  more  than  one  model,  a  sensitivity  analysis  can  be  used  to  establish whether or not the CEA results are sensitive to model choice.\\n\\n## 5. USING THE TECHNICAL SUPPORT DOCUMENTS\\n\\nTSD2 7 presents  a  general  framework  for  pairwise  and  network  meta-analysis  for  different data  types,  with  details  of  fixed  and  random  effects  models  for  different  outcome  types, assumptions and applications. It highlights the importance of using the appropriate model for the type of data available and shows how to combine data given in different formats.\\n\\nTSD3 19 considers  outlier  detection  and  covariate  and  bias  adjustment  in  detail. Models  for different  types  of  regression  in  both  pairwise  and  network  meta-analysis  are  given  with  a\\n\\ndiscussion  of  the  assumptions  and  risks  of  meta-regression,  as  well  as  its  implications  for decision-making.\\n\\nTSD4 21 defines  inconsistency  in  a  network  meta-analysis.  It  describes  how  to  detect  and locate inconsistency, its likely causes and steps that should be taken to avoid it.\\n\\nTSD5 6 provides  guidance  on  how  a  baseline  model  can  be  informed  and  built,  discusses sources of evidence which can be used to inform a baseline model, and provides examples of baseline models.\\n\\nTSDs 2, 3, 4 and 5 include an extensive set of worked examples of analyses using Bayesian Markov  chain  Monte  Carlo  methods  in  WinBUGS  and  provide  generic  code  applied  to illustrative  examples.  The  WinBUGS  code  is  also  available  for  download  as  WinBUGS system (.odc) files (users are advised to download these files instead of copying and pasting code from the TSDs).\\n\\nAlthough  the  models,  worked  examples  and  WinBUGS  code  in  TSDs  3,  4  and  5  are  for binary data, TSD2 shows how they can be changed to suit other types of data.\\n\\nTSD6 18 describes some of the software which can be used to implement the models described in TSDs 2 to 5 and to incorporate the results of the evidence synthesis into a decision model.\\n\\nFinally, TSD7 32 provides a reviewer's checklist. It focuses on a series of questions aimed at revealing the assumptions underlying the synthesis, the adequacy of the arguments in support of these assumptions, and aims to inform a decision on the need for further analyses.\\n\\n## 6. REFERENCES\\n\\n1.   National  Institute  for  health  and  Clinical  Excellence.  Guide  to  the  methods  of technology appraisal (updated June 2008). 2008.\\n2.   Brennan,  A.,  Bansback,  N.,  Nixon,  R.,  Madan,  J.,  Harrison,  M.,  Watson,  K.  et  al. Modelling  the  cost  effectiveness  of  TNF-alpha  antagonists  in  the  management  of rheumatoid  arthritis:  results  from  the  British  Society  for  Rheumatology  Biologics Registry. Rheumatology 2007; 46:1345-1354.\\n3.   Woolacott, N.F., Bravo Vergel, Y., Hawkins, N., Kainth, A., Khadjesari, Z., Misso, K. et  al.  Etanercept  and  infliximab  for  the  treatment  of  psoriatic  arthritis:  a  systematic review and economic evaluation. Health Technology Assessment 2006; 10(31).\\n4.   Woolacott, N.F., Jones, L., Ford, C.A., Mather, L.C., Sowden, A.J., Song, F.J. et al. The clinical  effectiveness  and  cost-effectiveness  of  buproprion  and  nicotine  replacement therapy  for  smoking  cessation:  a  systematic  review  and  economic  evaluation. Health Technology Assessment 2002; 6(16):1-245.\\n5.   Wang, D., Connock, M., Barton, P., Fry-Smith, A., Aveyard, P., Moore, D. 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis. Health Technology Assessment 2008; 12(2).\\n6.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  5:  Evidence  synthesis  in  the  baseline  natural  history  model.  2011;  last updated April 2012; available from http://www.nicedsu.org.uk\\n7.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  2:  A  generalised  linear  modelling  framework  for  pair-wise  and  network meta-analysis of randomised controlled trials. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n8.   Eccles,  M.,  Freemantle,  N.,  Mason,  J.  Using  systematic  reviews  in  clinical  guideline development. In: Egger M., Davey Smith G., Altman D.G., eds. Systematic Reviews in Health Care: meta-analysis in context . Second ed. BMJ; London: 2001; 400-409.\\n9.   Rubin, D.B. A new perspective. In: Wachter K.W., Straf M.L., eds. The Future of Metaanalysis . Russell Sage Foundation; New York: 1990.\\n10.   Greenland,  S.  Invited  commentary:  A  critical  look  at  some  popular  meta-analytic methods. American Journal Of Epidemiology 1994; 140(3):290-296.\\n11.   Higgins, J.P.T., Green, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, Wiley, Chichester; 2008.\\n12.   Russell,  K.,  Kiddoo,  D.  The  Cochrane  library  and  nocturnal  enuresis:  an  umbrella review. Evidence-Based Child Health: a Cochrane Review Journal 2006; 1(1):5-8.\\n\\n13.   Wells,  G.A.,  Sultan,  S.A.,  Chen,  L.,  Khan,  M.,  Coyle,  D.  Indirect  Evidence:  Indirect Treatment Comparisons in Meta-Analysis. Cochrane Database of Systematic Reviews 2009. Ottawa, Canadian Agency for Drugs and Technologies in Health.\\n14.   Iglehart, J.K. Prioritizing comparative-effectiveness research - IOM recommendations. New England Journal of Medicine 2009; 361:325-328.\\n15.   Glasziou,  P.P.,  Irwig,  L.M.  An  evidence-based  approach  to  individualising  treatment. British Medical Journal 1995; 311:1356-1359.\\n16.   Doubilet,  P.,  Begg,  C.B.,  Weinstein,  M.C.,  Braun,  P.,  McNeill,  B.J.  Probabilistic sensitivity  analysis  using  Monte  Carlo  simulation:  a  practical  approach. Medical Decision Making 1985; 5:157-177.\\n17.   Critchfield,  G.C.,  Willard,  K.E.  Probabilistic  analysis  of  decision  trees  using  Monte Carlo simulation. Med Decis Making, MED 1986; 6:85-92.\\n18.   Dias,  S.,  Sutton,  A.J.,  Welton,  N.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document 6: Embedding evidence synthesis in probabilistic cost-effectiveness analysis: software choices. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n19.   Dias,  S.,  Sutton,  A.J.,  Welton,  N.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  3:  Heterogeneity:  subgroups,  meta-regression,  bias  and  bias-adjustment. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n20.   Cooper,  N.J.,  Peters,  J.,  Lai,  M.C.W.,  Juni,  P.,  Wandel,  S.,  Palmer,  S.  et  al.  How valuable  are  multiple  treatment  comparison  methods  in  evidence-based  health-care evaluation? Value in Health 2011; 14:371-380.\\n21.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Caldwell,  D.M.,  Lu,  G.,  Ades,  A.E.  NICE  DSU Technical  Support  Document  4:  Inconsistency  in  networks  of  evidence  based  on randomised controlled trials. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n22.   Welton,  N.J.,  Willis,  S.R.,  Ades,  A.E.  Synthesis  of  Survival  and  Disease  Progression Outcomes for Health Technology Assessment of Cancer Therapies. Research Synthesis Methods 2010; 1:239-257.\\n23.   Welton, N.J., Cooper, N.J., Ades, A.E., Lu, G., Sutton, A.J. Mixed  treatment comparison with multiple outcomes reported inconsistently across trials: evaluation of antivirals  for  treatment  of  influenza  A  and  B. Statistics  In  Medicine 2008;  27:56205639.\\n24.   Burch, J., Paulden, M., Conti, S., Stock, C., Corbette, M., Welton, N.J. et al. Antiviral drugs  for  the  treatment  of  influenza:  a  systematic  review  and  economic  evaluation. Health Technology Assesment 2010; 13(58):1-290.\\n25.   Batagelj,  V.,  Mrvar,  A.  Pajek  -  Program  for  Large  Network  Analysis. Connections 1998; 21(2):47-57.\\n\\n26.   R:  A  Language  and  Environment  for  Statistical  Computing  [  Windows.  Vienna, Austria: R Foundation for Statistical Computing; 2010.\\n27.   Salanti, G. Multiple-treatments meta-analysis of a network of interventions. http://www mtm uoi gr/ 2011;  Available from http://www.mtm.uoi.gr/\\n28.   National  Institute  for  health  and  Clinical  Excellence.  Certolizumab  pegol  for  the treatment  of  rheumatoid  arthritis.  2010;  TA186.    National  Institute  for  Health  and Clinical Excellence. NICE technology appraisal guidance.\\n29.   Cipriani, A., Furukawa, T.A., Salanti, G., Geddes, J.R., Higgins, J.P.T., Churchill, R. et al.  Comparative  efficacy  and  acceptability  of  12  new  generation  antidepressants:  a multiple-treatments meta-analysis. Lancet 2009; 373:746-758.\\n30.   Ades,  A.E.,  Mavranezouli,  I.,  Dias,  S.,  Welton,  N.J.,  Whittington,  C.,  Kendall,  T. Network meta-analysis with competing risk outcomes. Value in Health 2010; 13(8):976-983.\\n31.   Salanti, G., Ades, A.E., Ioannidis, J.P.A. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011; 64:163-171.\\n32.   Ades, A.E., Caldwell, D.M., Reken, S., Welton, N.J., Sutton, A.J., Dias, S. NICE DSU Technical  Support  Document  7:  Evidence  synthesis  of  treatment  efficacy  in  decision making: a reviewer's checklist. 2012; available from http://www.nicedsu.org.uk\"),\n",
       " Document(id='a4d04a43-a78a-4e45-9baf-2e8e7c60b35e', metadata={'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content=\"## NICE DSU TECHNICAL SUPPORT DOCUMENT 6: EMBEDDING EVIDENCE SYNTHESIS IN PROBABILISTIC COST-EFFECTIVENESS ANALYSIS: SOFTWARE CHOICES\\n\\n## REPORT BY THE DECISION SUPPORT UNIT\\n\\nMay 2011 (last updated April 2012)\\n\\nSofia Dias 1 , Alex J Sutton 2 , Nicky J Welton 1 , AE Ades 1\\n\\n1 School  of  Social  and  Community  Medicine,  University  of  Bristol,  Canynge  Hall,  39 Whatley Road, Bristol BS8 2PS, UK\\n\\n2 Department  of  Health  Sciences,  University  of  Leicester,  2nd  Floor  Adrian  Building, University Road, Leicester LE1 7RH, UK\\n\\nDecision Support Unit, ScHARR, University of Sheffield, Regent Court, 30 Regent Street Sheffield, S1 4DA;\\n\\nTel (+44) (0)114 222 0734 E-mail dsuadmin@sheffield.ac.uk\\n\\n## ABOUT THE DECISION SUPPORT UNIT\\n\\nThe Decision Support Unit (DSU) is a collaboration between the Universities of Sheffield, York and Leicester. We also have members at the University of Bristol, London School of Hygiene and Tropical Medicine and Brunel University.\\n\\nThe  DSU  is  commissioned  by  The  National  Institute  for  Health  and  Clinical  Excellence (NICE)  to  provide  a  research  and  training  resource  to  support  the  Institute's  Technology Appraisal Programme. Please see our website for further information www.nicedsu.org.uk\\n\\n## ABOUT THE TECHNICAL SUPPORT DOCUMENT SERIES\\n\\nThe NICE Guide to the Methods of Technology Appraisal i is a regularly updated document that provides an overview of the key principles and methods of health technology assessment and  appraisal  for  use  in  NICE  appraisals.  The  Methods  Guide  does  not  provide  detailed advice  on  how  to  implement  and  apply  the  methods  it  describes.  This  DSU  series  of Technical  Support  Documents  (TSDs)  is  intended  to  complement  the  Methods  Guide  by providing detailed information on how to implement specific methods.\\n\\nThe TSDs provide a review of the current state of the art in each topic area, and make clear recommendations  on  the  implementation  of  methods  and  reporting  standards  where  it  is appropriate to do so. They aim to provide assistance to all those involved in submitting or critiquing evidence as part  of  NICE  Technology  Appraisals,  whether manufacturers, assessment groups or any other stakeholder type.\\n\\nWe recognise that there are areas of uncertainty, controversy and rapid development. It is our intention that such areas are indicated in the TSDs. All TSDs are extensively peer reviewed prior to publication (the names of peer reviewers appear in the acknowledgements for each document).  Nevertheless,  the  responsibility  for  each  TSD  lies  with  the  authors  and  we welcome any constructive feedback on the content or suggestions for further guides.\\n\\nPlease be aware that whilst the DSU is funded by NICE, these documents do not constitute formal NICE guidance or policy.\\n\\n## Dr Allan Wailoo\\n\\nDirector of DSU and TSD series editor.\\n\\ni National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal, 2008 (updated June 2008), London.\\n\\n## Competing interests\\n\\nAlex  Sutton  has  received  financial  reimbursement  when  working  as  an  advisor  on  the development of the Comprehensive Meta-Analysis software package.\\n\\n## Acknowledgements\\n\\nThe DSU thanks Rachael Fleurence, Jeroen Jansen, Alec Miners, Jaime Peters, Mike Spencer and the team at NICE, led by Gabriel Rogers, for reviewing this document. The editor for the TSD series is Allan Wailoo.\\n\\nThe production of this document was funded by the National Institute for Health and Clinical Excellence  (NICE)  through  its  Decision  Support  Unit.  The  views,  and  any  errors  or omissions, expressed in this document are of the author only. NICE may take account of part or all of this document if it considers it appropriate, but it is not bound to do so.\\n\\n## This report should be referenced as follows:\\n\\nDias, S., Sutton, A.J., Welton, N.J. &amp; Ades, A.E. NICE DSU Technical Support Document 6: Embedding evidence synthesis in probabilistic cost-effectiveness analysis: software choices. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n\\n## EXECUTIVE SUMMARY\\n\\nThis  document  sets  out  software  options  for  evidence  synthesis  that  are  compatible  with probabilistic  cost-effectiveness  analysis,  which  is  the  preferred  methodology  for  the  NICE reference case. Four possibilities are discussed:\\n\\n1. Evidence synthesis  by Bayesian posterior estimation, and posterior sampling. Other parameters  of  the  cost-effectiveness  models  can  be  incorporated  into  the  same software  platform.  Bayesian  Markov  chain  Monte  Carlo  simulation  methods  with WinBUGS software are the most popular choice.\\n2. Evidence synthesis by Bayesian posterior estimation. Posterior samples are exported to another package where the other parameters are generated and the costeffectiveness model evaluated.\\n3. Frequentist  methods  of  parameter  estimation  followed  by  forward  Monte  Carlo simulation  from  the  maximum  likelihood  estimates  and  their  variance-covariance matrix\\n4. Bootstrap re-sampling - a frequentist simulation approach to parameter estimation.\\n\\nWhen multiple parameters are estimated from the same synthesis model, we emphasise the need to choose a method that propagates the parameter correlation structure through the costeffectiveness  model.  A  table  is  provided  that  shows  the  possible  approaches  and  the restrictions on their use.\\n\\nSoftware packages for evidence synthesis are listed. Technical issues relating to software are covered in an Appendix. Finally we mention software suitable for transferring data between different software packages, and software that provides user-friendly interface for integrated software  platforms.  These  offer  investigators  a  flexible  way  of  examining  alternative scenarios.\\n\\n## CONTENTS\\n\\n| 1. 2.                                                                                                                                                                                                                                                                                                   | INTRODUCTION....................................................................................................... EMBEDDING EVIDENCE SYNTHESIS IN PROBABILISTIC CEA....................                                                                                                               | 7 8                                                                                                                                                                                                                                                                                                     |\\n|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\\n|                                                                                                                                                                                                                                                                                                         | 2.1. BAYESIAN POSTERIOR SIMULATION: ONE-STAGE APPROACH.....................................                                                                                                                                                                                                             | 2.1. BAYESIAN POSTERIOR SIMULATION: ONE-STAGE APPROACH.....................................                                                                                                                                                                                                             |\\n| 2.2.                                                                                                                                                                                                                                                                                                    | BAYESIAN POSTERIOR SIMULATION: TWO-STAGE APPROACH ....................................                                                                                                                                                                                                                  | 9                                                                                                                                                                                                                                                                                                       |\\n| 2.3.                                                                                                                                                                                                                                                                                                    | FREQUENTIST ESTIMATION WITH MONTE CARLO SAMPLING.....................................                                                                                                                                                                                                                   | 9                                                                                                                                                                                                                                                                                                       |\\n| 2.3.1.                                                                                                                                                                                                                                                                                                  | 2.3.1.                                                                                                                                                                                                                                                                                                  | Stand-alone meta-analysis packages.............................................................. 10                                                                                                                                                                                                     |\\n| 2.3.2.                                                                                                                                                                                                                                                                                                  | 2.3.2.                                                                                                                                                                                                                                                                                                  | General statistical packages with support for meta-analysis .......................... 10                                                                                                                                                                                                               |\\n| 2.3.3.                                                                                                                                                                                                                                                                                                  | 2.3.3.                                                                                                                                                                                                                                                                                                  | Software for network meta-analysis................................................................ 10                                                                                                                                                                                                   |\\n| 2.3.4.                                                                                                                                                                                                                                                                                                  | 2.3.4.                                                                                                                                                                                                                                                                                                  | Parameterisation of treatment effects............................................................. 11                                                                                                                                                                                                   |\\n| 2.4. FREQUENTIST                                                                                                                                                                                                                                                                                        | 2.4. FREQUENTIST                                                                                                                                                                                                                                                                                        | ESTIMATION WITH BOOTSTRAPPING ................................................. 11                                                                                                                                                                                                                      |\\n| 2.5. SUMMARY OF METHODS AND RESTRICTIONS ON THEIR USE                                                                                                                                                                                                                                                   | 2.5. SUMMARY OF METHODS AND RESTRICTIONS ON THEIR USE                                                                                                                                                                                                                                                   | .................................. 12                                                                                                                                                                                                                                                                   |\\n| 3.                                                                                                                                                                                                                                                                                                      | USE OF MULTIPLE SOFTWARE PLATFORMS................................................ 12                                                                                                                                                                                                                   | USE OF MULTIPLE SOFTWARE PLATFORMS................................................ 12                                                                                                                                                                                                                   |\\n| 3.1. COMMUNICATION BETWEEN SOFTWARE                                                                                                                                                                                                                                                                     | 3.1. COMMUNICATION BETWEEN SOFTWARE                                                                                                                                                                                                                                                                     | PACKAGES................................................ 13                                                                                                                                                                                                                                             |\\n| 3.2. INTEGRATED USE OF SOFTWARE                                                                                                                                                                                                                                                                         | 3.2. INTEGRATED USE OF SOFTWARE                                                                                                                                                                                                                                                                         | PLATFORMS.......................................................... 13                                                                                                                                                                                                                                  |\\n| 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 | 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 | 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 |\\n| TABLES                                                                                                                                                                                                                                                                                                  | TABLES                                                                                                                                                                                                                                                                                                  | TABLES                                                                                                                                                                                                                                                                                                  |\\n| Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   | Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   | Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   |\\n\\n## Abbreviations and Definitions\\n\\nCEA\\n\\ncost-effectiveness analysis\\n\\nFE\\n\\nFixed effects\\n\\nMC\\n\\nMonte Carlo\\n\\nMCMC\\n\\nMarkov chain Monte Carlo\\n\\nRE\\n\\nRandom effects\\n\\nVCV\\n\\nvariance-covariance\\n\\n## 1. INTRODUCTION\\n\\nProbabilistic  methods  in  decision  analysis  were  introduced  in  the  1980s. 1,2 Their  defining feature is that they allow for a full expression of the uncertainty in model parameters. There are two main reasons for advocating probabilistic methods in decision making. The first is that they can provide a form of sensitivity analysis which allows investigators to easily see the joint impact of the uncertainty in multiple parameters on the expected costs, benefits and on  decision  uncertainty.  For  this  reason  use  of  these  methods  is  often  called  probabilistic sensitivity  analysis.  A  second  reason  is  that,  faced  with  uncertainty  in  the  vector/matrix  of model parameters θ ,  decision makers generally choose the decision option, D ,  that delivers the highest expected net benefit. In other words, the decision maker selects decision D* , such that:\\n\\n$$D ^ { * } = M _ { \\\\partial } \\\\alpha E _ { \\\\theta } [ N B ( D , \\\\theta ) ]$$\\n\\nThis 'expectation' requires an integration of the net benefit function, ( , ) NB D θ over the joint distribution  of  parameters θ .  There  are  a  wide  range  of  methods  for  achieving  this integration, and the appropriate choice of method depends on the algebraic structure of the net benefit function. It must be emphasised that the expected Net Benefit is not the same as the Net Benefit at the expected value of the parameters, except in the cases where Net Benefit is  linear  in  all  its  parameters, and there  are  no  correlations  between  parameters.  This  is relatively rare, as most evidence synthesis is performed on log or logit scales, and many costeffectiveness  analysis  (CEA)  models  include  Markov  models,  which  are  notoriously  nonlinear. Further, modern methods of evidence synthesis tend to generate estimates of several parameters from a common dataset, in most cases leading to correlations between parameters. It  is  therefore  essential  that  software  solutions  are  adopted  that  ensure  that  the  complex uncertainty  structure  in  parameter  estimates  is  faithfully  propagated  through  the  decision model. 3 This  document provides guidance on the appropriate choice of  software to deliver probabilistic cost-effectiveness analysis in any situation.\\n\\nMonte Carlo (MC) simulation from the joint parameter distribution is not only the simplest way to evaluate the expected Net Benefit, but for any form of model it also delivers other crucial  tools  of  probabilistic  CEA  such  as:  plots  of  the  cost-effectiveness  plane,  costeffectiveness  acceptability  curves  and  estimates  of  the  probability  that  a  decision  is  costeffective. 4,5 MC  simulation  is  also  the  easiest  approach  to  Expected  Value  of  Information analysis. 6-8 Probabilistic  methods  have  been  recommended  in  a  range  of  leading  textbooks\\n\\nand tutorial papers, and are the preferred option for submissions to re-imbursement agencies such  as  the  National  Institute  of  Health  and  Clinical  Excellence  (NICE)  in  the  UK.  We therefore  recommend  MC  simulation-based  approaches  for all analyses,  even  for  strictly linear models.\\n\\nThe document confines  itself to the question of  which computational approaches  correctly preserve  the  properties  of  the  evidence  synthesis  within  a  probabilistic  cost-effectiveness analysis. No advice is given on the relative merits of cohort models compared to individual patient  simulation.  Indeed,  no  advice  is  given  in  this  document  on  how  to  choose the  best model, it is restricted to providing guidance on how to implement the model of choice.\\n\\nThis document is organised as follows. The main body of the document (Section 2) sets out the different analysis options. These include Bayesian Markov chain Monte Carlo (MCMC) methods  (2.1,  2.2),  and  frequentist  methods,  either  sampling  from  maximum  likelihood estimates  and  their  variance-covariance  (VCV)  matrices  (2.3),  or  bootstrapping  (2.4).  We then  provide  a  brief  summary  of  software  tools  that  can  be  used  to  help  interface  between different  software,  and  review  some  recent  developments  in  user-friendly  'front  ends',  to assist the integrated use  of multiple  software  platforms.  These  offer  ways in  which investigators can conduct scenario analyses, not just with individual parameters but also with different datasets  or different synthesis models  and  quickly  see  the impact  on  costeffectiveness results.\\n\\n## 2. EMBEDDING EVIDENCE SYNTHESIS IN PROBABILISTIC CEA\\n\\n## 2.1. BAYESIAN POSTERIOR SIMULATION: ONE-STAGE APPROACH\\n\\nWhen  estimation  of  the  synthesis  parameters  is  via  sampling  from  a  Bayesian  posterior distribution  of  the  relevant  parameters,  this  can  be  integrated  with  the  CEA  as  a  single process within a single programming package, in what has been referred to as 'Comprehensive Decision Analysis'. 9-11\\n\\nBayesian MCMC simulation, 12 using WinBUGS, 13 OpenBUGS 14 or other MCMC packages, provides the obvious example. The advantage of this approach is that it not only estimates a Bayesian posterior distribution, but that it is simulation-based, so that its outputs are perfectly compatible with the MC sampling approach that has become the standard modelling method in so many areas of science. Samples from the joint posterior distribution can be put directly through the decision analysis, so that Net Benefit and other outputs can be evaluated for each\\n\\nset of parameter samples, without requirements for assumptions about its distributional form. Distributions of additional parameters and costs can be readily incorporated.\\n\\nDevelopment of MCMC algorithms and sampling schemes is a specialised area of research. Although  users  need  not  have  a  detailed  knowledge  of  the  precise  working  of  MCMC software,  a  good  understanding  of  the  fundamentals  and  of  Bayesian  data  analysis  is essential.  For  completeness  it  is  worth  mentioning  that  a  broad  range  of non -MCMC simulation-based Bayesian updating schemes have also been proposed, including the Sample Importance  Re-sampling  algorithm, 15 Bayesian  Melding, 16,17 and  Bayesian  Monte  Carlo. 18 All these have the same properties as Bayesian MCMC in that they all feature both Bayesian estimation and sampling  from  joint posterior distributions.  The  latter two  were  specifically designed for evidence synthesis.\\n\\n## 2.2. BAYESIAN POSTERIOR SIMULATION: TWO-STAGE APPROACH\\n\\nIf investigators have a preferred software for CEA, either general software packages such as R, STATA, SAS, or spread-sheet or decision tree packages such as EXCEL or TreeAGE, a further option is to take the posterior samples from the Bayesian MCMC, or other posterior sampling scheme, and use them as input to the CEA package. This has the same technical properties  as  the  Bayesian  one-stage  approach  since  the  full  posterior  distribution is preserved. From WinBUGS, the CODA output, which lists all values generated from the full posterior  distribution,  can  be  exported  into  a  spreadsheet-based  program  such  as  EXCEL, using BUS - BUGS Utility for Spreadsheets. 19 When using the CODA output it is important that the correlations in the parameter estimates are preserved. This is done by ensuring that all parameter values are sampled from the same MCMC iteration . If the CODA output is in spreadsheet  format,  for  example  in  EXCEL,  this  would  correspond  to  sampling  all  the parameter values in one row, each time. The CODA output can also be converted to the freely available  statistical  software  R 20 for  convergence  diagnostics,  further  analysis  and  plotting using  add-on  packages  such  as  BOA  -  Bayesian  Output  Analysis  Program 21 or  CODA  Convergence Diagnostics and Output Analysis. 22\\n\\n## 2.3. FREQUENTIST ESTIMATION WITH MONTE CARLO SAMPLING\\n\\nIf evidence synthesis can be performed using frequentist software (which may use a variety of methods of estimation including, methods of moments, iterative weighted least-squares or\\n\\n(restricted) maximum likelihood ((RE)ML)), a two-stage approach is also possible. The first step is estimation, which produces parameter estimates and their variance-covariance (VCV) matrix. In the second step, these are used to populate a multivariate normal distribution which can be used for forward MC sampling (in the same or in a different package) along with the other CEA parameters. When single parameters are of interest, such as in simple pair-wise meta-analysis, this  may  be  the  simplest  option  as  only  one  variance  needs  to  be  estimated (there is no VCV matrix). In such situations it is particularly easy to find the treatment effect parameter  and  its  variance  using  either  specific  meta-analysis  software  or  implementing meta-analysis routines in standard statistical software packages. A systematic and comprehensive review of all  software options  capable of evidence synthesis  is beyond the scope  of  this  document,  but  noteworthy  options  are  described  below  and  more  detailed reviews and comparisons are available elsewhere. 23-26\\n\\n## 2.3.1. Stand-alone meta-analysis packages\\n\\nNumerous packages have been developed over the years, but probably those which include the most extensive and up-to-date feature sets, are\\n\\n- \\uf0b7 Comprehensive meta-analysis (commercial); 27\\n- \\uf0b7 Meta-Analyst (free); 26\\n- \\uf0b7 MIX, 28 which is an add-on to EXCEL (commercial and free versions available);\\n- \\uf0b7 RevMan, 29 which is the official software of the Cochrane Collaboration (free).\\n- \\uf0b7 EXCEL:  Simple meta-analysis can be carried out with a small amount of programming.\\n\\n## 2.3.2. General statistical packages with support for meta-analysis\\n\\nWhile it would be possible to program most standard meta-analysis models in any reasonably powerful  statistics  package,  probably  the  most  extensive  freely  available  software  routines which  allow  meta-analysis  to  be  conducted  and  numerous  graphical  outputs  produced  are available for STATA 30 and for R, such as the meta 31 and rmeta 32 packages.\\n\\nAlthough  all  the  above  options  will  conduct  pair-wise  meta-analysis,  not  all  have  the capability to do meta-regression, 33 which may be a decisive factor in choosing between them.\\n\\n## 2.3.3. Software for network meta-analysis\\n\\nSpecific comments on frequentist software options for network meta-analysis can be found in TSD2. 34 For  indirect  comparison  networks,  separate  syntheses  can  be  carried  out  for  AB\\n\\ntrials, and AC trials. Then the estimates obtained and their variances can be entered into the simulation package used for CEA, and the relative cost-effectiveness of A, B and C readily determined  (covariances  are  not  involved).  Although  this  is  an  acceptable  approach  in principle,  the  Bayesian  MCMC  approach  to  indirect  comparisons  (see  TSD2 34 )  may  be preferable in cases where one or more of the pair-wise comparisons is represented by a very small number of trials. This is because, MCMC has the flexibility to allow 'shared variance' Random Effects (RE) models, while with conventional methods it may be necessary to have some estimates from RE models and others from Fixed Effects (FE) models, which seems a less natural solution.\\n\\nIn many cases the use of frequentist estimates and their VCV matrix with RE models is likely to  produce  parameter  distributions  with  a  little  less  uncertainty,  because  Bayesian  methods take uncertainty in variance parameters into account. The extent of the difference is unlikely to  be  critical,  although  investigators  should  always  check  that  posterior  distributions  of variance parameters are sensible.\\n\\n## 2.3.4. Parameterisation of treatment effects\\n\\nWhatever software is used, model parameterisation requires care, as a number of apparently innocuous  variations  may  give  very  different  or  wrong  results.  To  date,  a  few  coding problems have come to light and these are set out in the Appendix.\\n\\n## 2.4. FREQUENTIST ESTIMATION WITH BOOTSTRAPPING\\n\\nThe final option of estimation and then Bootstrapping, 35 has been used from time to time in cost-effectiveness analysis. 36 In  its  original  form,  bootstrapping is a technique in which one generates  a  series  of  'new'  datasets  by  repeatedly  re-sampling with  replacement from  the original data, each time producing a new set of parameters estimates. This stream of estimates can  then  be  treated  in  the  same  way  as  samples  from  Bayesian  posterior  distributions. However, this procedure is not always straightforward, particularly with small sample sizes and zero cells.\\n\\nThere are, nonetheless, a very wide range of variant bootstrap procedures which can mitigate these and other problems. In the parametric bootstrap, for example a model is fitted to the data by maximum likelihood and is then used to generate a series of datasets with the same size and structure as the original. The analysis procedure is applied to each of these datasets\\n\\nto generate a stream of parameter values. Data analysis based on resampling is a rich area with an extensive literature. Readers are referred to texts for further information. 35,37,38\\n\\n## 2.5. SUMMARY OF METHODS AND RESTRICTIONS ON THEIR USE\\n\\nTable 1 summarises the methods and the restrictions on their use. Readers are referred to the text for further explanation.\\n\\nTable 1 Summary of methods and their properties and restrictions\\n\\n| Estimation                                       | Output to CEA Sotware                              | Restrictions                                                             |\\n|--------------------------------------------------|----------------------------------------------------|--------------------------------------------------------------------------|\\n| BayesianMCMC                                     | None: CEA within MCMC Software                     | None                                                                     |\\n| BayesianMCMC                                     | MCMCchains exported                                | None                                                                     |\\n| BayesianMCMC                                     | Posterior means, variances, correlations           | None, but assumes multi- variate normality in posterior distribution     |\\n| BayesianMCMC                                     | Posterior means and variances                      | Only suitable if no correlation between parameters*                      |\\n| Estimation by non-Bayesian (frequentist) methods | Parameter estimates and Variance-Covariance matrix | None, but assumes multi- variate normality of treatment effect estimates |\\n| Estimation by non-Bayesian (frequentist) methods | Parameter estimates and their variances            | Only suitable if no correlation between parameters*                      |\\n| Estimation by non-Bayesian (frequentist) methods | Bootstrap resampling                               | None, but special methods are necessary for sparse data                  |\\n\\n## 3. USE OF MULTIPLE SOFTWARE PLATFORMS\\n\\nIn  recent  years  interfaces  have  become  available  that  let  different  software  applications communicate with each other. These facilities allow for the integration of the components of a  CEA  which  may  have  been  conducted  in  different  packages.  The  motivations  and advantages of an integrated approach across software applications are potentially multifaceted. Firstly, it allows multidisciplinary teams who have different software skills and preferences  to  produce  an  integrated  analysis.  For  example,  statisticians  may  wish  to  use general statistical software, whereas decision modellers may wish to use EXCEL or specific decision  modelling  software.  It  also  allows  the  best  software  for  each  component  of  the analysis to be used therefore producing an 'optimal' mix. For example, if a network metaanalysis  is  required,  WinBUGS  may  be  the  best  software  to  implement  this  in,  but  it  has\\n\\nlimited  graphical  capabilities.  Therefore,  it  may  be  desirable  to  present  the  results  of  the synthesis  in  a  package  with  advanced  graphical  capability  such  as  R.  Furthermore,  the original dataset may have been prepared in spreadsheet software such as EXCEL. Although use of multiple pieces of software to conduct different components of the analysis is common historically, few have been integrated.\\n\\nSection 3.1 gives details of how to allow communication between different platforms, with the  primary  aim  of  transferring  data  between  them.  Section  3.2  explains  how  different software can be used to fully integrate data input, analysis and the display of results using multiple packages, into a single step.\\n\\n## 3.1. COMMUNICATION BETWEEN SOFTWARE PACKAGES\\n\\nTo facilitate communication, transparency and future data updates, it is good practice to keep all data collected for the analysis, including all annotations and details of any corrections, in a single file, for example an EXCEL workbook with multiple worksheets. If the analysis is to be carried out in WinBUGS, data columns can be copied directly from spreadsheet software into  WinBUGS and pasted  by  selecting Paste Special from  the  WinBUGS Edit menu and choosing  the Plain  text option.  Alternatively, XL2BUGS 39 is  an  EXCEL  add-in  which converts  EXCEL  data  into  WinBUGS  vector  format,  and BAUW 40 converts  data  in  text format into WinBUGS vector or matrix format.\\n\\nIf data is stored in R, R2WinBUGS 41 can be used to convert R objects into WinBUGS list data using the bugs.data function.\\n\\nSee http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/remote14.shtml for details.\\n\\n## 3.2. INTEGRATED USE OF SOFTWARE PLATFORMS\\n\\nIntegrated  platforms  reduce  the  need  to  copy  data  and  intermediate  results  from  one screen/system  to  another,  and  thereby  reduce  the  risk  of  transcription  errors.  Further advantages of integrating the analysis (which also exist if the Bayesian one-stage approach is conducted since in that approach the analysis is integrated by definition) include facilitating the modification and updating of any aspect of the analysis, conducting sensitivity analyses and, more generally, promoting transparency. For example, if a new trial is reported that is to be  added  to  the  evidence  synthesis,  then  in  an  integrated  approach  the  CEA  would automatically  be  updated.  This  goes  some  way  to  ensuring  the  appropriate  uncertainty  is\\n\\npropagated through to the decision model. If part of this integrated approach is the inclusion of a user-friendly interface, then this can also make the exploration of the synthesis and CEA accessible to non-technical experts including clinical experts and even NICE decision makers themselves, allowing them to interrogate the analysis.\\n\\nTo  this  end,  a  Transparent  Interactive  Decision  Interrogator  (TIDI) 42 which  integrated syntheses conducted in WinBUGS with graphical displays and the decision model conducted in  R  and  a  'point  and  click'  interface  in  EXCEL  was  developed  for  a  recent  Single Technology  Appraisal  (STA)  at  NICE.  This  pilot  'proof  of  concept'  initiative  allowed members  of  the  appraisal  committee  to  request  re-runs  of  the  CEA  using  alternative parameter values in real time in the committee meetings.\\n\\nSeveral (freely available) code routines have been developed for commonly used packages in Health Technology Assessment which allow them to communicate with other packages and these can be utilised in the creation of integrated analyses. For example, RExcel , 43 an add-on to  EXCEL,  provides  communication  between  EXCEL  and  R  and R2WinBUGS is  one  of several packages which allow the controlling of WinBUGS through R. Thus, if both of these linking packages are used in combination, then WinBUGS can be controlled through EXCEL (via R), and a Visual Basic interface can be written in EXCEL to facilitate this (which is the software  setup  used  in  the  TIDI  project  described  above).  Similar  control  of  WinBUGS through  STATA 44 and  several  other  packages  is  also  possible,  as  is  the  embedding  of OpenBUGS in R through rbugs 45 and the linking of many packages to each other.\\n\\n## 4. REFERENCES\\n\\n1.   Critchfield,  G.C.,  Willard,  K.E.  Probabilistic  analysis  of  decision  trees  using  Monte Carlo simulation. Medical Decision Making 1986; 6(2):85-92.\\n2.   Doubilet,  P.,  Begg,  C.B.,  Weinstein,  M.C.,  Braun,  P.,  McNeil,  B.J.  Probabilistic sensitivity  analysis  using  Monte  Carlo  simulation:  A  practical  approach. Medical Decision Making: an International Journal of the Society for Medical Decision Making 1985; 5(2):157-177.\\n3.   Ades,  A.E.,  Claxton,  K.,  Sculpher,  M.  Evidence  synthesis,  parameter  correlation  and probabilistic sensitivity analysis. Health Economics 2005; 14:1-9.\\n4.   Claxton,  K.,  Sculpher,  M.,  McCabe,  C.,  Briggs,  A.,  Akehurst,  R.,  Buxton,  M.  et  al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics 2005; 14(4):339-347.\\n5.   National  Institute  for  health  and  Clinical  Excellence.  Guide  to  the  methods  of technology appraisal (updated 2008). 2008.\\n6.   Thompson, K.M., Evans, J.S. The value of improved national exposure information for perchloroethylene (perc): a case study for dry cleaners. Risk Analysis 1997; 17(2):253271.\\n7.   Claxton,  K.,  Posnett,  J.  An  economic  approach  to  clinical  trial  design  and  research priority setting. Health Economics 1996; 5(6):513-524.\\n8.   Felli, J.C., Hazen,  G.B.  Sensitivity analysis and  the expected  value  of perfect information. Medical Decision Making 1998; 18(1):95-109.\\n9.   Cooper,  N.J.,  Sutton,  A.J.,  Abrams,  K.R.,  Turner,  D.,  Wailoo,  A.  Comprehensive decision  analytical  modelling  in  economic  evaluation:  a  Bayesian  approach. Health Economics 2003; 13(3):203-226.\\n10.   Parmigiani, G., Samsa, G.P., Ancukiewicz, M., Lipscomb, J., Hasselblad, V., Matchar, D.B.  Assessing  uncertainty  in  cost-effectiveness  analyses:  Application  to  a  complex decision model. Medical Decision Making 1997; 17(4):390-401.\\n11.   Spiegelhalter, D.J., Myles, J.P., Jones, D.R., Abrams, K.R. Bayesian methods in health technology assessment: a review. Health Technology Assessment 2000; 4(38).\\n12.   Gilks, W.R., Richardson, S., Spiegelhalter, D.J. Markov chain Monte Carlo in practice. Chapman &amp; Hall/CRC, 1996.\\n13.   Lunn, D.J., Thomas, A., Best, N., Spiegelhalter, D. WinBUGS - a Bayesian modelling framework:  concepts,  structure,  and  extensibility. Statistics  and  Computing 2000; 10(4):325-337.\\n14.   Lunn,  D.,  Spiegelhalter,  D.,  Thomas,  A.,  Best,  N.  The  BUGS  project:  Evolution, critique and future directions. Statistics in Medicine 2009; 28(25):3049-3067.\\n\\n15.   Rubin,  D.B.  Using  the  SIR  algorithm  to  simulate  posterior  distributions. Bayesian Statistics 1988; 3:395-402.\\n16.   Raftery,  A.E.,  Givens,  G.H.,  Zeh,  J.E.  Inference  from  a  Deterministic  Population Dynamics Model for Bowhead Whales. Journal of the American Statistical Association 1995; 90(430):402-416.\\n17.   Poole, D., Raftery, A.E. Inference for Deterministic Simulation Models: The Bayesian Melding Approach. Journal of the American Statistical Association 2000; 95(452):1244-1255.\\n18.   Brand,  K.P.,  Small,  M.J.  Updating  uncertainty  in  an  integrated  risk  assessment: conceptual framework and methods. Risk Analysis 1995; 15(6):719-731.\\n19.   Hahn,  G.  BUGS  Utility for Spreadsheets. Version 1.0.1. 2001; available from http://faculty.salisbury.edu/~edhahn/bus.htm\\n20.   R Development Core Team. R: A Language and Environment for Statistical Computing. 2010. Vienna, Austria, R Foundation for Statistical Computing.\\n21.   Smith,  B.J. The  boa Package. Version 1.1.5. 2005; available from http://www.publichealth.uiowa.edu/boa/\\n22.   Plummer,  M.,  Best,  N.,  Cowles,  K.,  Vines,  K.  CODA:  Convergence  diagnosis  and output analysis for MCMC. R News 2006; 6(1):7-11.\\n23.   Bax,  L.,  Yu,  L.M.,  Ikeda,  N.,  Moons,  K.G.M.  A  systematic  comparison  of  software dedicated  to  meta-analysis  of  causal  studies. BMC  Medical  Research  Methodology 2007; 7(1):40.\\n24.   Sterne, J.A.C., Egger, M., Sutton, A.J. Meta-Analysis Software. In: Egger M., DaveySmith  G.,  Altman  D.G.,  eds. Systematic  Reviews  in  Health  Care:  Meta-analysis  in context . second edn ed. BMJ Books; London: 2001; 336-346.\\n25.   Sutton,  A.J.,  Lambert,  P.C.,  Hellmich,  M.A.G.,  Abrams,  K.R.,  Jones,  D.R.  Metaanalysis in practice: a critical review of available software. In: Stangl D.K., Berry D.A., eds. Meta-analysis  in  medicine  and  health  policy .  Marcel  Dekker;  New  York:  1998; 315-339.\\n26.   Wallace, B.C., Schmid, C.H., Lau, J., Trikalinos, T.A. Meta-Analyst: software for metaanalysis of binary, continuous and diagnostic data. BMC  Medical Research Methodology 2009; 9(1):80.\\n27.   Borenstein,  M.,  Hedges,  L.,  Higgins,  J.,  Rothstein,  H.  Comprehensive  meta-analysis version 2. 2005; available from http://www.meta-analysis.com/\\n28.   Bax, L., Yu, L.M., Ikeda, N., Tsuruta, H., Moons, K.G.M. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Medical Research Methodology 2006; 6(1):50.\\n29.   The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.0. 2008; available from http://ims.cochrane.org/revman\\n\\n30.   Sterne,  J.A.C.  Meta-analysis  in  Stata:  an  updated  collection  from  the  Stata  Journal. CRC PRESS, 2009.\\n31.   Schwarzer,  G.  meta:  Meta-Analysis  with  R.  Version  1.6-1.  2010;  available  from http://cran.r-project.org/web/packages/meta/\\n32.   Lumley, T. rmeta:Meta-analysis. 2009; available from http://cran.rproject.org/web/packages/rmeta/\\n33.   Thompson, S.G., Sharp, S.J. Explaining heterogeneity in meta analysis: a comparison of methods. Statistics in Medicine 1999; 18(20):2693-2708.\\n34.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  2:  A  generalised  linear  modelling  framework  for  pair-wise  and  network meta-analysis of randomised controlled trials. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n35.   Efron,  B.,  Tibshirani,  R.J.  An  introduction  to  the  bootstrap.  Chapman  &amp;  Hall,  New York; 1993.\\n36.   Lord,  J.,  Asante,  M.A.  Estimating  uncertainty  ranges  for  costs  by  the  bootstrap procedure  combined  with  probabilistic  sensitivity  analysis1. Health  Economics 1999; 8(4):323-333.\\n37.   Davison, A.C., Hinkley, D.V. Bootstrap methods and their application. Cambridge Univ Pr, 1997.\\n38.   Lunneborg,  C.E.  Data  analysis  by  resampling:  Concepts  and  applications.  Duxbury, 2000.\\n39.   Misra,  S.  XL2BUGS:  Excel  Add-In  to  convert  data  for  WinBUGS.  2011;  available from http://www.simon.rochester.edu/fac/misra/software.htm\\n40.   Zhang, Z., Wang, L. Use BAUW  to convert data. 2006; available from http://www.psychstat.org/us/article.php/52.htm\\n41.   Sturtz,  S.,  Ligges,  U.,  Gelman,  A.  R2WinBUGS:  A  package  for  running  WinBUGS from R. Journal of Statistical Software 2005; 12.\\n42.   Bujkiewicz, S., Jones, H.E., Lai, M.C.W., Cooper, N.J., Hawkins, N., Squires, H. et al. Development  of  a  Transparent  Interactive  Decision  Interrogator  to  facilitate  the decision making process in health care. Value in Health 2011; (in press).\\n43.   Heiberger,  R.M.,  Neuwirth,  E.  R through  Excel:  a  spreadsheet  interface  for  statistics, data analysis, and graphics. Springer-Verlag New York Inc, 2009.\\n44.   Thompson, J., Palmer, T., Moreno, S. Bayesian analysis in Stata using WinBUGS. The Stata Journal 2006; 6(4):530-549.\\n45.   Yan,  J.,  Prates,  M.  Package  rbugs:  Fusing  R  and  OpenBugs.  Version  0.4-9.  2011; available from http://cran.r-project.org/web/packages/rbugs/index.html\\n\\n46.   Higgins,  J.P.T.,  Whitehead,  A.  Borrowing  strength  from  external  trials  in  a  metaanalysis. Statistics in Medicine 1996; 15:2733-2749.\\n47.   Caldwell,  D.M.,  Ades,  A.E.,  Higgins,  J.P.T.  Simultaneous  comparison  of  multiple treatments: combining direct and indirect evidence. BMJ 2005; 331:897-900.\\n48.   Lu,  G.,  Ades,  A.  Assessing  evidence  consistency  in  mixed  treatment  comparisons. Journal of the American Statistical Association 2006; 101:447-459.\\n49.   Ades,  A.E.,  Sculpher,  M.,  Sutton,  A.,  Abrams,  K.,  Copper,  N.,  Welton,  N.J.  et  al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics, PharmacoEcon 2006; 24(1):1-19.\\n50.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  2:  A  generalised  linear  modelling  framework  for  pair-wise  and  network meta-analysis of randomised controlled trials. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n51.   Woolacott, N., Bravo Vergel, Y., Hawkins, N., Kainth, A., Khadjesari, Z., Misso, K. et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment 2006; 10(31).\\n52.   Woods, B.S., Hawkins, N., Scott, D.A. Network meta-analysis on the log-hazard scale, combining counts and hazard ratio statistics accounting for multi-arm trials: A tutorial. BMC Medical Research Methodology 2010; 10(54).\\n53.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  5:  Evidence  synthesis  in  the  baseline  natural  history  model.  2011;  last updated April 2012; available from http://www.nicedsu.org.uk\\n\\n## APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS\\n\\nTwo ways of specifying network meta-analysis models have appeared in the literature. The main  area  of  difficulty  lies  in  the  precise  way  in  which  the  relative  effects  have  been parameterised, particularly in RE models. One way to write the model for binomial data is:\\n\\n$$r _ { i k } & \\\\sim \\\\binom { r _ { i } } { i _ { k } } \\\\\\\\ \\\\log ( p _ { i k } ) & = \\\\mu _ { i } & \\\\text {if } k = X \\\\\\\\ \\\\log ( p _ { i k } ) & = \\\\mu _ { i } + \\\\delta _ { i , X } & \\\\text {if } k = Y \\\\\\\\ \\\\delta _ { i , X Y } & \\\\sim N ( d _ { 1 Y } - d _ { 1 X } , \\\\sigma ^ { 2 } ) \\\\\\\\ \\\\mu _ { i } & \\\\sim N ( 0 , 1 0 ^ { 2 } ) \\\\\\\\ \\\\text {and} \\\\, \\\\text {treatment} \\\\, k \\\\, \\\\text { the numerators } \\\\, r _ { i } \\\\, \\\\text { are  have  binomial distributions with}$$\\n\\nHere,  for  trial i and  treatment k the  numerators rik are  have  binomial  distributions  with parameter pik and denominator nik . A logistic regression model says that, for a trial comparing treatments X and Y , the linear predictor consists of the 'baseline' term i \\uf06d if the treatment is X ,  and  the  baseline plus a relative treatment effect , i i XY \\uf06d \\uf064 \\uf02b if  the  treatment  is Y .  The key point is that the actual treatment that i \\uf06d refers to can be any treatment (except the last one). The  trial-specific  relative  effects  are  from  distributions,  whose  means  can  be  expressed  in terms of the mean treatment effects relative to treatment 1 (through the consistency relations). The baseline terms are usually given vague priors. 46-50\\n\\nIn  (2)  it  is  clear  that  the  term i \\uf06d refers  to  treatment X ,  but  it  is  also  clear  that  this  is  not necessarily treatment 1. In this formulation, one arm of a two arm trial informs a trial-specific 'baseline', while the other informs the baseline plus a treatment effect.\\n\\nAnother way of writing a network model that has appeared in certain submissions to NICE 51 contains this modification:\\n\\n$$\\\\log i ( p _ { i k } ) & = \\\\mu _ { i } + \\\\delta _ { i , 1 X } \\\\quad \\\\text {if } k = X \\\\\\\\ \\\\log i ( p _ { i k } ) & = \\\\mu _ { i } + \\\\delta _ { i , 1 Y } \\\\quad \\\\text {if } k = Y$$\\n\\nIn a general sense, this is the same model, except that here the i \\uf06d terms represent Treatment 1 in every trial. In a trial that includes Treatment 1, this parameterisation is adequate, as ,1 i X \\uf064 (the effect of X relative to itself) is zero. However, if any trial does not include treatment 1, then the model parameters cannot all be identified because there are three parameters to be estimated  from  only  two  arms.  Another  way  of  writing  an  MTC  model  that  has  appeared recently 52 has this same property. Models specified in this way should not be accepted unless\\n\\nthe  reference  treatment  is  the  same  treatment  in  every  trial,  and  therefore  appears  in  every trial.\\n\\nThe  instability  caused  by  this  parameterisation  can  be  avoided  if  a  model  is  placed  on  the baseline terms, i.e. 2 ~ ( , ) i m N m \\uf06d \\uf073 rather than 2 ~ (0,100 ) i N \\uf06d . However, this solution has a number of further difficulties and is not recommended (see TSD5 53 ).\")]"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "vdb.similarity_search(\"What is the main topic of the document?\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "fcae695e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "None\n"
     ]
    }
   ],
   "source": [
    "print(vdb.save_local(test_outfiles / \"mkd_docs_vectorstore\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "af1e987b",
   "metadata": {},
   "outputs": [],
   "source": [
    "vdb2 = FAISS.load_local(test_outfiles / \"mkd_docs_vectorstore\", embedding, allow_dangerous_deserialization = True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "9748a2a5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(id='2d3ec963-7c4f-4402-856a-721c00672ba3', metadata={'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"## NICE DSU TECHNICAL SUPPORT DOCUMENT 1: INTRODUCTION TO EVIDENCE SYNTHESIS FOR DECISION MAKING\\n\\n## REPORT BY THE DECISION SUPPORT UNIT\\n\\nApril 2011 (last updated April 2012)\\n\\nSofia Dias 1 , Nicky J Welton 1 , Alex J Sutton 2 , AE Ades 1\\n\\n1 School  of  Social  and  Community  Medicine,  University  of  Bristol,  Canynge  Hall,  39 Whatley Road, Bristol BS8 2PS, UK\\n\\n2 Department  of  Health  Sciences,  University  of  Leicester,  2nd  Floor  Adrian  Building, University Road, Leicester LE1 7RH, UK\\n\\nDecision Support Unit, ScHARR, University of Sheffield, Regent Court, 30 Regent Street\\n\\nSheffield, S1 4DA Tel (+44) (0)114 222 0734\\n\\nE-mail dsuadmin@sheffield.ac.uk\\n\\n## ABOUT THE DECISION SUPPORT UNIT\\n\\nThe Decision Support Unit (DSU) is a collaboration between the Universities of Sheffield, York and Leicester. We also have members at the University of Bristol, London School of Hygiene and Tropical Medicine and Brunel University. The DSU is commissioned by The National  Institute  for  Health  and  Clinical  Excellence  (NICE)  to  provide  a  research  and training resource to support the Institute's Technology Appraisal Programme.\\n\\nPlease see our website for further information www.nicedsu.org.uk\\n\\n## ABOUT THE TECHNICAL SUPPORT DOCUMENT SERIES\\n\\nThe NICE Guide to the Methods of Technology Appraisal i is a regularly updated document that provides an overview of the key principles and methods of health technology assessment and  appraisal  for  use  in  NICE  appraisals.  The  Methods  Guide  does  not  provide  detailed advice  on  how  to  implement  and  apply  the  methods  it  describes.  This  DSU  series  of Technical  Support  Documents  (TSDs)  is  intended  to  complement  the  Methods  Guide  by providing detailed information on how to implement specific methods.\\n\\nThe TSDs provide a review of the current state of the art in each topic area, and make clear recommendations  on  the  implementation  of  methods  and  reporting  standards  where  it  is appropriate to do so. They aim to provide assistance to all those involved in submitting or critiquing evidence as part  of  NICE  Technology  Appraisals,  whether manufacturers, assessment groups or any other stakeholder type.\\n\\nWe recognise that there are areas of uncertainty, controversy and rapid development. It is our intention that such areas are indicated in the TSDs. All TSDs are extensively peer reviewed prior to publication (the names of peer reviewers appear in the acknowledgements for each document).  Nevertheless,  the  responsibility  for  each  TSD  lies  with  the  authors  and  we welcome any constructive feedback on the content or suggestions for further guides.\\n\\nPlease be aware that whilst the DSU is funded by NICE, these documents do not constitute formal NICE guidance or policy.\\n\\n## Dr Allan Wailoo\\n\\nDirector of DSU and TSD series editor.\\n\\ni National  Institute  for  Health  and  Clinical  Excellence.  Guide  to  the  methods  of  technology  appraisal,  2008 (updated June 2008), London.\\n\\n## Acknowledgements\\n\\nThe DSU thanks Julian Higgins, Alec Miners, Georgia Salanti, Mike Spencer and the team at NICE led by Janet Robertson for reviewing this document. The editor for the TSD series is Allan Wailoo.\\n\\nThe production of this document was funded by the National Institute for Health and Clinical Excellence  (NICE)  through  its  Decision  Support  Unit.  The  views,  and  any  errors  or omissions, expressed in this document are of the authors only. NICE may take account of part or all of this document if it considers it appropriate, but it is not bound to do so.\\n\\n## This report should be referenced as follows:\\n\\nDias, S., Welton, N.J., Sutton, A.J., Ades, A.E. NICE DSU Technical Support Document 1: Introduction  to  evidence  synthesis  for  decision  making.  2011;  last  updated  April  2012; available from http://www.nicedsu.org.uk\\n\\n## EXECUTIVE SUMMARY\\n\\nThis  document  serves  as  a  brief  introduction  and  orientation  to  the  series  of  Technical Support  Documents  on  Evidence  Synthesis.  It  describes  (Section  2)  the  overall  analytic approach to evidence synthesis, in terms of separate models for the 'baseline', that represents the  natural  history  in  the  specified  target  population  under  a  standard  comparator,  and  the model for the treatment effects relative to that standard. It then clarifies  the  impact  of  the decision  making  context  on  synthesis  methodology.  It  concludes  that,  in  order  for  the estimates of treatment effects to be appropriate for cost-effectiveness analysis and comparative  effectiveness  research  alike  (and  indeed  for  any  scientific  enquiry  into  the relative  efficacy  of  medical  interventions),  the  decision  maker  should  restrict  the  study inclusion criteria to a target patient population that has a relatively narrow definition. In the specific  context  of  cost-effectiveness  analysis,  the  document  then  refers  to  the  need  for synthesis methods that are compatible with the use of probabilistic methods.\\n\\nCriteria  for  inclusion  of  treatments  are  described  (Section  3),  distinguishing  between  the comparator set of treatments  in the decision analysis, and the comparator set of treatments used  in  synthesis.  Once  a  target  patient  population  has  been  defined,  a  suggested  trial inclusion  rule  that  avoids  potential  ambiguity  regarding  the  relevance  of  evidence  is  to include any trial that compares at least two treatments in the synthesis comparator set. We suggest  that  any  exceptions  to  this  should  require  special  justification.  Trials  with  small sample  sizes  or  trials  with  sample  size  motivated  for  particular  reasons  (such  as  'noninferiority  trials')  should  not  be  excluded  unless  specific  reasons  can  be  given.  Attention should  be  drawn  to  known  or  potential  effect  modifiers,  biases  in  the  trial  evidence,  or markers associated with risk of bias, as consideration should be given to the potential role of methods for addressing heterogeneity and bias. Some guidance is suggested on approaches that can be taken to disconnected evidence networks.\\n\\nSection 4 sets out some 'good practice' in presenting the evidence base for relative treatment effects, transparency and reproducibility of methods, presentation of results, and presentation of model critique and model selection. We encourage the use of network diagrams and tables to clarify exactly what comparative evidence is used in the relative efficacy synthesis, and the production of tables that show both the relative and the absolute effects of treatments that are taken forward for use in the cost-effectiveness analysis. Justification and explanation should\\n\\nbe  given  for  choice  of  statistical  model,  for  example  fixed  or  random  effects  synthesis. Sensitivity  analyses  should  be  used  to  explore  robustness  of  conclusions  to  variations  in assumptions, when the evidence is compatible with alternative interpretations or analyses. The document ends with a brief description of the other documents in the series.\\n\\n## CONTENTS\\n\\n| 1. INTRODUCTION.......................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1. INTRODUCTION.......................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 8                                                                                           |\\n|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|\\n| 2. OVERALL ANALYTIC APPROACH TO SYNTHESIS FOR COST EFFECTIVENESS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ANALYSIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ......................................................................................... 9 |\\n| 2.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | SEPARATE MODELS FOR BASELINE NATURALHISTORY AND FOR RELATIVE TREATMENT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                             |\\n| EFFECTS .............................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | EFFECTS .............................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 9                                                                                           |\\n| 2.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | THE DECISION-MAKINGCONTEXTAND METHODOLOGY FOR EVIDENCE SYNTHESIS......                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 9                                                                                           |\\n| 2.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | ANALYTIC METHODS COMPATIBLE WITH PROBABILISTIC COST-EFFECTIVENESS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                             |\\n| ANALYSIS.........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | ANALYSIS.........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11                                                                                          |\\n| 3. DATASET FOR EVIDENCE SYNTHESIS OF RELATIVE TREATMENT EFFECTS..........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 3. DATASET FOR EVIDENCE SYNTHESIS OF RELATIVE TREATMENT EFFECTS..........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 11                                                                                          |\\n| 3.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | COMPARATOR SETS FOR DECISIONAND FOR SYNTHESIS ...........................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12                                                                                          |\\n| 3.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | TRIAL INCLUSION AND EXCLUSION .........................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12                                                                                          |\\n| 3.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | EXTENSION OF THE SYNTHESIS COMPARATOR SET ...................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 14                                                                                          |\\n| 3.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | RECORDING OF TREATMENTEFFECTMODIFIERS ......................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15                                                                                          |\\n| 3.5.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | DEALING WITH DISCONNECTED NETWORKS.............................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 15                                                                                          |\\n| 4. PRESENTATION OF THE EVIDENCE AND THE RESULTS OF EVIDENCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 4. PRESENTATION OF THE EVIDENCE AND THE RESULTS OF EVIDENCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                             |\\n|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16                                                                                          |\\n| SYNTHESIS...................................................................................................................... 4.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | THE EVIDENCE BASE ..............................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 16                                                                                          |\\n| 4.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | DESCRIPTION OF SYNTHESIS METHODOLOGY...........................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 17                                                                                          |\\n| 4.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | PRESENTATION OF SYNTHESIS RESULTS ..................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 18                                                                                          |\\n| 4.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | MODELDIAGNOSIS AND SELECTION ........................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20                                                                                          |\\n| 5.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | USING THE TECHNICAL SUPPORT DOCUMENTS.........................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 20                                                                                          |\\n| 6.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | REFERENCES..........................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22                                                                                          |\\n| TABLES AND FIGURES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | TABLES AND FIGURES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | mean                                                                                        |\\n| Table 1 Certolizumab Pegol (CZP) for Rheumatoid Arthritis: 28 number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with Placebo, and mean disease duration (in years) for patients in each trial. Blank cells indicate that the treatment was not compared in that trial. All trial arms had Methotrexate in addition to the placebo or active treatment. .....17 Table 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5....................................18 Table 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the | Table 1 Certolizumab Pegol (CZP) for Rheumatoid Arthritis: 28 number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with Placebo, and mean disease duration (in years) for patients in each trial. Blank cells indicate that the treatment was not compared in that trial. All trial arms had Methotrexate in addition to the placebo or active treatment. .....17 Table 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5....................................18 Table 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the |                                                                                             |\\n| relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta- analysis and separate pairwise meta-analyses with fixed effects..............................................................19 Figure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in                                                                                                                                                                                                                                                                                                                                                                                                                                  | relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta- analysis and separate pairwise meta-analyses with fixed effects..............................................................19 Figure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                             |\\n| bold. Treatment X has been added to the synthesis set because it links treatment C to the rest of the network (dashed lines)...........................................................................................................................12 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | bold. Treatment X has been added to the synthesis set because it links treatment C to the rest of the network (dashed lines)...........................................................................................................................12 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                             |\\n| Figure one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments Xand Y................................................................................................................................16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Figure one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments Xand Y................................................................................................................................16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                             |\\n| Figure 3 Parkinson network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers trials making that comparison................................................................................................................19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Figure 3 Parkinson network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers trials making that comparison................................................................................................................19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | of                                                                                          |\\n\\n## Abbreviations and definitions\\n\\nCEA\\n\\nCost-effectiveness analysis\\n\\nCrI\\n\\nCredible interval\\n\\nDMARD\\n\\nDisease Modifying Anti-Rheumatics Drugs\\n\\nIPD\\n\\nIndividual patient data\\n\\nRCT\\n\\nRandomised controlled trial\\n\\nTSD\\n\\nTechnical Support Document\\n\\n## 1. INTRODUCTION\\n\\nThis  Technical  Support  Document  (TSD)  is  the  first  in  a  series  of  seven  documents  on evidence  synthesis  methods  in  decision  making.  These  are  intended  to  support  those presenting submissions to the National Institute for Health and Clinical Excellence (NICE). While the 2008 revision of the NICE Methods Guide 1 sets out what properties submissions should have,  the  evidence  synthesis  TSDs  show  how  the  required  analyses  can be implemented.  There  is  no  attempt  to  'prescribe'  the  form  that  analyses  must  take  or  the methods  that  must  be  used.  Any  methods  can  be  used,  as  long  as  they  have  the  required properties.  The  purpose  of  the  TSDs  is  to  further  explain  these  properties,  to  set  out  the implications for what kinds of analyses meet the requirements, and to describe some methods that can be used.\\n\\nThe series is intended primarily to address the issues of the relative and absolute efficacy of interventions.  Although oriented to the health technology appraisal process, they would  be equally  relevant  to  clinical  guideline  development,  or  to  comparisons  between  medical devices,  or  between  public  health  interventions.  The  series  does  not,  however,  cover questions arising in the synthesis of data on diagnostic test performance, or general synthesis of epidemiological data.\\n\\nThis  document  sets  the  scene  for  the  remaining  TSDs,  providing  a  general  outline  of  the overall  evidence  synthesis  process,  and  referring  forward  to  subsequent  TSDs  for  more detailed  information. We begin (Section 2) by describing the overall analytic approach, the distinction between a 'baseline' model, and the relative treatment effect usually informed by randomised  controlled  trial  (RCT)  evidence.  The  distinction  between  evidence  synthesis undertaken  specifically  for  decision  making  and  more  general  ideas  of  synthesis  as  a summary  of  what  appears  in  the  literature  is  also  explored.  Section  3  is  about  inclusion criteria for treatments and for trials. Here we suggest some simple rules that provide answers to questions such as: how far should an evidence network be extended? We also note the need to  address  potential  effect  modifiers  or  biases.  Section  4  deals  with  presentation  of  the evidence base, the synthesis methodology, the synthesis results, and the attention that must be given to model diagnosis and model choice. Finally, Section 5 provides a brief description of the  other  documents  in  the  series,  guiding  users  to  the  most  appropriate  document  for different analyses.\\n\\n## 2. OVERALL ANALYTIC APPROACH TO SYNTHESIS FOR COST EFFECTIVENESS ANALYSIS\\n\\n## 2.1. SEPARATE MODELS FOR BASELINE NATURAL HISTORY AND FOR RELATIVE TREATMENT EFFECTS\\n\\nThe  most  common  formula  that  is  followed  in  constructing  cost-effectiveness  analyses (CEAs)  is  to  divide  the  model  into  two  distinct  components:  a  'baseline'  natural  history model,  which  in  effect  represents  the  natural  history  of  patients  with  the  target  condition under  a  'standard'  comparator  treatment,  and  the  relative  treatment  effects.  The  natural history  for  the  'treatment  arms'  is  based  on  a  second  model  where  the  relative  treatment effects  are  appropriately  combined  with  the  baseline  model  to  generate  predicted  absolute effects for the non-standard treatments. The point in the natural history model at which the relative  effects  are  considered  to  act  depends  on  the  model.  In  models  for  Rheumatoid Arthritis, for example, the treatment effect generally acts on the probability that patients will stay  on  treatment  beyond  the  initial  3  to  6  months  trial  period. 2,3 In  models  of  smoking cessation, treatments are assumed to act on the probability of relapse within say 12 months. 4,5 A common, though not invariable feature of such natural history models is that, conditional on the initial response, the subsequent 'downstream' outcomes do not depend on treatment. Where  Markov  models  are  used,  treatment  effects  are  assumed  to  act  on  one  or  more transition probabilities.\\n\\nThe 2008 Methods Guide 1 requires that systematic literature search should be used to identify the data sources for both baseline, and relative treatment effects. TSD5 6 gives further details on methods for constructing the baseline model, while synthesis of relative effects is covered in TSD2. 7\\n\\n## 2.2. THE  DECISION-MAKING  CONTEXT  AND  METHODOLOGY  FOR  EVIDENCE SYNTHESIS\\n\\nThe methods proposed throughout this series of documents are designed for decision making and, indeed, for probabilistic modelling (see below). It is important, however, to be clear that the decision making context impresses itself on evidence synthesis methodology in a way that goes far beyond the choice of analytic methods and software. A decision maker has to have in\\n\\nmind a well-defined decision problem . This will consist of a target population of individuals not only with a specific condition, but probably at a specific point in a disease progression pathway. Accompanying this there will be a set of comparator interventions. Each candidate intervention  has  to  consist  of  a  pre-specified  dosing  regimen  and/or  a  particular  mode  of delivery, possibly with concomitant treatments that must also be defined. There is latitude, of course, for dosing regimens that start at one level and may then be increased or decreased according to a pre-specified monitoring system. However, it has to be possible, at the end of the  CEA to ascribe a single cost and a single effect to each  intervention alternative. Costs may be variable, and if so they should be appropriately averaged. Effects may vary as well, and may need to be modelled. But, eventually, expected lifetime costs and effects must be calculable, if necessary under some set of clearly stated assumptions.\\n\\nAs  a  result  it  has  long  been  recognised  that  the  trial  inclusion  criteria  for  a  synthesis undertaken for decision making, whether based on CEA or on an efficacy analysis alone, 8 is likely  to  be  drawn  more  narrowly  than  for  syntheses  whose  objective  can  be  described, perhaps, as a summary of literature. Likewise, previous authors have distinguished between evidence synthesis as 'science' and evidence synthesis as 'summary', 9 and the common use of  random  effect  models  to  average  over  important  heterogeneity  has  attracted  particular criticism. 10 Expressing  a  similar  view,  the  Cochrane  Handbook 11 states:  'meta-analysis should only be considered when a group of studies is sufficiently homogeneous in terms of participants, interventions and outcomes to provide a meaningful summary'.\\n\\nNevertheless,  this  advice  is  not  always  followed.  For  example,  an  overview  of  reviews  of treatments for enuresis presented trials that involved young children who were being treated for the first time alongside trials of older children and adolescents who had failed on the firstline  treatments. 12 Similarly,  in  treatments  for  Rheumatoid  Arthritis,  one  cannot  assess  the relative efficacy of biologics by combining trials of biologics in patients who have failed on standard therapies, with trials of patients who have failed on biologics. 13 Summaries of effect sizes  in  these  cases  lack  validity  because  young  children  and  adolescents  with  enuresis,  or patients who are naïve to biologics and those who have failed on them, represent different clinical  populations  and  require  different  decisions,  informed  by  different  summaries  of treatment effects. The effect of the decision-making context, therefore, is often to markedly reduce the clinical heterogeneity of the trials assembled for synthesis.\\n\\nSynthesis of evidence from clinically heterogeneous populations, not only increases the risk of statistical heterogeneity and inconsistency, but often requires highly implausible assumptions, such as assuming that interventions are equally effective in a naïve population\\n\\nor in a population that has already failed on that intervention or has contra-indications to its use.\\n\\nThe focus of this series of TSDs is, therefore, to provide a formal underpinning of studies of relative  efficacy  in  specific  decision  contexts.  These  synthesis  methods  can  be  applied equally  well  within  CEA,  Comparative  Effectiveness  Research, 14 or  within  intermediate forms  of  analysis  that  attempt  to  weigh  the  benefits  of  treatments  against  harms. 15 What distinguishes the decision context from a literature summary rationale for synthesis appears to be the clinical heterogeneity and the degree to which it needs to be addressed. The methods we propose can be used outside what we have referred to as a decision making context, but certain  key  assumptions  (TSD2 7 )  may  not  hold.  Furthermore,  without  a  clearly  defined decision problem it is not clear how the results should be interpreted.\\n\\n## 2.3. ANALYTIC METHODS COMPATIBLE WITH PROBABILISTIC COSTEFFECTIVENESS ANALYSIS.\\n\\nThere are a wide range of methods for synthesising information on relative treatment effects. The  NICE  methods  guide 1 states  that  probabilistic  methods 16,17 are  preferred  for  costeffectiveness analyses. This puts some constraints, if not on the kinds of synthesis methods that must be used, then certainly on the way outputs from the synthesis are fed into the CEA. The  synthesis  methods  described  in  TSDs  2,  3  and  5  are  specifically  designed  to  be compatible with probabilistic CEA. A set of alternative approaches to incorporate the results from the synthesis into the CEA are described in TSD6. 18\\n\\n## 3. DATASET FOR EVIDENCE SYNTHESIS OF RELATIVE TREATMENT EFFECTS\\n\\nWithin the context of NICE Technology Appraisals or Guidelines, an initial scoping exercise will  have defined the target population(s)  for whom one or more decisions are to be made. The specification may refer, for example, to a stage of disease progression, a level of disease severity, previous treatments that have failed or that are contra-indicated for whatever reason, or  to  various  combinations  of  these.  The  wider  the  definition  of  the  target  population,  the greater  the  potential  for  clinical  and  statistical  heterogeneity,  as  discussed  in  Section  2, raising the possibility of different decisions in different groups of patients.\\n\\n## 3.1. COMPARATOR SETS FOR DECISION AND FOR SYNTHESIS\\n\\nAn initial set of treatments that are to be compared will have been identified in the scoping exercise.  We will  call  this  the decision comparator set. Ideally,  this  should  include  all  the candidate  treatments  for  the  target  population  in  question.  If  it  is  not  possible  to  form  a connected network of comparisons of these treatments based on randomised data, it may be possible  to  introduce  further  treatments  so  that  a  connected  network  can  be  formed.  For example, in Figure 1 the treatments A and B have been compared in RCTs, but treatment C has  not  been  compared  to  either  A  or  B.  An  additional  treatment  X  has  been  introduced because  there  are  AX  and  CX  trials,  forming  a  connected  network.  Thus,  the synthesis comparator set consists of A, B, C, and X and is different from the decision comparator set A, B, C.\\n\\nOther ways to deal with disconnected networks are discussed in Section 3.5.\\n\\nFigure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in bold.  Treatment X has  been  added  to  the  synthesis  set  because  it  links  treatment  C  to  the  rest  of  the network (dashed lines).\\n\\n<!-- image -->\\n\\n## 3.2. TRIAL INCLUSION AND EXCLUSION\\n\\nOnce  the  target  population  and  the  synthesis  comparator  set  have  been  defined,  the  trial inclusion criteria are, in principle, relatively easy to implement. All trials on the target patient population that  compare  two  or  more  of  the  treatments  from  the  synthesis comparator  set should be included. This wording is constructed with the intent of producing an unambiguous definition that eliminates the risk of what could be perceived as 'gaming' with trial inclusion and exclusion criteria, that is, deliberately leaving out or including trials in order to obtain a particular result. It also clarifies that, even though the key comparisons might be considered\\n\\nto  be  those  involving  a  particular  active  treatment  and  one  or  more  standard  comparators, 'head-to-head' trials comparing similar active treatments must also be included. Note that if there was a three arm trial comparing A vs B vs Z, and treatment Z is not in the synthesis comparator set, the Z arm would be dropped as it adds no further information, but the A vs B comparison would be used, as long as it was on the same patient population. It is important to include all the trials that compare any of the treatments in the synthesis comparator set. This is  because  decisions  are  usually  based  on  an  incremental  CEA,  which  means  that,  for  any treatments  A,  B,  C,  trials  comparing  AB,  AC,  and  BC  must  all  be  considered  equally informative. Indeed,  in  this  context,  it  is  technically  impossible  to  distinguish  'direct'  and 'indirect'  evidence  -  direct  evidence  for  one  model  parameter  is  indirect  evidence  for another.\\n\\nIt  is  sometime  argued  that  trials  which  are  not  'double-blind',  or  trials  which  are  small should  be  excluded.  In  general,  no  trials  that  would  be  included  if  the  above  rules  were followed  should  be  excluded  without  a  clear  reason  being  given.  For  example,  one conceivable reason for excluding small trials might be on the basis that they were more likely to be biased, often termed 'small study bias', where trial size is used as a proxy for factors associating trial quality with increased effect size. However, in this case, it would be prudent to consider how sensitive the CEA would be to inclusion or exclusion of 'small' trials, and also what effect bias adjustment procedures might have (see TSD3 19 ). Another reason that is sometimes given for excluding a trial is on the basis that it was designed as a 'non-inferiority trial'.  This  is  not,  however, a  valid reason  for exclusion. The rationale  for the sample size calculations has no obvious connection to the size or direction of the effect estimate.\\n\\nAnother reason given for not including data is that outcomes are reported in a different way. We show in later documents 6,7,19 how different outcomes can in many cases be synthesized in a single coherent analysis, although this may not always be possible. However one frames the 'rules'  for  trial  inclusion  and  exclusion,  subjective  judgement  is  required  about  whether  a trial's target population does or does not match the target population for the present decision, or  there  may  be  doubts  on  whether  the  interventions  compared  are  sufficiently  similar  to those  defined  in  the  synthesis  comparator  set.  Investigators  may  wish  to  argue  that  the relative  treatment  effects  will  be  the  same  in  this  group  and  that  such  trials  should  be included, or that they are not, in which case they would be excluded. In such cases it may be possible  to  use  bias  or  covariate  adjustment  methods  (TSD3 19 ).  Alternatively,  some  of  the trial evidence could involve a mixture of patients, for example children and adults, while the target  population  for  decision  is  adults  alone.  Whether  or  not  such  evidence  should  be\\n\\nincluded depends on whether it can be used to inform the parameter of interest. Regression adjustment for the proportion of adults, for example, may be possible (see TSD3 19 ), but the comments on ecological  and  aggregation  biases  in  TSD3 19 (Section  1)  must  be  taken  into account.  Whenever  trial  inclusion  or  exclusion  is  debatable  or  depends  on  judgement, sensitivity analyses should be used to assess the impact on the decision.\\n\\n## 3.3. EXTENSION OF THE SYNTHESIS COMPARATOR SET\\n\\nIt is  sometimes asked: how far should a network be extended? There is no specific need to extend the synthesis comparator set beyond the comparator set for decision making, unless such an extension is required to produce a connected network. Extending the network further does have potential advantages such as, for example, strengthening inference, 20 producing a more robust analysis which is less sensitive to specific sources of data, the ability to check consistency  more  thoroughly  (see  TSD4 21 ),  and  the  ability  to  identify  effect  modifiers  or carry out bias adjustment (see TSD3 19 ). Thus, while extension of the network is not ruled out, in  the  spirit  of  the  2008  Methods  Guide, 1 it  would  not  be  considered  as  the  'base-case' analysis.  Further,  counter-balancing  the  potential  advantages  outlined  above,  there  are  a number of potential dis advantages. These would include an increased danger of introducing effect modifiers as the more 'remotely' connected treatments are more likely to have been trialled  on  somewhat  different  patient  populations.  There  may  be  a  particular  danger  in extending the network to include treatments that were trialled earlier, particularly if - as is so often the case - date is associated with severity of condition.\\n\\nThe  situation  in  Figure  1,  where  a  new  treatment  is  introduced  to  connect  the  network, suggests an exception to the above. In this case, if the network could have been connected either by the addition of BY and CY trials, or by the addition of AX and CX trials, then it would seem logical that both X and Y should be added to the synthesis comparison set. Then, in accordance with the rules given for trial inclusion, X vs Y trials would need to be included as well.\\n\\nFinally,  another  reason for  extending  the  set  of  trials  beyond  the  set  of  immediate comparators  is  to  estimate  relationships  between  outcomes  and  use  this  to  fill  gaps  in  the evidence base. For example, a cost-effectiveness model for cancers may require information on  percent  responders,  on  time  to  tumour  progression,  and  time  to  death.  Some  of  this information may  not be reported within the synthesis comparator set. Under  these circumstances it may be possible to estimate the relationships from a wider set of trials, either\\n\\nin  the  same  statistical  analysis  (preferable)  or  separately,  and  then  apply  the  estimated relationship  to  the  treatments  where  it  is  missing.  This  approach  has  been  adopted  in advanced  breast  cancer 22 but  it  can  be  applied  in  any  situation  where  there  are  related multiple outcomes. Another example would be in treatments for influenza where trials may report one or more of time to end of fever, time to end of symptoms, time to return to work, and so on. 23,24 The advantage of these more complex forms of synthesis is that they provide more stable estimates where data are sparse, and allow investigators to produce estimates for less  commonly reported outcomes that are appropriately  'calibrated' to the available data. However, they require a range of assumptions, particularly regarding the constancy of certain relationships between outcomes, that need to be checked against expert clinical opinion, and wherever possible, empirically.\\n\\n## 3.4. RECORDING OF TREATMENT EFFECT MODIFIERS\\n\\nIt is  important that investigators thoroughly research previous literature and consult clinical experts to assess whether there are known or likely treatment effect modifiers for any of the interventions in the comparator set for synthesis. The presence of effect modifiers in the trials should  be  recorded,  and  taken  into  consideration  during  the  synthesis,  as  they  may  have  a bearing  on  heterogeneity  and  bias  adjustment  (TSD3 19 )  or  inconsistency  in  networks (TSD4 21 ).\\n\\n## 3.5. DEALING WITH DISCONNECTED NETWORKS\\n\\nAlthough the focus of the TSDs is for situations where a connected evidence network can be constructed  from  randomised  evidence,  there  may  be  situations  like  the  one  depicted  in Figure 2 where the evidence forms two, or even more, disconnected elements. In these cases the methods described in TSD2 7 cannot be applied without further assumptions being made.\\n\\n<!-- image -->\\n\\nC\\n\\nFigure 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments X and Y.\\n\\nThese assumptions must take the form of a relative treatment effect linking the two networks. For example an assumption may be made about the relative efficacy of treatment X relative to A, of treatment Y relative to A, or of treatment X relative to B, and so on. From a technical point of view a distribution for such a treatment effect can readily be inserted into a synthesis (see  methods  for  shared  parameter  models  in  TSD2 7 )  and  expert  opinion  or  observational data  can  be  used  to  inform  the  treatment  effect. The  difficulty,  of  course,  lies  in  making  a convincing case for the central estimate of the 'missing' treatment effect and assigning it a variance that appropriately reflects the  increased  uncertainty attaching to a non-randomised comparison. The increased uncertainty will affect comparisons between, but not within, the two networks.\\n\\n## 4. PRESENTATION OF THE EVIDENCE AND THE RESULTS OF EVIDENCE SYNTHESIS\\n\\n## 4.1. THE EVIDENCE BASE\\n\\nWhere there are more than two treatments in the comparator set for synthesis, it is helpful to show  a  network  diagram  (such  as  Figure  1).  Software  for  automatically  drawing  such diagrams is available as stand-alone programs with multiple capabilities (e.g. Pajek 25 ) or as packages and routines developed for R 26 among other programs.\\n\\nFurther  refinements  in  network  diagrams  which  can  be  implemented  in  various  software include: adding the number of studies making that comparison to each connecting line (see Figure 3);  having  the  thickness  of  the  connecting  lines  reflect  the  number  of  trials  on  that\\n\\ncontrast  and  the  size  of  the  vertices  reflect  the  number  of  patients  included  in  that comparison. 27 A second useful presentation is a table of the sort shown as Table 1. This has a separate  row  for  each  trial,  with  columns  for  each  treatment  where  the  presence  of  data indicates which treatments have been compared in each trial arm. It is also convenient to add to  the  table  trial  level  covariate  values,  or  to  indicate  whether  individual  participant  data (IPD) are available. Another useful representation of the same data is given in TSD3. 19\\n\\nTable 1 Certolizumab Pegol (CZP) for Rheumatoid Arthritis: 28 number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with Placebo, and mean disease  duration  (in  years)  for  patients  in  each  trial.  Blank  cells  indicate  that  the  treatment  was  not compared in that trial. All trial arms had Methotrexate in addition to the placebo or active treatment.\\n\\n| Study Name     | Placebo   | CZP     | Adalimumab   | Etanercept   | Infliximab   | Rituximab   | Tocilizumab   |   Mean disease duration (years) |\\n|----------------|-----------|---------|--------------|--------------|--------------|-------------|---------------|---------------------------------|\\n| Kim 2007       | 9/63      |         | 28/65        |              |              |             |               |                           6.85  |\\n| DE019          | 19/200    |         | 81/207       |              |              |             |               |                          10.95  |\\n| ARMADA         | 5/62      |         | 37/67        |              |              |             |               |                          11.65  |\\n| RAPID 1        | 15/199    | 146/393 |              |              |              |             |               |                           6.15  |\\n| RAPID 2        | 4/127     | 80/246  |              |              |              |             |               |                           5.85  |\\n| START          | 33/363    |         |              |              | 110/360      |             |               |                           8.1   |\\n| ATTEST         | 22/110    |         |              |              | 61/165       |             |               |                           7.85  |\\n| Abe 2006*      | 0/47      |         |              |              | 15/49        |             |               |                           8.3   |\\n| Weinblatt 1999 | 1/30      |         |              | 23/59        |              |             |               |                          13     |\\n| Strand 2006    | 5/40      |         |              |              |              | 5/40        |               |                          11.25  |\\n| CHARISMA*      | 14/49     |         |              |              |              |             | 26/50         |                           0.915 |\\n| OPTION         | 22/204    |         |              |              |              |             | 90/205        |                           7.65  |\\n\\n* ACR50 at 3 months\\n\\n## 4.2. DESCRIPTION OF SYNTHESIS METHODOLOGY\\n\\nIn  the  interests  of  transparency,  reviewers  and  general  readers  must  be  provided  with sufficient information that would allow them to exactly reproduce the analyses, if they had access  to  the  data.  If  possible  journal  citations  for  the  precise  model  of  the  data  being assumed,  and/or  citation  of  the  source  of  software  code,  must  be  provided.  Otherwise  the statistical model for the synthesis should be set out fully in algebraic form. The software code used  for  the  synthesis  should  be  annotated  and  made  available,  along  with  the  data  used, although  in  some  situations confidentiality  requirements  may  prevent the  latter  from  being released.\\n\\nA clear discussion of the underlying statistical and clinical assumptions implied by the model, and  their  impact  on  the  final  decision  should  also  be  provided.  In  particular,  reasons  for\\n\\nchoosing  to  model  the  outcomes  on  a  particular  scale  (e.g.  odds  ratio,  hazard  ratio,  risk difference  etc)  and  the  assumptions  implied  in  any  transformation  from  the  relative  to  the absolute effects should be clearly presented (see TSD2 7 , Section 2).\\n\\n## 4.3. PRESENTATION OF SYNTHESIS RESULTS\\n\\nAlthough the parameters required  by the  CEA tend to be the absolute treatment effects of each treatment, it  is  essential that both the relative treatment effects, which are the outputs from  the  evidence  synthesis,  and  the  absolute  effects  on  which  the  CEA  is  based  are presented.  It  is  important  for  those  reviewing  and  evaluating  submissions  that  there  is absolute clarity  and  transparency  about  exactly  what  relative  efficacies  between  treatments are being assumed, and exactly what absolute effects are going forward into the CEA. This can  be  achieved  in  a  number  of  ways.  Perhaps  the  simplest  method  is  a  table  of  the  mean treatment effect with 95% Credible Intervals (CrI), of every treatment relative to placebo, or to a standard comparator. Table 2 gives an example, of the relative and absolute mean offtime reduction in patients given four dopamine agonists and Placebo as adjunct therapy for Parkinson's disease. The treatment network is presented in Figure 3 (for further details see TSD2 7 , Example 5).\\n\\nTable 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the  mean off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5.\\n\\n|             |             | mean                                          | sd                                            | 95% CrI                                       |\\n|-------------|-------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|\\n| X           | Y           | Relative effects of treatment Y compared to X | Relative effects of treatment Y compared to X | Relative effects of treatment Y compared to X |\\n| Placebo     | Treatment 2 | -1.81                                         | 0.33                                          | (-2.46,-1.16)                                 |\\n| Placebo     | Treatment 3 | -0.47                                         | 0.49                                          | (-1.43,0.49)                                  |\\n| Placebo     | Treatment 4 | -0.52                                         | 0.48                                          | (-1.46,0.43)                                  |\\n| Placebo     | Treatment 5 | -0.82                                         | 0.52                                          | (-1.84,0.22)                                  |\\n|             |             | Absolute treatment effects                    | Absolute treatment effects                    | Absolute treatment effects                    |\\n| Placebo     | Placebo     | -0.73                                         | 0.22                                          | (-1.16,-0.30)                                 |\\n| Treatment 2 | Treatment 2 | -2.54                                         | 0.40                                          | (-3.32,-1.76)                                 |\\n| Treatment 3 | Treatment 3 | -1.21                                         | 0.53                                          | (-2.25,-0.15)                                 |\\n| Treatment 4 | Treatment 4 | -1.25                                         | 0.53                                          | (-2.28,-0.21)                                 |\\n| Treatment 5 | Treatment 5 | -1.55                                         | 0.57                                          | (-2.66,-0.43)                                 |\\n\\n<!-- image -->\\n\\nTreatment 3\\n\\nFigure  3  Parkinson  network:  each  edge  represents  a  treatment,  connecting  lines  indicate  pairs  of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers of trials making that comparison.\\n\\nAnother format (Table 3) allows investigators to contrast results of pair-wise meta-analyses with  the  results  of  a  network  synthesis.  Although  this  table  does  not  constitute  a  formal analysis of inconsistency in the network (see TSD4 21 ), if the direct estimates are very close to their  network counter-parts, there  may  be  no need to proceed with further consideration of inconsistency. Similarly, graphical displays such as forest plots which summarise the results in  the  tables  along  with  the  raw  effect  estimates  from  each  trial  informing  that  treatment comparison, can also be presented. TSD3 19 shows an example of these plots (Example 2 in the Appendix).\\n\\nTable 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta-analysis and separate pairwise meta-analyses with fixed effects.\\n\\n|             |             | Network Meta-analysis   | Network Meta-analysis   | Network Meta-analysis   | Pairwise Meta-analyses   | Pairwise Meta-analyses   | Pairwise Meta-analyses   |\\n|-------------|-------------|-------------------------|-------------------------|-------------------------|--------------------------|--------------------------|--------------------------|\\n| X           | Y           | mean                    | sd                      | 95% CrI                 | mean                     | sd                       | 95% CrI                  |\\n| Placebo     | Treatment 2 | -1.81                   | 0.33                    | (-2.46,-1.16)           | -1.83                    | 0.34                     | (-2.49,-1.17)            |\\n| Placebo     | Treatment 3 | -0.47                   | 0.49                    | (-1.43,0.49)            | -0.31                    | 0.67                     | (-1.62,1.00)             |\\n| Placebo     | Treatment 4 | -0.52                   | 0.48                    | (-1.46,0.43)            | -0.90                    | 0.69                     | (-2.26,0.46)             |\\n| Placebo     | Treatment 5 | -0.82                   | 0.52                    | (-1.84,0.22)            | -                        | -                        | -                        |\\n| Treatment 2 | Treatment 3 | 1.34                    | 0.54                    | (0.28,2.41)             | -                        | -                        | -                        |\\n| Treatment 2 | Treatment 4 | 1.29                    | 0.52                    | (0.27,2.32)             | 1.40                     | 0.70                     | (0.03,2.77)              |\\n| Treatment 2 | Treatment 5 | 0.99                    | 0.56                    | (-0.10,2.10)            | -                        | -                        | -                        |\\n| Treatment 3 | Treatment 4 | -0.04                   | 0.32                    | (-0.68,0.59)            | 0.00                     | 0.35                     | (-0.68,0.68)             |\\n| Treatment 3 | Treatment 5 | -0.34                   | 0.38                    | (-1.10,0.41)            | -                        | -                        | -                        |\\n| Treatment 4 | Treatment 5 | -0.30                   | 0.21                    | (-0.71,0.11)            | -0.30                    | 0.21                     | (-0.71,0.11)             |\\n\\nA number of authors tabulate the probability that each treatment is best, which is an output available  from  Bayesian or other simulation-based approaches. This should be treated with\\n\\ngreat caution, however, particularly when there are many treatment alternatives. A treatment whose mean effect ranks quite low may still have a high probability of being best if there is relatively more uncertainty in its mean effect. This is misleading because for a given set of expected  (mean)  treatment  effects,  greater  uncertainty  may  flatter  a  treatment.  Differences between  treatments  in  probability  of  being  best  of  less  than  90%  cannot  be  given  much credence. A more reliable indicator is a plot of the rankings of each treatment. When there are multiple  outcomes,  for  example  remission,  relapse,  discontinuation  due  to  side  effects, 'rankograms'  for  each  treatment,  which  plot  the  ranks  on  each  outcome,  can  be  very informative. Readers are referred to Cipriani et al. 29 , where these plots first appeared, and to Ades  et  al. 30 for  a  further  application.  Salanti  et  al. 31 suggest  a  number  of  graphical presentations of results that may be useful in different circumstances.\\n\\n## 4.4. MODEL DIAGNOSIS AND SELECTION\\n\\nIt is essential that the model that is chosen is compatible with the evidence. While questions of statistical  inference  are  less relevant  in decision  making, where a  'balance of evidence' approach, takes precedence over 'significance testing', the question of whether the model fits the data is still relevant. Decisions must be based on an internally coherent model, which is compatible with all the available evidence. Methods for assessing model fit are discussed in TSD2, 7 and  there  is  a  discussion  of  heterogeneity  and  outlier  detection  in  TSD3. 19 Where several synthesis models were examined, an explanation must be provided for the choice of model  that  is  put  forward  into  the  CEA.  Choice  of  fixed  or  random  effects  models  for synthesis of relative treatment effects is a common example (see TSD2 7 ). Where the evidence is  compatible  with  more  than  one  model,  a  sensitivity  analysis  can  be  used  to  establish whether or not the CEA results are sensitive to model choice.\\n\\n## 5. USING THE TECHNICAL SUPPORT DOCUMENTS\\n\\nTSD2 7 presents  a  general  framework  for  pairwise  and  network  meta-analysis  for  different data  types,  with  details  of  fixed  and  random  effects  models  for  different  outcome  types, assumptions and applications. It highlights the importance of using the appropriate model for the type of data available and shows how to combine data given in different formats.\\n\\nTSD3 19 considers  outlier  detection  and  covariate  and  bias  adjustment  in  detail. Models  for different  types  of  regression  in  both  pairwise  and  network  meta-analysis  are  given  with  a\\n\\ndiscussion  of  the  assumptions  and  risks  of  meta-regression,  as  well  as  its  implications  for decision-making.\\n\\nTSD4 21 defines  inconsistency  in  a  network  meta-analysis.  It  describes  how  to  detect  and locate inconsistency, its likely causes and steps that should be taken to avoid it.\\n\\nTSD5 6 provides  guidance  on  how  a  baseline  model  can  be  informed  and  built,  discusses sources of evidence which can be used to inform a baseline model, and provides examples of baseline models.\\n\\nTSDs 2, 3, 4 and 5 include an extensive set of worked examples of analyses using Bayesian Markov  chain  Monte  Carlo  methods  in  WinBUGS  and  provide  generic  code  applied  to illustrative  examples.  The  WinBUGS  code  is  also  available  for  download  as  WinBUGS system (.odc) files (users are advised to download these files instead of copying and pasting code from the TSDs).\\n\\nAlthough  the  models,  worked  examples  and  WinBUGS  code  in  TSDs  3,  4  and  5  are  for binary data, TSD2 shows how they can be changed to suit other types of data.\\n\\nTSD6 18 describes some of the software which can be used to implement the models described in TSDs 2 to 5 and to incorporate the results of the evidence synthesis into a decision model.\\n\\nFinally, TSD7 32 provides a reviewer's checklist. It focuses on a series of questions aimed at revealing the assumptions underlying the synthesis, the adequacy of the arguments in support of these assumptions, and aims to inform a decision on the need for further analyses.\\n\\n## 6. REFERENCES\\n\\n1.   National  Institute  for  health  and  Clinical  Excellence.  Guide  to  the  methods  of technology appraisal (updated June 2008). 2008.\\n2.   Brennan,  A.,  Bansback,  N.,  Nixon,  R.,  Madan,  J.,  Harrison,  M.,  Watson,  K.  et  al. Modelling  the  cost  effectiveness  of  TNF-alpha  antagonists  in  the  management  of rheumatoid  arthritis:  results  from  the  British  Society  for  Rheumatology  Biologics Registry. Rheumatology 2007; 46:1345-1354.\\n3.   Woolacott, N.F., Bravo Vergel, Y., Hawkins, N., Kainth, A., Khadjesari, Z., Misso, K. et  al.  Etanercept  and  infliximab  for  the  treatment  of  psoriatic  arthritis:  a  systematic review and economic evaluation. Health Technology Assessment 2006; 10(31).\\n4.   Woolacott, N.F., Jones, L., Ford, C.A., Mather, L.C., Sowden, A.J., Song, F.J. et al. The clinical  effectiveness  and  cost-effectiveness  of  buproprion  and  nicotine  replacement therapy  for  smoking  cessation:  a  systematic  review  and  economic  evaluation. Health Technology Assessment 2002; 6(16):1-245.\\n5.   Wang, D., Connock, M., Barton, P., Fry-Smith, A., Aveyard, P., Moore, D. 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis. Health Technology Assessment 2008; 12(2).\\n6.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  5:  Evidence  synthesis  in  the  baseline  natural  history  model.  2011;  last updated April 2012; available from http://www.nicedsu.org.uk\\n7.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  2:  A  generalised  linear  modelling  framework  for  pair-wise  and  network meta-analysis of randomised controlled trials. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n8.   Eccles,  M.,  Freemantle,  N.,  Mason,  J.  Using  systematic  reviews  in  clinical  guideline development. In: Egger M., Davey Smith G., Altman D.G., eds. Systematic Reviews in Health Care: meta-analysis in context . Second ed. BMJ; London: 2001; 400-409.\\n9.   Rubin, D.B. A new perspective. In: Wachter K.W., Straf M.L., eds. The Future of Metaanalysis . Russell Sage Foundation; New York: 1990.\\n10.   Greenland,  S.  Invited  commentary:  A  critical  look  at  some  popular  meta-analytic methods. American Journal Of Epidemiology 1994; 140(3):290-296.\\n11.   Higgins, J.P.T., Green, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, Wiley, Chichester; 2008.\\n12.   Russell,  K.,  Kiddoo,  D.  The  Cochrane  library  and  nocturnal  enuresis:  an  umbrella review. Evidence-Based Child Health: a Cochrane Review Journal 2006; 1(1):5-8.\\n\\n13.   Wells,  G.A.,  Sultan,  S.A.,  Chen,  L.,  Khan,  M.,  Coyle,  D.  Indirect  Evidence:  Indirect Treatment Comparisons in Meta-Analysis. Cochrane Database of Systematic Reviews 2009. Ottawa, Canadian Agency for Drugs and Technologies in Health.\\n14.   Iglehart, J.K. Prioritizing comparative-effectiveness research - IOM recommendations. New England Journal of Medicine 2009; 361:325-328.\\n15.   Glasziou,  P.P.,  Irwig,  L.M.  An  evidence-based  approach  to  individualising  treatment. British Medical Journal 1995; 311:1356-1359.\\n16.   Doubilet,  P.,  Begg,  C.B.,  Weinstein,  M.C.,  Braun,  P.,  McNeill,  B.J.  Probabilistic sensitivity  analysis  using  Monte  Carlo  simulation:  a  practical  approach. Medical Decision Making 1985; 5:157-177.\\n17.   Critchfield,  G.C.,  Willard,  K.E.  Probabilistic  analysis  of  decision  trees  using  Monte Carlo simulation. Med Decis Making, MED 1986; 6:85-92.\\n18.   Dias,  S.,  Sutton,  A.J.,  Welton,  N.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document 6: Embedding evidence synthesis in probabilistic cost-effectiveness analysis: software choices. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n19.   Dias,  S.,  Sutton,  A.J.,  Welton,  N.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  3:  Heterogeneity:  subgroups,  meta-regression,  bias  and  bias-adjustment. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n20.   Cooper,  N.J.,  Peters,  J.,  Lai,  M.C.W.,  Juni,  P.,  Wandel,  S.,  Palmer,  S.  et  al.  How valuable  are  multiple  treatment  comparison  methods  in  evidence-based  health-care evaluation? Value in Health 2011; 14:371-380.\\n21.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Caldwell,  D.M.,  Lu,  G.,  Ades,  A.E.  NICE  DSU Technical  Support  Document  4:  Inconsistency  in  networks  of  evidence  based  on randomised controlled trials. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n22.   Welton,  N.J.,  Willis,  S.R.,  Ades,  A.E.  Synthesis  of  Survival  and  Disease  Progression Outcomes for Health Technology Assessment of Cancer Therapies. Research Synthesis Methods 2010; 1:239-257.\\n23.   Welton, N.J., Cooper, N.J., Ades, A.E., Lu, G., Sutton, A.J. Mixed  treatment comparison with multiple outcomes reported inconsistently across trials: evaluation of antivirals  for  treatment  of  influenza  A  and  B. Statistics  In  Medicine 2008;  27:56205639.\\n24.   Burch, J., Paulden, M., Conti, S., Stock, C., Corbette, M., Welton, N.J. et al. Antiviral drugs  for  the  treatment  of  influenza:  a  systematic  review  and  economic  evaluation. Health Technology Assesment 2010; 13(58):1-290.\\n25.   Batagelj,  V.,  Mrvar,  A.  Pajek  -  Program  for  Large  Network  Analysis. Connections 1998; 21(2):47-57.\\n\\n26.   R:  A  Language  and  Environment  for  Statistical  Computing  [  Windows.  Vienna, Austria: R Foundation for Statistical Computing; 2010.\\n27.   Salanti, G. Multiple-treatments meta-analysis of a network of interventions. http://www mtm uoi gr/ 2011;  Available from http://www.mtm.uoi.gr/\\n28.   National  Institute  for  health  and  Clinical  Excellence.  Certolizumab  pegol  for  the treatment  of  rheumatoid  arthritis.  2010;  TA186.    National  Institute  for  Health  and Clinical Excellence. NICE technology appraisal guidance.\\n29.   Cipriani, A., Furukawa, T.A., Salanti, G., Geddes, J.R., Higgins, J.P.T., Churchill, R. et al.  Comparative  efficacy  and  acceptability  of  12  new  generation  antidepressants:  a multiple-treatments meta-analysis. Lancet 2009; 373:746-758.\\n30.   Ades,  A.E.,  Mavranezouli,  I.,  Dias,  S.,  Welton,  N.J.,  Whittington,  C.,  Kendall,  T. Network meta-analysis with competing risk outcomes. Value in Health 2010; 13(8):976-983.\\n31.   Salanti, G., Ades, A.E., Ioannidis, J.P.A. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011; 64:163-171.\\n32.   Ades, A.E., Caldwell, D.M., Reken, S., Welton, N.J., Sutton, A.J., Dias, S. NICE DSU Technical  Support  Document  7:  Evidence  synthesis  of  treatment  efficacy  in  decision making: a reviewer's checklist. 2012; available from http://www.nicedsu.org.uk\"),\n",
       " Document(id='a4d04a43-a78a-4e45-9baf-2e8e7c60b35e', metadata={'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content=\"## NICE DSU TECHNICAL SUPPORT DOCUMENT 6: EMBEDDING EVIDENCE SYNTHESIS IN PROBABILISTIC COST-EFFECTIVENESS ANALYSIS: SOFTWARE CHOICES\\n\\n## REPORT BY THE DECISION SUPPORT UNIT\\n\\nMay 2011 (last updated April 2012)\\n\\nSofia Dias 1 , Alex J Sutton 2 , Nicky J Welton 1 , AE Ades 1\\n\\n1 School  of  Social  and  Community  Medicine,  University  of  Bristol,  Canynge  Hall,  39 Whatley Road, Bristol BS8 2PS, UK\\n\\n2 Department  of  Health  Sciences,  University  of  Leicester,  2nd  Floor  Adrian  Building, University Road, Leicester LE1 7RH, UK\\n\\nDecision Support Unit, ScHARR, University of Sheffield, Regent Court, 30 Regent Street Sheffield, S1 4DA;\\n\\nTel (+44) (0)114 222 0734 E-mail dsuadmin@sheffield.ac.uk\\n\\n## ABOUT THE DECISION SUPPORT UNIT\\n\\nThe Decision Support Unit (DSU) is a collaboration between the Universities of Sheffield, York and Leicester. We also have members at the University of Bristol, London School of Hygiene and Tropical Medicine and Brunel University.\\n\\nThe  DSU  is  commissioned  by  The  National  Institute  for  Health  and  Clinical  Excellence (NICE)  to  provide  a  research  and  training  resource  to  support  the  Institute's  Technology Appraisal Programme. Please see our website for further information www.nicedsu.org.uk\\n\\n## ABOUT THE TECHNICAL SUPPORT DOCUMENT SERIES\\n\\nThe NICE Guide to the Methods of Technology Appraisal i is a regularly updated document that provides an overview of the key principles and methods of health technology assessment and  appraisal  for  use  in  NICE  appraisals.  The  Methods  Guide  does  not  provide  detailed advice  on  how  to  implement  and  apply  the  methods  it  describes.  This  DSU  series  of Technical  Support  Documents  (TSDs)  is  intended  to  complement  the  Methods  Guide  by providing detailed information on how to implement specific methods.\\n\\nThe TSDs provide a review of the current state of the art in each topic area, and make clear recommendations  on  the  implementation  of  methods  and  reporting  standards  where  it  is appropriate to do so. They aim to provide assistance to all those involved in submitting or critiquing evidence as part  of  NICE  Technology  Appraisals,  whether manufacturers, assessment groups or any other stakeholder type.\\n\\nWe recognise that there are areas of uncertainty, controversy and rapid development. It is our intention that such areas are indicated in the TSDs. All TSDs are extensively peer reviewed prior to publication (the names of peer reviewers appear in the acknowledgements for each document).  Nevertheless,  the  responsibility  for  each  TSD  lies  with  the  authors  and  we welcome any constructive feedback on the content or suggestions for further guides.\\n\\nPlease be aware that whilst the DSU is funded by NICE, these documents do not constitute formal NICE guidance or policy.\\n\\n## Dr Allan Wailoo\\n\\nDirector of DSU and TSD series editor.\\n\\ni National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal, 2008 (updated June 2008), London.\\n\\n## Competing interests\\n\\nAlex  Sutton  has  received  financial  reimbursement  when  working  as  an  advisor  on  the development of the Comprehensive Meta-Analysis software package.\\n\\n## Acknowledgements\\n\\nThe DSU thanks Rachael Fleurence, Jeroen Jansen, Alec Miners, Jaime Peters, Mike Spencer and the team at NICE, led by Gabriel Rogers, for reviewing this document. The editor for the TSD series is Allan Wailoo.\\n\\nThe production of this document was funded by the National Institute for Health and Clinical Excellence  (NICE)  through  its  Decision  Support  Unit.  The  views,  and  any  errors  or omissions, expressed in this document are of the author only. NICE may take account of part or all of this document if it considers it appropriate, but it is not bound to do so.\\n\\n## This report should be referenced as follows:\\n\\nDias, S., Sutton, A.J., Welton, N.J. &amp; Ades, A.E. NICE DSU Technical Support Document 6: Embedding evidence synthesis in probabilistic cost-effectiveness analysis: software choices. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n\\n## EXECUTIVE SUMMARY\\n\\nThis  document  sets  out  software  options  for  evidence  synthesis  that  are  compatible  with probabilistic  cost-effectiveness  analysis,  which  is  the  preferred  methodology  for  the  NICE reference case. Four possibilities are discussed:\\n\\n1. Evidence synthesis  by Bayesian posterior estimation, and posterior sampling. Other parameters  of  the  cost-effectiveness  models  can  be  incorporated  into  the  same software  platform.  Bayesian  Markov  chain  Monte  Carlo  simulation  methods  with WinBUGS software are the most popular choice.\\n2. Evidence synthesis by Bayesian posterior estimation. Posterior samples are exported to another package where the other parameters are generated and the costeffectiveness model evaluated.\\n3. Frequentist  methods  of  parameter  estimation  followed  by  forward  Monte  Carlo simulation  from  the  maximum  likelihood  estimates  and  their  variance-covariance matrix\\n4. Bootstrap re-sampling - a frequentist simulation approach to parameter estimation.\\n\\nWhen multiple parameters are estimated from the same synthesis model, we emphasise the need to choose a method that propagates the parameter correlation structure through the costeffectiveness  model.  A  table  is  provided  that  shows  the  possible  approaches  and  the restrictions on their use.\\n\\nSoftware packages for evidence synthesis are listed. Technical issues relating to software are covered in an Appendix. Finally we mention software suitable for transferring data between different software packages, and software that provides user-friendly interface for integrated software  platforms.  These  offer  investigators  a  flexible  way  of  examining  alternative scenarios.\\n\\n## CONTENTS\\n\\n| 1. 2.                                                                                                                                                                                                                                                                                                   | INTRODUCTION....................................................................................................... EMBEDDING EVIDENCE SYNTHESIS IN PROBABILISTIC CEA....................                                                                                                               | 7 8                                                                                                                                                                                                                                                                                                     |\\n|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\\n|                                                                                                                                                                                                                                                                                                         | 2.1. BAYESIAN POSTERIOR SIMULATION: ONE-STAGE APPROACH.....................................                                                                                                                                                                                                             | 2.1. BAYESIAN POSTERIOR SIMULATION: ONE-STAGE APPROACH.....................................                                                                                                                                                                                                             |\\n| 2.2.                                                                                                                                                                                                                                                                                                    | BAYESIAN POSTERIOR SIMULATION: TWO-STAGE APPROACH ....................................                                                                                                                                                                                                                  | 9                                                                                                                                                                                                                                                                                                       |\\n| 2.3.                                                                                                                                                                                                                                                                                                    | FREQUENTIST ESTIMATION WITH MONTE CARLO SAMPLING.....................................                                                                                                                                                                                                                   | 9                                                                                                                                                                                                                                                                                                       |\\n| 2.3.1.                                                                                                                                                                                                                                                                                                  | 2.3.1.                                                                                                                                                                                                                                                                                                  | Stand-alone meta-analysis packages.............................................................. 10                                                                                                                                                                                                     |\\n| 2.3.2.                                                                                                                                                                                                                                                                                                  | 2.3.2.                                                                                                                                                                                                                                                                                                  | General statistical packages with support for meta-analysis .......................... 10                                                                                                                                                                                                               |\\n| 2.3.3.                                                                                                                                                                                                                                                                                                  | 2.3.3.                                                                                                                                                                                                                                                                                                  | Software for network meta-analysis................................................................ 10                                                                                                                                                                                                   |\\n| 2.3.4.                                                                                                                                                                                                                                                                                                  | 2.3.4.                                                                                                                                                                                                                                                                                                  | Parameterisation of treatment effects............................................................. 11                                                                                                                                                                                                   |\\n| 2.4. FREQUENTIST                                                                                                                                                                                                                                                                                        | 2.4. FREQUENTIST                                                                                                                                                                                                                                                                                        | ESTIMATION WITH BOOTSTRAPPING ................................................. 11                                                                                                                                                                                                                      |\\n| 2.5. SUMMARY OF METHODS AND RESTRICTIONS ON THEIR USE                                                                                                                                                                                                                                                   | 2.5. SUMMARY OF METHODS AND RESTRICTIONS ON THEIR USE                                                                                                                                                                                                                                                   | .................................. 12                                                                                                                                                                                                                                                                   |\\n| 3.                                                                                                                                                                                                                                                                                                      | USE OF MULTIPLE SOFTWARE PLATFORMS................................................ 12                                                                                                                                                                                                                   | USE OF MULTIPLE SOFTWARE PLATFORMS................................................ 12                                                                                                                                                                                                                   |\\n| 3.1. COMMUNICATION BETWEEN SOFTWARE                                                                                                                                                                                                                                                                     | 3.1. COMMUNICATION BETWEEN SOFTWARE                                                                                                                                                                                                                                                                     | PACKAGES................................................ 13                                                                                                                                                                                                                                             |\\n| 3.2. INTEGRATED USE OF SOFTWARE                                                                                                                                                                                                                                                                         | 3.2. INTEGRATED USE OF SOFTWARE                                                                                                                                                                                                                                                                         | PLATFORMS.......................................................... 13                                                                                                                                                                                                                                  |\\n| 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 | 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 | 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 |\\n| TABLES                                                                                                                                                                                                                                                                                                  | TABLES                                                                                                                                                                                                                                                                                                  | TABLES                                                                                                                                                                                                                                                                                                  |\\n| Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   | Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   | Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   |\\n\\n## Abbreviations and Definitions\\n\\nCEA\\n\\ncost-effectiveness analysis\\n\\nFE\\n\\nFixed effects\\n\\nMC\\n\\nMonte Carlo\\n\\nMCMC\\n\\nMarkov chain Monte Carlo\\n\\nRE\\n\\nRandom effects\\n\\nVCV\\n\\nvariance-covariance\\n\\n## 1. INTRODUCTION\\n\\nProbabilistic  methods  in  decision  analysis  were  introduced  in  the  1980s. 1,2 Their  defining feature is that they allow for a full expression of the uncertainty in model parameters. There are two main reasons for advocating probabilistic methods in decision making. The first is that they can provide a form of sensitivity analysis which allows investigators to easily see the joint impact of the uncertainty in multiple parameters on the expected costs, benefits and on  decision  uncertainty.  For  this  reason  use  of  these  methods  is  often  called  probabilistic sensitivity  analysis.  A  second  reason  is  that,  faced  with  uncertainty  in  the  vector/matrix  of model parameters θ ,  decision makers generally choose the decision option, D ,  that delivers the highest expected net benefit. In other words, the decision maker selects decision D* , such that:\\n\\n$$D ^ { * } = M _ { \\\\partial } \\\\alpha E _ { \\\\theta } [ N B ( D , \\\\theta ) ]$$\\n\\nThis 'expectation' requires an integration of the net benefit function, ( , ) NB D θ over the joint distribution  of  parameters θ .  There  are  a  wide  range  of  methods  for  achieving  this integration, and the appropriate choice of method depends on the algebraic structure of the net benefit function. It must be emphasised that the expected Net Benefit is not the same as the Net Benefit at the expected value of the parameters, except in the cases where Net Benefit is  linear  in  all  its  parameters, and there  are  no  correlations  between  parameters.  This  is relatively rare, as most evidence synthesis is performed on log or logit scales, and many costeffectiveness  analysis  (CEA)  models  include  Markov  models,  which  are  notoriously  nonlinear. Further, modern methods of evidence synthesis tend to generate estimates of several parameters from a common dataset, in most cases leading to correlations between parameters. It  is  therefore  essential  that  software  solutions  are  adopted  that  ensure  that  the  complex uncertainty  structure  in  parameter  estimates  is  faithfully  propagated  through  the  decision model. 3 This  document provides guidance on the appropriate choice of  software to deliver probabilistic cost-effectiveness analysis in any situation.\\n\\nMonte Carlo (MC) simulation from the joint parameter distribution is not only the simplest way to evaluate the expected Net Benefit, but for any form of model it also delivers other crucial  tools  of  probabilistic  CEA  such  as:  plots  of  the  cost-effectiveness  plane,  costeffectiveness  acceptability  curves  and  estimates  of  the  probability  that  a  decision  is  costeffective. 4,5 MC  simulation  is  also  the  easiest  approach  to  Expected  Value  of  Information analysis. 6-8 Probabilistic  methods  have  been  recommended  in  a  range  of  leading  textbooks\\n\\nand tutorial papers, and are the preferred option for submissions to re-imbursement agencies such  as  the  National  Institute  of  Health  and  Clinical  Excellence  (NICE)  in  the  UK.  We therefore  recommend  MC  simulation-based  approaches  for all analyses,  even  for  strictly linear models.\\n\\nThe document confines  itself to the question of  which computational approaches  correctly preserve  the  properties  of  the  evidence  synthesis  within  a  probabilistic  cost-effectiveness analysis. No advice is given on the relative merits of cohort models compared to individual patient  simulation.  Indeed,  no  advice  is  given  in  this  document  on  how  to  choose the  best model, it is restricted to providing guidance on how to implement the model of choice.\\n\\nThis document is organised as follows. The main body of the document (Section 2) sets out the different analysis options. These include Bayesian Markov chain Monte Carlo (MCMC) methods  (2.1,  2.2),  and  frequentist  methods,  either  sampling  from  maximum  likelihood estimates  and  their  variance-covariance  (VCV)  matrices  (2.3),  or  bootstrapping  (2.4).  We then  provide  a  brief  summary  of  software  tools  that  can  be  used  to  help  interface  between different  software,  and  review  some  recent  developments  in  user-friendly  'front  ends',  to assist the integrated use  of multiple  software  platforms.  These  offer  ways in  which investigators can conduct scenario analyses, not just with individual parameters but also with different datasets  or different synthesis models  and  quickly  see  the impact  on  costeffectiveness results.\\n\\n## 2. EMBEDDING EVIDENCE SYNTHESIS IN PROBABILISTIC CEA\\n\\n## 2.1. BAYESIAN POSTERIOR SIMULATION: ONE-STAGE APPROACH\\n\\nWhen  estimation  of  the  synthesis  parameters  is  via  sampling  from  a  Bayesian  posterior distribution  of  the  relevant  parameters,  this  can  be  integrated  with  the  CEA  as  a  single process within a single programming package, in what has been referred to as 'Comprehensive Decision Analysis'. 9-11\\n\\nBayesian MCMC simulation, 12 using WinBUGS, 13 OpenBUGS 14 or other MCMC packages, provides the obvious example. The advantage of this approach is that it not only estimates a Bayesian posterior distribution, but that it is simulation-based, so that its outputs are perfectly compatible with the MC sampling approach that has become the standard modelling method in so many areas of science. Samples from the joint posterior distribution can be put directly through the decision analysis, so that Net Benefit and other outputs can be evaluated for each\\n\\nset of parameter samples, without requirements for assumptions about its distributional form. Distributions of additional parameters and costs can be readily incorporated.\\n\\nDevelopment of MCMC algorithms and sampling schemes is a specialised area of research. Although  users  need  not  have  a  detailed  knowledge  of  the  precise  working  of  MCMC software,  a  good  understanding  of  the  fundamentals  and  of  Bayesian  data  analysis  is essential.  For  completeness  it  is  worth  mentioning  that  a  broad  range  of non -MCMC simulation-based Bayesian updating schemes have also been proposed, including the Sample Importance  Re-sampling  algorithm, 15 Bayesian  Melding, 16,17 and  Bayesian  Monte  Carlo. 18 All these have the same properties as Bayesian MCMC in that they all feature both Bayesian estimation and sampling  from  joint posterior distributions.  The  latter two  were  specifically designed for evidence synthesis.\\n\\n## 2.2. BAYESIAN POSTERIOR SIMULATION: TWO-STAGE APPROACH\\n\\nIf investigators have a preferred software for CEA, either general software packages such as R, STATA, SAS, or spread-sheet or decision tree packages such as EXCEL or TreeAGE, a further option is to take the posterior samples from the Bayesian MCMC, or other posterior sampling scheme, and use them as input to the CEA package. This has the same technical properties  as  the  Bayesian  one-stage  approach  since  the  full  posterior  distribution is preserved. From WinBUGS, the CODA output, which lists all values generated from the full posterior  distribution,  can  be  exported  into  a  spreadsheet-based  program  such  as  EXCEL, using BUS - BUGS Utility for Spreadsheets. 19 When using the CODA output it is important that the correlations in the parameter estimates are preserved. This is done by ensuring that all parameter values are sampled from the same MCMC iteration . If the CODA output is in spreadsheet  format,  for  example  in  EXCEL,  this  would  correspond  to  sampling  all  the parameter values in one row, each time. The CODA output can also be converted to the freely available  statistical  software  R 20 for  convergence  diagnostics,  further  analysis  and  plotting using  add-on  packages  such  as  BOA  -  Bayesian  Output  Analysis  Program 21 or  CODA  Convergence Diagnostics and Output Analysis. 22\\n\\n## 2.3. FREQUENTIST ESTIMATION WITH MONTE CARLO SAMPLING\\n\\nIf evidence synthesis can be performed using frequentist software (which may use a variety of methods of estimation including, methods of moments, iterative weighted least-squares or\\n\\n(restricted) maximum likelihood ((RE)ML)), a two-stage approach is also possible. The first step is estimation, which produces parameter estimates and their variance-covariance (VCV) matrix. In the second step, these are used to populate a multivariate normal distribution which can be used for forward MC sampling (in the same or in a different package) along with the other CEA parameters. When single parameters are of interest, such as in simple pair-wise meta-analysis, this  may  be  the  simplest  option  as  only  one  variance  needs  to  be  estimated (there is no VCV matrix). In such situations it is particularly easy to find the treatment effect parameter  and  its  variance  using  either  specific  meta-analysis  software  or  implementing meta-analysis routines in standard statistical software packages. A systematic and comprehensive review of all  software options  capable of evidence synthesis  is beyond the scope  of  this  document,  but  noteworthy  options  are  described  below  and  more  detailed reviews and comparisons are available elsewhere. 23-26\\n\\n## 2.3.1. Stand-alone meta-analysis packages\\n\\nNumerous packages have been developed over the years, but probably those which include the most extensive and up-to-date feature sets, are\\n\\n- \\uf0b7 Comprehensive meta-analysis (commercial); 27\\n- \\uf0b7 Meta-Analyst (free); 26\\n- \\uf0b7 MIX, 28 which is an add-on to EXCEL (commercial and free versions available);\\n- \\uf0b7 RevMan, 29 which is the official software of the Cochrane Collaboration (free).\\n- \\uf0b7 EXCEL:  Simple meta-analysis can be carried out with a small amount of programming.\\n\\n## 2.3.2. General statistical packages with support for meta-analysis\\n\\nWhile it would be possible to program most standard meta-analysis models in any reasonably powerful  statistics  package,  probably  the  most  extensive  freely  available  software  routines which  allow  meta-analysis  to  be  conducted  and  numerous  graphical  outputs  produced  are available for STATA 30 and for R, such as the meta 31 and rmeta 32 packages.\\n\\nAlthough  all  the  above  options  will  conduct  pair-wise  meta-analysis,  not  all  have  the capability to do meta-regression, 33 which may be a decisive factor in choosing between them.\\n\\n## 2.3.3. Software for network meta-analysis\\n\\nSpecific comments on frequentist software options for network meta-analysis can be found in TSD2. 34 For  indirect  comparison  networks,  separate  syntheses  can  be  carried  out  for  AB\\n\\ntrials, and AC trials. Then the estimates obtained and their variances can be entered into the simulation package used for CEA, and the relative cost-effectiveness of A, B and C readily determined  (covariances  are  not  involved).  Although  this  is  an  acceptable  approach  in principle,  the  Bayesian  MCMC  approach  to  indirect  comparisons  (see  TSD2 34 )  may  be preferable in cases where one or more of the pair-wise comparisons is represented by a very small number of trials. This is because, MCMC has the flexibility to allow 'shared variance' Random Effects (RE) models, while with conventional methods it may be necessary to have some estimates from RE models and others from Fixed Effects (FE) models, which seems a less natural solution.\\n\\nIn many cases the use of frequentist estimates and their VCV matrix with RE models is likely to  produce  parameter  distributions  with  a  little  less  uncertainty,  because  Bayesian  methods take uncertainty in variance parameters into account. The extent of the difference is unlikely to  be  critical,  although  investigators  should  always  check  that  posterior  distributions  of variance parameters are sensible.\\n\\n## 2.3.4. Parameterisation of treatment effects\\n\\nWhatever software is used, model parameterisation requires care, as a number of apparently innocuous  variations  may  give  very  different  or  wrong  results.  To  date,  a  few  coding problems have come to light and these are set out in the Appendix.\\n\\n## 2.4. FREQUENTIST ESTIMATION WITH BOOTSTRAPPING\\n\\nThe final option of estimation and then Bootstrapping, 35 has been used from time to time in cost-effectiveness analysis. 36 In  its  original  form,  bootstrapping is a technique in which one generates  a  series  of  'new'  datasets  by  repeatedly  re-sampling with  replacement from  the original data, each time producing a new set of parameters estimates. This stream of estimates can  then  be  treated  in  the  same  way  as  samples  from  Bayesian  posterior  distributions. However, this procedure is not always straightforward, particularly with small sample sizes and zero cells.\\n\\nThere are, nonetheless, a very wide range of variant bootstrap procedures which can mitigate these and other problems. In the parametric bootstrap, for example a model is fitted to the data by maximum likelihood and is then used to generate a series of datasets with the same size and structure as the original. The analysis procedure is applied to each of these datasets\\n\\nto generate a stream of parameter values. Data analysis based on resampling is a rich area with an extensive literature. Readers are referred to texts for further information. 35,37,38\\n\\n## 2.5. SUMMARY OF METHODS AND RESTRICTIONS ON THEIR USE\\n\\nTable 1 summarises the methods and the restrictions on their use. Readers are referred to the text for further explanation.\\n\\nTable 1 Summary of methods and their properties and restrictions\\n\\n| Estimation                                       | Output to CEA Sotware                              | Restrictions                                                             |\\n|--------------------------------------------------|----------------------------------------------------|--------------------------------------------------------------------------|\\n| BayesianMCMC                                     | None: CEA within MCMC Software                     | None                                                                     |\\n| BayesianMCMC                                     | MCMCchains exported                                | None                                                                     |\\n| BayesianMCMC                                     | Posterior means, variances, correlations           | None, but assumes multi- variate normality in posterior distribution     |\\n| BayesianMCMC                                     | Posterior means and variances                      | Only suitable if no correlation between parameters*                      |\\n| Estimation by non-Bayesian (frequentist) methods | Parameter estimates and Variance-Covariance matrix | None, but assumes multi- variate normality of treatment effect estimates |\\n| Estimation by non-Bayesian (frequentist) methods | Parameter estimates and their variances            | Only suitable if no correlation between parameters*                      |\\n| Estimation by non-Bayesian (frequentist) methods | Bootstrap resampling                               | None, but special methods are necessary for sparse data                  |\\n\\n## 3. USE OF MULTIPLE SOFTWARE PLATFORMS\\n\\nIn  recent  years  interfaces  have  become  available  that  let  different  software  applications communicate with each other. These facilities allow for the integration of the components of a  CEA  which  may  have  been  conducted  in  different  packages.  The  motivations  and advantages of an integrated approach across software applications are potentially multifaceted. Firstly, it allows multidisciplinary teams who have different software skills and preferences  to  produce  an  integrated  analysis.  For  example,  statisticians  may  wish  to  use general statistical software, whereas decision modellers may wish to use EXCEL or specific decision  modelling  software.  It  also  allows  the  best  software  for  each  component  of  the analysis to be used therefore producing an 'optimal' mix. For example, if a network metaanalysis  is  required,  WinBUGS  may  be  the  best  software  to  implement  this  in,  but  it  has\\n\\nlimited  graphical  capabilities.  Therefore,  it  may  be  desirable  to  present  the  results  of  the synthesis  in  a  package  with  advanced  graphical  capability  such  as  R.  Furthermore,  the original dataset may have been prepared in spreadsheet software such as EXCEL. Although use of multiple pieces of software to conduct different components of the analysis is common historically, few have been integrated.\\n\\nSection 3.1 gives details of how to allow communication between different platforms, with the  primary  aim  of  transferring  data  between  them.  Section  3.2  explains  how  different software can be used to fully integrate data input, analysis and the display of results using multiple packages, into a single step.\\n\\n## 3.1. COMMUNICATION BETWEEN SOFTWARE PACKAGES\\n\\nTo facilitate communication, transparency and future data updates, it is good practice to keep all data collected for the analysis, including all annotations and details of any corrections, in a single file, for example an EXCEL workbook with multiple worksheets. If the analysis is to be carried out in WinBUGS, data columns can be copied directly from spreadsheet software into  WinBUGS and pasted  by  selecting Paste Special from  the  WinBUGS Edit menu and choosing  the Plain  text option.  Alternatively, XL2BUGS 39 is  an  EXCEL  add-in  which converts  EXCEL  data  into  WinBUGS  vector  format,  and BAUW 40 converts  data  in  text format into WinBUGS vector or matrix format.\\n\\nIf data is stored in R, R2WinBUGS 41 can be used to convert R objects into WinBUGS list data using the bugs.data function.\\n\\nSee http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/remote14.shtml for details.\\n\\n## 3.2. INTEGRATED USE OF SOFTWARE PLATFORMS\\n\\nIntegrated  platforms  reduce  the  need  to  copy  data  and  intermediate  results  from  one screen/system  to  another,  and  thereby  reduce  the  risk  of  transcription  errors.  Further advantages of integrating the analysis (which also exist if the Bayesian one-stage approach is conducted since in that approach the analysis is integrated by definition) include facilitating the modification and updating of any aspect of the analysis, conducting sensitivity analyses and, more generally, promoting transparency. For example, if a new trial is reported that is to be  added  to  the  evidence  synthesis,  then  in  an  integrated  approach  the  CEA  would automatically  be  updated.  This  goes  some  way  to  ensuring  the  appropriate  uncertainty  is\\n\\npropagated through to the decision model. If part of this integrated approach is the inclusion of a user-friendly interface, then this can also make the exploration of the synthesis and CEA accessible to non-technical experts including clinical experts and even NICE decision makers themselves, allowing them to interrogate the analysis.\\n\\nTo  this  end,  a  Transparent  Interactive  Decision  Interrogator  (TIDI) 42 which  integrated syntheses conducted in WinBUGS with graphical displays and the decision model conducted in  R  and  a  'point  and  click'  interface  in  EXCEL  was  developed  for  a  recent  Single Technology  Appraisal  (STA)  at  NICE.  This  pilot  'proof  of  concept'  initiative  allowed members  of  the  appraisal  committee  to  request  re-runs  of  the  CEA  using  alternative parameter values in real time in the committee meetings.\\n\\nSeveral (freely available) code routines have been developed for commonly used packages in Health Technology Assessment which allow them to communicate with other packages and these can be utilised in the creation of integrated analyses. For example, RExcel , 43 an add-on to  EXCEL,  provides  communication  between  EXCEL  and  R  and R2WinBUGS is  one  of several packages which allow the controlling of WinBUGS through R. Thus, if both of these linking packages are used in combination, then WinBUGS can be controlled through EXCEL (via R), and a Visual Basic interface can be written in EXCEL to facilitate this (which is the software  setup  used  in  the  TIDI  project  described  above).  Similar  control  of  WinBUGS through  STATA 44 and  several  other  packages  is  also  possible,  as  is  the  embedding  of OpenBUGS in R through rbugs 45 and the linking of many packages to each other.\\n\\n## 4. REFERENCES\\n\\n1.   Critchfield,  G.C.,  Willard,  K.E.  Probabilistic  analysis  of  decision  trees  using  Monte Carlo simulation. Medical Decision Making 1986; 6(2):85-92.\\n2.   Doubilet,  P.,  Begg,  C.B.,  Weinstein,  M.C.,  Braun,  P.,  McNeil,  B.J.  Probabilistic sensitivity  analysis  using  Monte  Carlo  simulation:  A  practical  approach. Medical Decision Making: an International Journal of the Society for Medical Decision Making 1985; 5(2):157-177.\\n3.   Ades,  A.E.,  Claxton,  K.,  Sculpher,  M.  Evidence  synthesis,  parameter  correlation  and probabilistic sensitivity analysis. Health Economics 2005; 14:1-9.\\n4.   Claxton,  K.,  Sculpher,  M.,  McCabe,  C.,  Briggs,  A.,  Akehurst,  R.,  Buxton,  M.  et  al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics 2005; 14(4):339-347.\\n5.   National  Institute  for  health  and  Clinical  Excellence.  Guide  to  the  methods  of technology appraisal (updated 2008). 2008.\\n6.   Thompson, K.M., Evans, J.S. The value of improved national exposure information for perchloroethylene (perc): a case study for dry cleaners. Risk Analysis 1997; 17(2):253271.\\n7.   Claxton,  K.,  Posnett,  J.  An  economic  approach  to  clinical  trial  design  and  research priority setting. Health Economics 1996; 5(6):513-524.\\n8.   Felli, J.C., Hazen,  G.B.  Sensitivity analysis and  the expected  value  of perfect information. Medical Decision Making 1998; 18(1):95-109.\\n9.   Cooper,  N.J.,  Sutton,  A.J.,  Abrams,  K.R.,  Turner,  D.,  Wailoo,  A.  Comprehensive decision  analytical  modelling  in  economic  evaluation:  a  Bayesian  approach. Health Economics 2003; 13(3):203-226.\\n10.   Parmigiani, G., Samsa, G.P., Ancukiewicz, M., Lipscomb, J., Hasselblad, V., Matchar, D.B.  Assessing  uncertainty  in  cost-effectiveness  analyses:  Application  to  a  complex decision model. Medical Decision Making 1997; 17(4):390-401.\\n11.   Spiegelhalter, D.J., Myles, J.P., Jones, D.R., Abrams, K.R. Bayesian methods in health technology assessment: a review. Health Technology Assessment 2000; 4(38).\\n12.   Gilks, W.R., Richardson, S., Spiegelhalter, D.J. Markov chain Monte Carlo in practice. Chapman &amp; Hall/CRC, 1996.\\n13.   Lunn, D.J., Thomas, A., Best, N., Spiegelhalter, D. WinBUGS - a Bayesian modelling framework:  concepts,  structure,  and  extensibility. Statistics  and  Computing 2000; 10(4):325-337.\\n14.   Lunn,  D.,  Spiegelhalter,  D.,  Thomas,  A.,  Best,  N.  The  BUGS  project:  Evolution, critique and future directions. Statistics in Medicine 2009; 28(25):3049-3067.\\n\\n15.   Rubin,  D.B.  Using  the  SIR  algorithm  to  simulate  posterior  distributions. Bayesian Statistics 1988; 3:395-402.\\n16.   Raftery,  A.E.,  Givens,  G.H.,  Zeh,  J.E.  Inference  from  a  Deterministic  Population Dynamics Model for Bowhead Whales. Journal of the American Statistical Association 1995; 90(430):402-416.\\n17.   Poole, D., Raftery, A.E. Inference for Deterministic Simulation Models: The Bayesian Melding Approach. Journal of the American Statistical Association 2000; 95(452):1244-1255.\\n18.   Brand,  K.P.,  Small,  M.J.  Updating  uncertainty  in  an  integrated  risk  assessment: conceptual framework and methods. Risk Analysis 1995; 15(6):719-731.\\n19.   Hahn,  G.  BUGS  Utility for Spreadsheets. Version 1.0.1. 2001; available from http://faculty.salisbury.edu/~edhahn/bus.htm\\n20.   R Development Core Team. R: A Language and Environment for Statistical Computing. 2010. Vienna, Austria, R Foundation for Statistical Computing.\\n21.   Smith,  B.J. The  boa Package. Version 1.1.5. 2005; available from http://www.publichealth.uiowa.edu/boa/\\n22.   Plummer,  M.,  Best,  N.,  Cowles,  K.,  Vines,  K.  CODA:  Convergence  diagnosis  and output analysis for MCMC. R News 2006; 6(1):7-11.\\n23.   Bax,  L.,  Yu,  L.M.,  Ikeda,  N.,  Moons,  K.G.M.  A  systematic  comparison  of  software dedicated  to  meta-analysis  of  causal  studies. BMC  Medical  Research  Methodology 2007; 7(1):40.\\n24.   Sterne, J.A.C., Egger, M., Sutton, A.J. Meta-Analysis Software. In: Egger M., DaveySmith  G.,  Altman  D.G.,  eds. Systematic  Reviews  in  Health  Care:  Meta-analysis  in context . second edn ed. BMJ Books; London: 2001; 336-346.\\n25.   Sutton,  A.J.,  Lambert,  P.C.,  Hellmich,  M.A.G.,  Abrams,  K.R.,  Jones,  D.R.  Metaanalysis in practice: a critical review of available software. In: Stangl D.K., Berry D.A., eds. Meta-analysis  in  medicine  and  health  policy .  Marcel  Dekker;  New  York:  1998; 315-339.\\n26.   Wallace, B.C., Schmid, C.H., Lau, J., Trikalinos, T.A. Meta-Analyst: software for metaanalysis of binary, continuous and diagnostic data. BMC  Medical Research Methodology 2009; 9(1):80.\\n27.   Borenstein,  M.,  Hedges,  L.,  Higgins,  J.,  Rothstein,  H.  Comprehensive  meta-analysis version 2. 2005; available from http://www.meta-analysis.com/\\n28.   Bax, L., Yu, L.M., Ikeda, N., Tsuruta, H., Moons, K.G.M. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Medical Research Methodology 2006; 6(1):50.\\n29.   The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.0. 2008; available from http://ims.cochrane.org/revman\\n\\n30.   Sterne,  J.A.C.  Meta-analysis  in  Stata:  an  updated  collection  from  the  Stata  Journal. CRC PRESS, 2009.\\n31.   Schwarzer,  G.  meta:  Meta-Analysis  with  R.  Version  1.6-1.  2010;  available  from http://cran.r-project.org/web/packages/meta/\\n32.   Lumley, T. rmeta:Meta-analysis. 2009; available from http://cran.rproject.org/web/packages/rmeta/\\n33.   Thompson, S.G., Sharp, S.J. Explaining heterogeneity in meta analysis: a comparison of methods. Statistics in Medicine 1999; 18(20):2693-2708.\\n34.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  2:  A  generalised  linear  modelling  framework  for  pair-wise  and  network meta-analysis of randomised controlled trials. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n35.   Efron,  B.,  Tibshirani,  R.J.  An  introduction  to  the  bootstrap.  Chapman  &amp;  Hall,  New York; 1993.\\n36.   Lord,  J.,  Asante,  M.A.  Estimating  uncertainty  ranges  for  costs  by  the  bootstrap procedure  combined  with  probabilistic  sensitivity  analysis1. Health  Economics 1999; 8(4):323-333.\\n37.   Davison, A.C., Hinkley, D.V. Bootstrap methods and their application. Cambridge Univ Pr, 1997.\\n38.   Lunneborg,  C.E.  Data  analysis  by  resampling:  Concepts  and  applications.  Duxbury, 2000.\\n39.   Misra,  S.  XL2BUGS:  Excel  Add-In  to  convert  data  for  WinBUGS.  2011;  available from http://www.simon.rochester.edu/fac/misra/software.htm\\n40.   Zhang, Z., Wang, L. Use BAUW  to convert data. 2006; available from http://www.psychstat.org/us/article.php/52.htm\\n41.   Sturtz,  S.,  Ligges,  U.,  Gelman,  A.  R2WinBUGS:  A  package  for  running  WinBUGS from R. Journal of Statistical Software 2005; 12.\\n42.   Bujkiewicz, S., Jones, H.E., Lai, M.C.W., Cooper, N.J., Hawkins, N., Squires, H. et al. Development  of  a  Transparent  Interactive  Decision  Interrogator  to  facilitate  the decision making process in health care. Value in Health 2011; (in press).\\n43.   Heiberger,  R.M.,  Neuwirth,  E.  R through  Excel:  a  spreadsheet  interface  for  statistics, data analysis, and graphics. Springer-Verlag New York Inc, 2009.\\n44.   Thompson, J., Palmer, T., Moreno, S. Bayesian analysis in Stata using WinBUGS. The Stata Journal 2006; 6(4):530-549.\\n45.   Yan,  J.,  Prates,  M.  Package  rbugs:  Fusing  R  and  OpenBugs.  Version  0.4-9.  2011; available from http://cran.r-project.org/web/packages/rbugs/index.html\\n\\n46.   Higgins,  J.P.T.,  Whitehead,  A.  Borrowing  strength  from  external  trials  in  a  metaanalysis. Statistics in Medicine 1996; 15:2733-2749.\\n47.   Caldwell,  D.M.,  Ades,  A.E.,  Higgins,  J.P.T.  Simultaneous  comparison  of  multiple treatments: combining direct and indirect evidence. BMJ 2005; 331:897-900.\\n48.   Lu,  G.,  Ades,  A.  Assessing  evidence  consistency  in  mixed  treatment  comparisons. Journal of the American Statistical Association 2006; 101:447-459.\\n49.   Ades,  A.E.,  Sculpher,  M.,  Sutton,  A.,  Abrams,  K.,  Copper,  N.,  Welton,  N.J.  et  al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics, PharmacoEcon 2006; 24(1):1-19.\\n50.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  2:  A  generalised  linear  modelling  framework  for  pair-wise  and  network meta-analysis of randomised controlled trials. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n51.   Woolacott, N., Bravo Vergel, Y., Hawkins, N., Kainth, A., Khadjesari, Z., Misso, K. et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment 2006; 10(31).\\n52.   Woods, B.S., Hawkins, N., Scott, D.A. Network meta-analysis on the log-hazard scale, combining counts and hazard ratio statistics accounting for multi-arm trials: A tutorial. BMC Medical Research Methodology 2010; 10(54).\\n53.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  5:  Evidence  synthesis  in  the  baseline  natural  history  model.  2011;  last updated April 2012; available from http://www.nicedsu.org.uk\\n\\n## APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS\\n\\nTwo ways of specifying network meta-analysis models have appeared in the literature. The main  area  of  difficulty  lies  in  the  precise  way  in  which  the  relative  effects  have  been parameterised, particularly in RE models. One way to write the model for binomial data is:\\n\\n$$r _ { i k } & \\\\sim \\\\binom { r _ { i } } { i _ { k } } \\\\\\\\ \\\\log ( p _ { i k } ) & = \\\\mu _ { i } & \\\\text {if } k = X \\\\\\\\ \\\\log ( p _ { i k } ) & = \\\\mu _ { i } + \\\\delta _ { i , X } & \\\\text {if } k = Y \\\\\\\\ \\\\delta _ { i , X Y } & \\\\sim N ( d _ { 1 Y } - d _ { 1 X } , \\\\sigma ^ { 2 } ) \\\\\\\\ \\\\mu _ { i } & \\\\sim N ( 0 , 1 0 ^ { 2 } ) \\\\\\\\ \\\\text {and} \\\\, \\\\text {treatment} \\\\, k \\\\, \\\\text { the numerators } \\\\, r _ { i } \\\\, \\\\text { are  have  binomial distributions with}$$\\n\\nHere,  for  trial i and  treatment k the  numerators rik are  have  binomial  distributions  with parameter pik and denominator nik . A logistic regression model says that, for a trial comparing treatments X and Y , the linear predictor consists of the 'baseline' term i \\uf06d if the treatment is X ,  and  the  baseline plus a relative treatment effect , i i XY \\uf06d \\uf064 \\uf02b if  the  treatment  is Y .  The key point is that the actual treatment that i \\uf06d refers to can be any treatment (except the last one). The  trial-specific  relative  effects  are  from  distributions,  whose  means  can  be  expressed  in terms of the mean treatment effects relative to treatment 1 (through the consistency relations). The baseline terms are usually given vague priors. 46-50\\n\\nIn  (2)  it  is  clear  that  the  term i \\uf06d refers  to  treatment X ,  but  it  is  also  clear  that  this  is  not necessarily treatment 1. In this formulation, one arm of a two arm trial informs a trial-specific 'baseline', while the other informs the baseline plus a treatment effect.\\n\\nAnother way of writing a network model that has appeared in certain submissions to NICE 51 contains this modification:\\n\\n$$\\\\log i ( p _ { i k } ) & = \\\\mu _ { i } + \\\\delta _ { i , 1 X } \\\\quad \\\\text {if } k = X \\\\\\\\ \\\\log i ( p _ { i k } ) & = \\\\mu _ { i } + \\\\delta _ { i , 1 Y } \\\\quad \\\\text {if } k = Y$$\\n\\nIn a general sense, this is the same model, except that here the i \\uf06d terms represent Treatment 1 in every trial. In a trial that includes Treatment 1, this parameterisation is adequate, as ,1 i X \\uf064 (the effect of X relative to itself) is zero. However, if any trial does not include treatment 1, then the model parameters cannot all be identified because there are three parameters to be estimated  from  only  two  arms.  Another  way  of  writing  an  MTC  model  that  has  appeared recently 52 has this same property. Models specified in this way should not be accepted unless\\n\\nthe  reference  treatment  is  the  same  treatment  in  every  trial,  and  therefore  appears  in  every trial.\\n\\nThe  instability  caused  by  this  parameterisation  can  be  avoided  if  a  model  is  placed  on  the baseline terms, i.e. 2 ~ ( , ) i m N m \\uf06d \\uf073 rather than 2 ~ (0,100 ) i N \\uf06d . However, this solution has a number of further difficulties and is not recommended (see TSD5 53 ).\")]"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "vdb2.similarity_search(\"What is the main topic of the document?\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "f149dcd0",
   "metadata": {},
   "outputs": [],
   "source": [
    "path = test_outfiles / \"chroma_vectorstore\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "41e41c2a",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\DevanshUpadhyay\\AppData\\Local\\Temp\\ipykernel_33064\\1028540467.py:3: LangChainDeprecationWarning: The class `Chroma` was deprecated in LangChain 0.2.9 and will be removed in 1.0. An updated version of the class exists in the `langchain-chroma package and should be used instead. To use it run `pip install -U `langchain-chroma` and import as `from `langchain_chroma import Chroma``.\n",
      "  vector_store = Chroma(\n"
     ]
    }
   ],
   "source": [
    "from langchain_community.vectorstores import Chroma\n",
    "\n",
    "vector_store = Chroma(\n",
    "    collection_name=\"markdown_docs\",\n",
    "    embedding_function=embedding,\n",
    "    persist_directory=str(test_outfiles / \"chroma_vectorstore\"),\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "8c5f6b80",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['b9819e83-2c10-493d-9278-3c28b39a5b8d',\n",
       " 'a06012bc-ee1c-4d9d-b82b-bc21e8b2b902',\n",
       " 'df6019af-6a52-4faf-8804-78ffb656b5fc',\n",
       " 'c3bfbe4d-f31d-43a7-8c28-8d4586f39bc8',\n",
       " '856b423f-fa02-4474-a46c-32f3414351f9',\n",
       " '2f06324c-0faf-4ed4-9cb4-2128b943f1fa',\n",
       " '871f519e-646c-4894-ace3-150525e73025',\n",
       " '9438d34a-305c-46ba-8dad-0b639ead5df0',\n",
       " 'cd7d78a0-392f-4636-9339-8f04914fb24e',\n",
       " '9c541c0f-f31a-46ab-ba9c-c1e5cfcd2fc3',\n",
       " '39de421b-d76a-4419-be79-05befc6cb3f8',\n",
       " '348b8323-9b99-4813-bf60-9fa86811e9d2',\n",
       " '014a105f-7d6e-4aed-86ec-2fea58665fcb',\n",
       " '72176b1a-fd8a-4479-ad91-625c16caa0aa',\n",
       " '73d059b6-b3eb-4699-8ee8-eebbf2b51cd9',\n",
       " 'd82e59c0-12d2-4fc9-bc21-d5c360fdde49',\n",
       " '2e3aae61-f3ed-4f19-8ca0-4c935a764a26',\n",
       " '137b5d6e-a0de-4011-95c5-e6eb89e628b2',\n",
       " '79df3481-0ddc-49e1-a672-4ec27dbd9bb2',\n",
       " 'b7cd8637-2d0c-4113-bc38-880a43d31403',\n",
       " '77ac912d-76d5-46a0-8490-533921c31705',\n",
       " 'f594552a-baa9-41ef-984a-6185817187e8',\n",
       " 'da7ece40-0f44-4e6f-bef3-b1d70047319e',\n",
       " 'f0270147-7c8a-4f5b-92e9-29f6a126585d',\n",
       " '34d51cc5-1e7c-4a0a-95e7-f0191be8738f',\n",
       " '9dd3ebd5-a59c-417a-854d-914e010fe7b6',\n",
       " 'fb44b83d-e978-4613-bf5b-9081c6076755',\n",
       " 'f6682d8c-bd2f-465a-898c-0d254d06fa05',\n",
       " 'b796e1cc-b1c4-4808-8d3c-dc533c603b61',\n",
       " '06e1e1f9-2dd8-4f33-892a-98901cdef7a2',\n",
       " 'e91c4ac0-0473-4eb4-81a4-facee3441615',\n",
       " '76d01054-c563-449b-82ae-f2d9b9db7de1',\n",
       " 'd74f8d62-8555-4ac5-87ef-fdee69122895',\n",
       " 'bbcff471-c3f7-419d-8157-d9b5b5d7e511',\n",
       " 'fa62b32a-20df-4b66-a67f-09b37ab9313a',\n",
       " 'c10abe58-4c27-4522-842b-b5bc0024fe48',\n",
       " '54ca96c0-7fff-45a3-866a-9555045881b8',\n",
       " 'dc5ee96c-e7e4-4c02-b82e-c5a3b14bfa8c',\n",
       " '19d9ca9c-a21c-4ab2-9cd2-f7748ef6e0ad',\n",
       " '5e146b6e-c26c-4294-9d19-b54b66e70765',\n",
       " '831de4dd-36b4-4eb1-ad12-9346d62147d5',\n",
       " '9a5709aa-a927-41f7-86e2-00ec5b15b825',\n",
       " '5cbe3f76-9365-44f3-905c-6dce3af9198b',\n",
       " 'e1c53ab6-3e85-4eff-a157-f2afc449873c',\n",
       " '103e0010-3e8a-41d2-9ba6-248ddebdec8f',\n",
       " '60eaa896-c606-431b-981d-f4de7a0b5d5a',\n",
       " 'b57def8a-965f-496a-8cf5-d6acc87228e3',\n",
       " '850b5932-b4eb-49af-a294-5b0de2ffb956',\n",
       " '503636c6-9f48-4040-a17d-85f5300417de',\n",
       " '3288c369-8801-43a4-bf76-b512cf432135']"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "vector_store.add_documents(mkd_docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "574f3f3b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'doc_type': 'TSD', 'type': 'text'}, page_content='| 1. 2.                                                                                                                                                                                                                                                                                                   | INTRODUCTION....................................................................................................... EMBEDDING EVIDENCE SYNTHESIS IN PROBABILISTIC CEA....................                                                                                                               | 7 8                                                                                                                                                                                                                                                                                                     |\\n|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\\n|                                                                                                                                                                                                                                                                                                         | 2.1. BAYESIAN POSTERIOR SIMULATION: ONE-STAGE APPROACH.....................................                                                                                                                                                                                                             | 2.1. BAYESIAN POSTERIOR SIMULATION: ONE-STAGE APPROACH.....................................                                                                                                                                                                                                             |\\n| 2.2.                                                                                                                                                                                                                                                                                                    | BAYESIAN POSTERIOR SIMULATION: TWO-STAGE APPROACH ....................................                                                                                                                                                                                                                  | 9                                                                                                                                                                                                                                                                                                       |\\n| 2.3.                                                                                                                                                                                                                                                                                                    | FREQUENTIST ESTIMATION WITH MONTE CARLO SAMPLING.....................................                                                                                                                                                                                                                   | 9                                                                                                                                                                                                                                                                                                       |\\n| 2.3.1.                                                                                                                                                                                                                                                                                                  | 2.3.1.                                                                                                                                                                                                                                                                                                  | Stand-alone meta-analysis packages.............................................................. 10                                                                                                                                                                                                     |\\n| 2.3.2.                                                                                                                                                                                                                                                                                                  | 2.3.2.                                                                                                                                                                                                                                                                                                  | General statistical packages with support for meta-analysis .......................... 10                                                                                                                                                                                                               |\\n| 2.3.3.                                                                                                                                                                                                                                                                                                  | 2.3.3.                                                                                                                                                                                                                                                                                                  | Software for network meta-analysis................................................................ 10                                                                                                                                                                                                   |\\n| 2.3.4.                                                                                                                                                                                                                                                                                                  | 2.3.4.                                                                                                                                                                                                                                                                                                  | Parameterisation of treatment effects............................................................. 11                                                                                                                                                                                                   |\\n| 2.4. FREQUENTIST                                                                                                                                                                                                                                                                                        | 2.4. FREQUENTIST                                                                                                                                                                                                                                                                                        | ESTIMATION WITH BOOTSTRAPPING ................................................. 11                                                                                                                                                                                                                      |\\n| 2.5. SUMMARY OF METHODS AND RESTRICTIONS ON THEIR USE                                                                                                                                                                                                                                                   | 2.5. SUMMARY OF METHODS AND RESTRICTIONS ON THEIR USE                                                                                                                                                                                                                                                   | .................................. 12                                                                                                                                                                                                                                                                   |\\n| 3.                                                                                                                                                                                                                                                                                                      | USE OF MULTIPLE SOFTWARE PLATFORMS................................................ 12                                                                                                                                                                                                                   | USE OF MULTIPLE SOFTWARE PLATFORMS................................................ 12                                                                                                                                                                                                                   |\\n| 3.1. COMMUNICATION BETWEEN SOFTWARE                                                                                                                                                                                                                                                                     | 3.1. COMMUNICATION BETWEEN SOFTWARE                                                                                                                                                                                                                                                                     | PACKAGES................................................ 13                                                                                                                                                                                                                                             |\\n| 3.2. INTEGRATED USE OF SOFTWARE                                                                                                                                                                                                                                                                         | 3.2. INTEGRATED USE OF SOFTWARE                                                                                                                                                                                                                                                                         | PLATFORMS.......................................................... 13                                                                                                                                                                                                                                  |\\n| 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 | 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 | 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 |\\n| TABLES                                                                                                                                                                                                                                                                                                  | TABLES                                                                                                                                                                                                                                                                                                  | TABLES                                                                                                                                                                                                                                                                                                  |\\n| Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   | Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   | Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   |'),\n",
       " Document(metadata={'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'type': 'text', 'doc_type': 'TSD', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades'}, page_content=\"In  recent  years  interfaces  have  become  available  that  let  different  software  applications communicate with each other. These facilities allow for the integration of the components of a  CEA  which  may  have  been  conducted  in  different  packages.  The  motivations  and advantages of an integrated approach across software applications are potentially multifaceted. Firstly, it allows multidisciplinary teams who have different software skills and preferences  to  produce  an  integrated  analysis.  For  example,  statisticians  may  wish  to  use general statistical software, whereas decision modellers may wish to use EXCEL or specific decision  modelling  software.  It  also  allows  the  best  software  for  each  component  of  the analysis to be used therefore producing an 'optimal' mix. For example, if a network metaanalysis  is  required,  WinBUGS  may  be  the  best  software  to  implement  this  in,  but  it  has  \\nlimited  graphical  capabilities.  Therefore,  it  may  be  desirable  to  present  the  results  of  the synthesis  in  a  package  with  advanced  graphical  capability  such  as  R.  Furthermore,  the original dataset may have been prepared in spreadsheet software such as EXCEL. Although use of multiple pieces of software to conduct different components of the analysis is common historically, few have been integrated.  \\nSection 3.1 gives details of how to allow communication between different platforms, with the  primary  aim  of  transferring  data  between  them.  Section  3.2  explains  how  different software can be used to fully integrate data input, analysis and the display of results using multiple packages, into a single step.\"),\n",
       " Document(metadata={'type': 'text', 'doc_type': 'TSD', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades'}, page_content=\"Although the focus of the TSDs is for situations where a connected evidence network can be constructed  from  randomised  evidence,  there  may  be  situations  like  the  one  depicted  in Figure 2 where the evidence forms two, or even more, disconnected elements. In these cases the methods described in TSD2 7 cannot be applied without further assumptions being made.  \\n<!-- image -->  \\nC  \\nFigure 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments X and Y.  \\nThese assumptions must take the form of a relative treatment effect linking the two networks. For example an assumption may be made about the relative efficacy of treatment X relative to A, of treatment Y relative to A, or of treatment X relative to B, and so on. From a technical point of view a distribution for such a treatment effect can readily be inserted into a synthesis (see  methods  for  shared  parameter  models  in  TSD2 7 )  and  expert  opinion  or  observational data  can  be  used  to  inform  the  treatment  effect. The  difficulty,  of  course,  lies  in  making  a convincing case for the central estimate of the 'missing' treatment effect and assigning it a variance that appropriately reflects the  increased  uncertainty attaching to a non-randomised comparison. The increased uncertainty will affect comparisons between, but not within, the two networks.\"),\n",
       " Document(metadata={'doc_type': 'TSD', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices'}, page_content=\"Specific comments on frequentist software options for network meta-analysis can be found in TSD2. 34 For  indirect  comparison  networks,  separate  syntheses  can  be  carried  out  for  AB  \\ntrials, and AC trials. Then the estimates obtained and their variances can be entered into the simulation package used for CEA, and the relative cost-effectiveness of A, B and C readily determined  (covariances  are  not  involved).  Although  this  is  an  acceptable  approach  in principle,  the  Bayesian  MCMC  approach  to  indirect  comparisons  (see  TSD2 34 )  may  be preferable in cases where one or more of the pair-wise comparisons is represented by a very small number of trials. This is because, MCMC has the flexibility to allow 'shared variance' Random Effects (RE) models, while with conventional methods it may be necessary to have some estimates from RE models and others from Fixed Effects (FE) models, which seems a less natural solution.  \\nIn many cases the use of frequentist estimates and their VCV matrix with RE models is likely to  produce  parameter  distributions  with  a  little  less  uncertainty,  because  Bayesian  methods take uncertainty in variance parameters into account. The extent of the difference is unlikely to  be  critical,  although  investigators  should  always  check  that  posterior  distributions  of variance parameters are sensible.\")]"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "vector_store.similarity_search(\"Network\", filter = {\"doc_type\": \"TSD\"})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "e3412933",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_classic.retrievers import SelfQueryRetriever\n",
    "from langchain_classic.chains.query_constructor.base import AttributeInfo\n",
    "from langchain_community.retrievers import BM25Retriever\n",
    "from langchain_classic.retrievers import EnsembleRetriever"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "9bb64876",
   "metadata": {},
   "outputs": [],
   "source": [
    "metadata_field_info = [\n",
    "    AttributeInfo(\n",
    "        name=\"doc_type\",\n",
    "        description=\"Whether the document is a TSD (Technical Support Document) or a TA (Technical Assessment).\",\n",
    "        type=\"string\",\n",
    "    )]\n",
    "\n",
    "llm = ChatOpenAI(model=\"gpt-4o-mini\", temperature=0)\n",
    "\n",
    "retriever = SelfQueryRetriever.from_llm(\n",
    "    llm, \n",
    "    vector_store,  # Your FAISS object\n",
    "    \"NICE technical document database\",  # A description of the data in the vector store\n",
    "    metadata_field_info, \n",
    "    verbose=True\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "502195a5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'type': 'text', 'doc_type': 'TSD', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades'}, page_content='| 1. 2.                                                                                                                                                                                                                                                                                                   | INTRODUCTION....................................................................................................... EMBEDDING EVIDENCE SYNTHESIS IN PROBABILISTIC CEA....................                                                                                                               | 7 8                                                                                                                                                                                                                                                                                                     |\\n|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\\n|                                                                                                                                                                                                                                                                                                         | 2.1. BAYESIAN POSTERIOR SIMULATION: ONE-STAGE APPROACH.....................................                                                                                                                                                                                                             | 2.1. BAYESIAN POSTERIOR SIMULATION: ONE-STAGE APPROACH.....................................                                                                                                                                                                                                             |\\n| 2.2.                                                                                                                                                                                                                                                                                                    | BAYESIAN POSTERIOR SIMULATION: TWO-STAGE APPROACH ....................................                                                                                                                                                                                                                  | 9                                                                                                                                                                                                                                                                                                       |\\n| 2.3.                                                                                                                                                                                                                                                                                                    | FREQUENTIST ESTIMATION WITH MONTE CARLO SAMPLING.....................................                                                                                                                                                                                                                   | 9                                                                                                                                                                                                                                                                                                       |\\n| 2.3.1.                                                                                                                                                                                                                                                                                                  | 2.3.1.                                                                                                                                                                                                                                                                                                  | Stand-alone meta-analysis packages.............................................................. 10                                                                                                                                                                                                     |\\n| 2.3.2.                                                                                                                                                                                                                                                                                                  | 2.3.2.                                                                                                                                                                                                                                                                                                  | General statistical packages with support for meta-analysis .......................... 10                                                                                                                                                                                                               |\\n| 2.3.3.                                                                                                                                                                                                                                                                                                  | 2.3.3.                                                                                                                                                                                                                                                                                                  | Software for network meta-analysis................................................................ 10                                                                                                                                                                                                   |\\n| 2.3.4.                                                                                                                                                                                                                                                                                                  | 2.3.4.                                                                                                                                                                                                                                                                                                  | Parameterisation of treatment effects............................................................. 11                                                                                                                                                                                                   |\\n| 2.4. FREQUENTIST                                                                                                                                                                                                                                                                                        | 2.4. FREQUENTIST                                                                                                                                                                                                                                                                                        | ESTIMATION WITH BOOTSTRAPPING ................................................. 11                                                                                                                                                                                                                      |\\n| 2.5. SUMMARY OF METHODS AND RESTRICTIONS ON THEIR USE                                                                                                                                                                                                                                                   | 2.5. SUMMARY OF METHODS AND RESTRICTIONS ON THEIR USE                                                                                                                                                                                                                                                   | .................................. 12                                                                                                                                                                                                                                                                   |\\n| 3.                                                                                                                                                                                                                                                                                                      | USE OF MULTIPLE SOFTWARE PLATFORMS................................................ 12                                                                                                                                                                                                                   | USE OF MULTIPLE SOFTWARE PLATFORMS................................................ 12                                                                                                                                                                                                                   |\\n| 3.1. COMMUNICATION BETWEEN SOFTWARE                                                                                                                                                                                                                                                                     | 3.1. COMMUNICATION BETWEEN SOFTWARE                                                                                                                                                                                                                                                                     | PACKAGES................................................ 13                                                                                                                                                                                                                                             |\\n| 3.2. INTEGRATED USE OF SOFTWARE                                                                                                                                                                                                                                                                         | 3.2. INTEGRATED USE OF SOFTWARE                                                                                                                                                                                                                                                                         | PLATFORMS.......................................................... 13                                                                                                                                                                                                                                  |\\n| 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 | 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 | 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 |\\n| TABLES                                                                                                                                                                                                                                                                                                  | TABLES                                                                                                                                                                                                                                                                                                  | TABLES                                                                                                                                                                                                                                                                                                  |\\n| Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   | Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   | Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   |'),\n",
       " Document(metadata={'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'type': 'text', 'doc_type': 'TSD', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades'}, page_content=\"In  recent  years  interfaces  have  become  available  that  let  different  software  applications communicate with each other. These facilities allow for the integration of the components of a  CEA  which  may  have  been  conducted  in  different  packages.  The  motivations  and advantages of an integrated approach across software applications are potentially multifaceted. Firstly, it allows multidisciplinary teams who have different software skills and preferences  to  produce  an  integrated  analysis.  For  example,  statisticians  may  wish  to  use general statistical software, whereas decision modellers may wish to use EXCEL or specific decision  modelling  software.  It  also  allows  the  best  software  for  each  component  of  the analysis to be used therefore producing an 'optimal' mix. For example, if a network metaanalysis  is  required,  WinBUGS  may  be  the  best  software  to  implement  this  in,  but  it  has  \\nlimited  graphical  capabilities.  Therefore,  it  may  be  desirable  to  present  the  results  of  the synthesis  in  a  package  with  advanced  graphical  capability  such  as  R.  Furthermore,  the original dataset may have been prepared in spreadsheet software such as EXCEL. Although use of multiple pieces of software to conduct different components of the analysis is common historically, few have been integrated.  \\nSection 3.1 gives details of how to allow communication between different platforms, with the  primary  aim  of  transferring  data  between  them.  Section  3.2  explains  how  different software can be used to fully integrate data input, analysis and the display of results using multiple packages, into a single step.\"),\n",
       " Document(metadata={'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'type': 'text', 'doc_type': 'TSD', 'title': 'Introduction to evidence synthesis for decision making'}, page_content=\"Although the focus of the TSDs is for situations where a connected evidence network can be constructed  from  randomised  evidence,  there  may  be  situations  like  the  one  depicted  in Figure 2 where the evidence forms two, or even more, disconnected elements. In these cases the methods described in TSD2 7 cannot be applied without further assumptions being made.  \\n<!-- image -->  \\nC  \\nFigure 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments X and Y.  \\nThese assumptions must take the form of a relative treatment effect linking the two networks. For example an assumption may be made about the relative efficacy of treatment X relative to A, of treatment Y relative to A, or of treatment X relative to B, and so on. From a technical point of view a distribution for such a treatment effect can readily be inserted into a synthesis (see  methods  for  shared  parameter  models  in  TSD2 7 )  and  expert  opinion  or  observational data  can  be  used  to  inform  the  treatment  effect. The  difficulty,  of  course,  lies  in  making  a convincing case for the central estimate of the 'missing' treatment effect and assigning it a variance that appropriately reflects the  increased  uncertainty attaching to a non-randomised comparison. The increased uncertainty will affect comparisons between, but not within, the two networks.\"),\n",
       " Document(metadata={'doc_type': 'TSD', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'type': 'text', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades'}, page_content=\"Specific comments on frequentist software options for network meta-analysis can be found in TSD2. 34 For  indirect  comparison  networks,  separate  syntheses  can  be  carried  out  for  AB  \\ntrials, and AC trials. Then the estimates obtained and their variances can be entered into the simulation package used for CEA, and the relative cost-effectiveness of A, B and C readily determined  (covariances  are  not  involved).  Although  this  is  an  acceptable  approach  in principle,  the  Bayesian  MCMC  approach  to  indirect  comparisons  (see  TSD2 34 )  may  be preferable in cases where one or more of the pair-wise comparisons is represented by a very small number of trials. This is because, MCMC has the flexibility to allow 'shared variance' Random Effects (RE) models, while with conventional methods it may be necessary to have some estimates from RE models and others from Fixed Effects (FE) models, which seems a less natural solution.  \\nIn many cases the use of frequentist estimates and their VCV matrix with RE models is likely to  produce  parameter  distributions  with  a  little  less  uncertainty,  because  Bayesian  methods take uncertainty in variance parameters into account. The extent of the difference is unlikely to  be  critical,  although  investigators  should  always  check  that  posterior  distributions  of variance parameters are sensible.\")]"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "retriever.invoke(\"Find documents about Network that are TSDs.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "651ca3ed",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "retriever.invoke(\"Find documents about Network that are TAs.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "261b85c7",
   "metadata": {},
   "outputs": [],
   "source": [
    "bm25 = BM25Retriever.from_documents(mkd_docs, search_kwargs={\"k\": 5})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "c8966585",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='| 1. INTRODUCTION.......................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1. INTRODUCTION.......................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 8                                                                                           |\\n|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|\\n| 2. OVERALL ANALYTIC APPROACH TO SYNTHESIS FOR COST EFFECTIVENESS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ANALYSIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ......................................................................................... 9 |\\n| 2.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | SEPARATE MODELS FOR BASELINE NATURALHISTORY AND FOR RELATIVE TREATMENT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                             |\\n| EFFECTS .............................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | EFFECTS .............................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 9                                                                                           |\\n| 2.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | THE DECISION-MAKINGCONTEXTAND METHODOLOGY FOR EVIDENCE SYNTHESIS......                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 9                                                                                           |\\n| 2.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | ANALYTIC METHODS COMPATIBLE WITH PROBABILISTIC COST-EFFECTIVENESS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                             |\\n| ANALYSIS.........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | ANALYSIS.........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11                                                                                          |\\n| 3. DATASET FOR EVIDENCE SYNTHESIS OF RELATIVE TREATMENT EFFECTS..........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 3. DATASET FOR EVIDENCE SYNTHESIS OF RELATIVE TREATMENT EFFECTS..........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 11                                                                                          |\\n| 3.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | COMPARATOR SETS FOR DECISIONAND FOR SYNTHESIS ...........................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12                                                                                          |\\n| 3.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | TRIAL INCLUSION AND EXCLUSION .........................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12                                                                                          |\\n| 3.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | EXTENSION OF THE SYNTHESIS COMPARATOR SET ...................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 14                                                                                          |\\n| 3.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | RECORDING OF TREATMENTEFFECTMODIFIERS ......................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15                                                                                          |\\n| 3.5.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | DEALING WITH DISCONNECTED NETWORKS.............................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 15                                                                                          |\\n| 4. PRESENTATION OF THE EVIDENCE AND THE RESULTS OF EVIDENCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 4. PRESENTATION OF THE EVIDENCE AND THE RESULTS OF EVIDENCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                             |\\n|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16                                                                                          |\\n| SYNTHESIS...................................................................................................................... 4.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | THE EVIDENCE BASE ..............................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 16                                                                                          |\\n| 4.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | DESCRIPTION OF SYNTHESIS METHODOLOGY...........................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 17                                                                                          |\\n| 4.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | PRESENTATION OF SYNTHESIS RESULTS ..................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 18                                                                                          |\\n| 4.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | MODELDIAGNOSIS AND SELECTION ........................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20                                                                                          |\\n| 5.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | USING THE TECHNICAL SUPPORT DOCUMENTS.........................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 20                                                                                          |\\n| 6.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | REFERENCES..........................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22                                                                                          |\\n| TABLES AND FIGURES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | TABLES AND FIGURES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | mean                                                                                        |\\n| Table 1 Certolizumab Pegol (CZP) for Rheumatoid Arthritis: 28 number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with Placebo, and mean disease duration (in years) for patients in each trial. Blank cells indicate that the treatment was not compared in that trial. All trial arms had Methotrexate in addition to the placebo or active treatment. .....17 Table 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5....................................18 Table 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the | Table 1 Certolizumab Pegol (CZP) for Rheumatoid Arthritis: 28 number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with Placebo, and mean disease duration (in years) for patients in each trial. Blank cells indicate that the treatment was not compared in that trial. All trial arms had Methotrexate in addition to the placebo or active treatment. .....17 Table 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5....................................18 Table 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the |                                                                                             |\\n| relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta- analysis and separate pairwise meta-analyses with fixed effects..............................................................19 Figure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in                                                                                                                                                                                                                                                                                                                                                                                                                                  | relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta- analysis and separate pairwise meta-analyses with fixed effects..............................................................19 Figure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                             |\\n| bold. Treatment X has been added to the synthesis set because it links treatment C to the rest of the network (dashed lines)...........................................................................................................................12 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | bold. Treatment X has been added to the synthesis set because it links treatment C to the rest of the network (dashed lines)...........................................................................................................................12 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                             |\\n| Figure one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments Xand Y................................................................................................................................16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Figure one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments Xand Y................................................................................................................................16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                             |\\n| Figure 3 Parkinson network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers trials making that comparison................................................................................................................19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Figure 3 Parkinson network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers trials making that comparison................................................................................................................19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | of                                                                                          |'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"Although the parameters required  by the  CEA tend to be the absolute treatment effects of each treatment, it  is  essential that both the relative treatment effects, which are the outputs from  the  evidence  synthesis,  and  the  absolute  effects  on  which  the  CEA  is  based  are presented.  It  is  important  for  those  reviewing  and  evaluating  submissions  that  there  is absolute clarity  and  transparency  about  exactly  what  relative  efficacies  between  treatments are being assumed, and exactly what absolute effects are going forward into the CEA. This can  be  achieved  in  a  number  of  ways.  Perhaps  the  simplest  method  is  a  table  of  the  mean treatment effect with 95% Credible Intervals (CrI), of every treatment relative to placebo, or to a standard comparator. Table 2 gives an example, of the relative and absolute mean offtime reduction in patients given four dopamine agonists and Placebo as adjunct therapy for Parkinson's disease. The treatment network is presented in Figure 3 (for further details see TSD2 7 , Example 5).  \\nTable 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the  mean off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5.  \\n|             |             | mean                                          | sd                                            | 95% CrI                                       |\\n|-------------|-------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|\\n| X           | Y           | Relative effects of treatment Y compared to X | Relative effects of treatment Y compared to X | Relative effects of treatment Y compared to X |\\n| Placebo     | Treatment 2 | -1.81                                         | 0.33                                          | (-2.46,-1.16)                                 |\\n| Placebo     | Treatment 3 | -0.47                                         | 0.49                                          | (-1.43,0.49)                                  |\\n| Placebo     | Treatment 4 | -0.52                                         | 0.48                                          | (-1.46,0.43)                                  |\\n| Placebo     | Treatment 5 | -0.82                                         | 0.52                                          | (-1.84,0.22)                                  |\\n|             |             | Absolute treatment effects                    | Absolute treatment effects                    | Absolute treatment effects                    |\\n| Placebo     | Placebo     | -0.73                                         | 0.22                                          | (-1.16,-0.30)                                 |\\n| Treatment 2 | Treatment 2 | -2.54                                         | 0.40                                          | (-3.32,-1.76)                                 |\\n| Treatment 3 | Treatment 3 | -1.21                                         | 0.53                                          | (-2.25,-0.15)                                 |\\n| Treatment 4 | Treatment 4 | -1.25                                         | 0.53                                          | (-2.28,-0.21)                                 |\\n| Treatment 5 | Treatment 5 | -1.55                                         | 0.57                                          | (-2.66,-0.43)                                 |  \\n<!-- image -->  \\nTreatment 3  \\nFigure  3  Parkinson  network:  each  edge  represents  a  treatment,  connecting  lines  indicate  pairs  of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers of trials making that comparison.  \\nAnother format (Table 3) allows investigators to contrast results of pair-wise meta-analyses with  the  results  of  a  network  synthesis.  Although  this  table  does  not  constitute  a  formal analysis of inconsistency in the network (see TSD4 21 ), if the direct estimates are very close to their  network counter-parts, there  may  be  no need to proceed with further consideration of inconsistency. Similarly, graphical displays such as forest plots which summarise the results in  the  tables  along  with  the  raw  effect  estimates  from  each  trial  informing  that  treatment comparison, can also be presented. TSD3 19 shows an example of these plots (Example 2 in the Appendix).  \\nTable 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta-analysis and separate pairwise meta-analyses with fixed effects.  \\n|             |             | Network Meta-analysis   | Network Meta-analysis   | Network Meta-analysis   | Pairwise Meta-analyses   | Pairwise Meta-analyses   | Pairwise Meta-analyses   |\\n|-------------|-------------|-------------------------|-------------------------|-------------------------|--------------------------|--------------------------|--------------------------|\\n| X           | Y           | mean                    | sd                      | 95% CrI                 | mean                     | sd                       | 95% CrI                  |\\n| Placebo     | Treatment 2 | -1.81                   | 0.33                    | (-2.46,-1.16)           | -1.83                    | 0.34                     | (-2.49,-1.17)            |\\n| Placebo     | Treatment 3 | -0.47                   | 0.49                    | (-1.43,0.49)            | -0.31                    | 0.67                     | (-1.62,1.00)             |\\n| Placebo     | Treatment 4 | -0.52                   | 0.48                    | (-1.46,0.43)            | -0.90                    | 0.69                     | (-2.26,0.46)             |\\n| Placebo     | Treatment 5 | -0.82                   | 0.52                    | (-1.84,0.22)            | -                        | -                        | -                        |\\n| Treatment 2 | Treatment 3 | 1.34                    | 0.54                    | (0.28,2.41)             | -                        | -                        | -                        |\\n| Treatment 2 | Treatment 4 | 1.29                    | 0.52                    | (0.27,2.32)             | 1.40                     | 0.70                     | (0.03,2.77)              |\\n| Treatment 2 | Treatment 5 | 0.99                    | 0.56                    | (-0.10,2.10)            | -                        | -                        | -                        |\\n| Treatment 3 | Treatment 4 | -0.04                   | 0.32                    | (-0.68,0.59)            | 0.00                     | 0.35                     | (-0.68,0.68)             |\\n| Treatment 3 | Treatment 5 | -0.34                   | 0.38                    | (-1.10,0.41)            | -                        | -                        | -                        |\\n| Treatment 4 | Treatment 5 | -0.30                   | 0.21                    | (-0.71,0.11)            | -0.30                    | 0.21                     | (-0.71,0.11)             |  \\nA number of authors tabulate the probability that each treatment is best, which is an output available  from  Bayesian or other simulation-based approaches. This should be treated with  \\ngreat caution, however, particularly when there are many treatment alternatives. A treatment whose mean effect ranks quite low may still have a high probability of being best if there is relatively more uncertainty in its mean effect. This is misleading because for a given set of expected  (mean)  treatment  effects,  greater  uncertainty  may  flatter  a  treatment.  Differences between  treatments  in  probability  of  being  best  of  less  than  90%  cannot  be  given  much credence. A more reliable indicator is a plot of the rankings of each treatment. When there are multiple  outcomes,  for  example  remission,  relapse,  discontinuation  due  to  side  effects, 'rankograms'  for  each  treatment,  which  plot  the  ranks  on  each  outcome,  can  be  very informative. Readers are referred to Cipriani et al. 29 , where these plots first appeared, and to Ades  et  al. 30 for  a  further  application.  Salanti  et  al. 31 suggest  a  number  of  graphical presentations of results that may be useful in different circumstances.\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='An initial set of treatments that are to be compared will have been identified in the scoping exercise.  We will  call  this  the decision comparator set. Ideally,  this  should  include  all  the candidate  treatments  for  the  target  population  in  question.  If  it  is  not  possible  to  form  a connected network of comparisons of these treatments based on randomised data, it may be possible  to  introduce  further  treatments  so  that  a  connected  network  can  be  formed.  For example, in Figure 1 the treatments A and B have been compared in RCTs, but treatment C has  not  been  compared  to  either  A  or  B.  An  additional  treatment  X  has  been  introduced because  there  are  AX  and  CX  trials,  forming  a  connected  network.  Thus,  the synthesis comparator set consists of A, B, C, and X and is different from the decision comparator set A, B, C.  \\nOther ways to deal with disconnected networks are discussed in Section 3.5.  \\nFigure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in bold.  Treatment X has  been  added  to  the  synthesis  set  because  it  links  treatment  C  to  the  rest  of  the network (dashed lines).  \\n<!-- image -->'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"Although the focus of the TSDs is for situations where a connected evidence network can be constructed  from  randomised  evidence,  there  may  be  situations  like  the  one  depicted  in Figure 2 where the evidence forms two, or even more, disconnected elements. In these cases the methods described in TSD2 7 cannot be applied without further assumptions being made.  \\n<!-- image -->  \\nC  \\nFigure 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments X and Y.  \\nThese assumptions must take the form of a relative treatment effect linking the two networks. For example an assumption may be made about the relative efficacy of treatment X relative to A, of treatment Y relative to A, or of treatment X relative to B, and so on. From a technical point of view a distribution for such a treatment effect can readily be inserted into a synthesis (see  methods  for  shared  parameter  models  in  TSD2 7 )  and  expert  opinion  or  observational data  can  be  used  to  inform  the  treatment  effect. The  difficulty,  of  course,  lies  in  making  a convincing case for the central estimate of the 'missing' treatment effect and assigning it a variance that appropriately reflects the  increased  uncertainty attaching to a non-randomised comparison. The increased uncertainty will affect comparisons between, but not within, the two networks.\")]"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "bm25.invoke(\"Parkinson network\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "bed3507e",
   "metadata": {},
   "outputs": [],
   "source": [
    "ensemble_retriever = EnsembleRetriever(\n",
    "    retrievers=[retriever, bm25],\n",
    "    weights=[0.5, 0.5]\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "5b46bf09",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='The NICE Guide to the Methods of Technology Appraisal i is a regularly updated document that provides an overview of the key principles and methods of health technology assessment and  appraisal  for  use  in  NICE  appraisals.  The  Methods  Guide  does  not  provide  detailed advice  on  how  to  implement  and  apply  the  methods  it  describes.  This  DSU  series  of Technical  Support  Documents  (TSDs)  is  intended  to  complement  the  Methods  Guide  by providing detailed information on how to implement specific methods.  \\nThe TSDs provide a review of the current state of the art in each topic area, and make clear recommendations  on  the  implementation  of  methods  and  reporting  standards  where  it  is appropriate to do so. They aim to provide assistance to all those involved in submitting or critiquing evidence as part  of  NICE  Technology  Appraisals,  whether manufacturers, assessment groups or any other stakeholder type.  \\nWe recognise that there are areas of uncertainty, controversy and rapid development. It is our intention that such areas are indicated in the TSDs. All TSDs are extensively peer reviewed prior to publication (the names of peer reviewers appear in the acknowledgements for each document).  Nevertheless,  the  responsibility  for  each  TSD  lies  with  the  authors  and  we welcome any constructive feedback on the content or suggestions for further guides.  \\nPlease be aware that whilst the DSU is funded by NICE, these documents do not constitute formal NICE guidance or policy.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='| 1. INTRODUCTION.......................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1. INTRODUCTION.......................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 8                                                                                           |\\n|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|\\n| 2. OVERALL ANALYTIC APPROACH TO SYNTHESIS FOR COST EFFECTIVENESS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ANALYSIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ......................................................................................... 9 |\\n| 2.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | SEPARATE MODELS FOR BASELINE NATURALHISTORY AND FOR RELATIVE TREATMENT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                             |\\n| EFFECTS .............................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | EFFECTS .............................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 9                                                                                           |\\n| 2.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | THE DECISION-MAKINGCONTEXTAND METHODOLOGY FOR EVIDENCE SYNTHESIS......                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 9                                                                                           |\\n| 2.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | ANALYTIC METHODS COMPATIBLE WITH PROBABILISTIC COST-EFFECTIVENESS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                             |\\n| ANALYSIS.........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | ANALYSIS.........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11                                                                                          |\\n| 3. DATASET FOR EVIDENCE SYNTHESIS OF RELATIVE TREATMENT EFFECTS..........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 3. DATASET FOR EVIDENCE SYNTHESIS OF RELATIVE TREATMENT EFFECTS..........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 11                                                                                          |\\n| 3.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | COMPARATOR SETS FOR DECISIONAND FOR SYNTHESIS ...........................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12                                                                                          |\\n| 3.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | TRIAL INCLUSION AND EXCLUSION .........................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12                                                                                          |\\n| 3.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | EXTENSION OF THE SYNTHESIS COMPARATOR SET ...................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 14                                                                                          |\\n| 3.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | RECORDING OF TREATMENTEFFECTMODIFIERS ......................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15                                                                                          |\\n| 3.5.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | DEALING WITH DISCONNECTED NETWORKS.............................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 15                                                                                          |\\n| 4. PRESENTATION OF THE EVIDENCE AND THE RESULTS OF EVIDENCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 4. PRESENTATION OF THE EVIDENCE AND THE RESULTS OF EVIDENCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                             |\\n|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16                                                                                          |\\n| SYNTHESIS...................................................................................................................... 4.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | THE EVIDENCE BASE ..............................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 16                                                                                          |\\n| 4.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | DESCRIPTION OF SYNTHESIS METHODOLOGY...........................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 17                                                                                          |\\n| 4.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | PRESENTATION OF SYNTHESIS RESULTS ..................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 18                                                                                          |\\n| 4.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | MODELDIAGNOSIS AND SELECTION ........................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20                                                                                          |\\n| 5.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | USING THE TECHNICAL SUPPORT DOCUMENTS.........................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 20                                                                                          |\\n| 6.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | REFERENCES..........................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22                                                                                          |\\n| TABLES AND FIGURES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | TABLES AND FIGURES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | mean                                                                                        |\\n| Table 1 Certolizumab Pegol (CZP) for Rheumatoid Arthritis: 28 number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with Placebo, and mean disease duration (in years) for patients in each trial. Blank cells indicate that the treatment was not compared in that trial. All trial arms had Methotrexate in addition to the placebo or active treatment. .....17 Table 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5....................................18 Table 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the | Table 1 Certolizumab Pegol (CZP) for Rheumatoid Arthritis: 28 number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with Placebo, and mean disease duration (in years) for patients in each trial. Blank cells indicate that the treatment was not compared in that trial. All trial arms had Methotrexate in addition to the placebo or active treatment. .....17 Table 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5....................................18 Table 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the |                                                                                             |\\n| relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta- analysis and separate pairwise meta-analyses with fixed effects..............................................................19 Figure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in                                                                                                                                                                                                                                                                                                                                                                                                                                  | relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta- analysis and separate pairwise meta-analyses with fixed effects..............................................................19 Figure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                             |\\n| bold. Treatment X has been added to the synthesis set because it links treatment C to the rest of the network (dashed lines)...........................................................................................................................12 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | bold. Treatment X has been added to the synthesis set because it links treatment C to the rest of the network (dashed lines)...........................................................................................................................12 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                             |\\n| Figure one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments Xand Y................................................................................................................................16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Figure one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments Xand Y................................................................................................................................16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                             |\\n| Figure 3 Parkinson network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers trials making that comparison................................................................................................................19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Figure 3 Parkinson network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers trials making that comparison................................................................................................................19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | of                                                                                          |'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"Although the parameters required  by the  CEA tend to be the absolute treatment effects of each treatment, it  is  essential that both the relative treatment effects, which are the outputs from  the  evidence  synthesis,  and  the  absolute  effects  on  which  the  CEA  is  based  are presented.  It  is  important  for  those  reviewing  and  evaluating  submissions  that  there  is absolute clarity  and  transparency  about  exactly  what  relative  efficacies  between  treatments are being assumed, and exactly what absolute effects are going forward into the CEA. This can  be  achieved  in  a  number  of  ways.  Perhaps  the  simplest  method  is  a  table  of  the  mean treatment effect with 95% Credible Intervals (CrI), of every treatment relative to placebo, or to a standard comparator. Table 2 gives an example, of the relative and absolute mean offtime reduction in patients given four dopamine agonists and Placebo as adjunct therapy for Parkinson's disease. The treatment network is presented in Figure 3 (for further details see TSD2 7 , Example 5).  \\nTable 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the  mean off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5.  \\n|             |             | mean                                          | sd                                            | 95% CrI                                       |\\n|-------------|-------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|\\n| X           | Y           | Relative effects of treatment Y compared to X | Relative effects of treatment Y compared to X | Relative effects of treatment Y compared to X |\\n| Placebo     | Treatment 2 | -1.81                                         | 0.33                                          | (-2.46,-1.16)                                 |\\n| Placebo     | Treatment 3 | -0.47                                         | 0.49                                          | (-1.43,0.49)                                  |\\n| Placebo     | Treatment 4 | -0.52                                         | 0.48                                          | (-1.46,0.43)                                  |\\n| Placebo     | Treatment 5 | -0.82                                         | 0.52                                          | (-1.84,0.22)                                  |\\n|             |             | Absolute treatment effects                    | Absolute treatment effects                    | Absolute treatment effects                    |\\n| Placebo     | Placebo     | -0.73                                         | 0.22                                          | (-1.16,-0.30)                                 |\\n| Treatment 2 | Treatment 2 | -2.54                                         | 0.40                                          | (-3.32,-1.76)                                 |\\n| Treatment 3 | Treatment 3 | -1.21                                         | 0.53                                          | (-2.25,-0.15)                                 |\\n| Treatment 4 | Treatment 4 | -1.25                                         | 0.53                                          | (-2.28,-0.21)                                 |\\n| Treatment 5 | Treatment 5 | -1.55                                         | 0.57                                          | (-2.66,-0.43)                                 |  \\n<!-- image -->  \\nTreatment 3  \\nFigure  3  Parkinson  network:  each  edge  represents  a  treatment,  connecting  lines  indicate  pairs  of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers of trials making that comparison.  \\nAnother format (Table 3) allows investigators to contrast results of pair-wise meta-analyses with  the  results  of  a  network  synthesis.  Although  this  table  does  not  constitute  a  formal analysis of inconsistency in the network (see TSD4 21 ), if the direct estimates are very close to their  network counter-parts, there  may  be  no need to proceed with further consideration of inconsistency. Similarly, graphical displays such as forest plots which summarise the results in  the  tables  along  with  the  raw  effect  estimates  from  each  trial  informing  that  treatment comparison, can also be presented. TSD3 19 shows an example of these plots (Example 2 in the Appendix).  \\nTable 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta-analysis and separate pairwise meta-analyses with fixed effects.  \\n|             |             | Network Meta-analysis   | Network Meta-analysis   | Network Meta-analysis   | Pairwise Meta-analyses   | Pairwise Meta-analyses   | Pairwise Meta-analyses   |\\n|-------------|-------------|-------------------------|-------------------------|-------------------------|--------------------------|--------------------------|--------------------------|\\n| X           | Y           | mean                    | sd                      | 95% CrI                 | mean                     | sd                       | 95% CrI                  |\\n| Placebo     | Treatment 2 | -1.81                   | 0.33                    | (-2.46,-1.16)           | -1.83                    | 0.34                     | (-2.49,-1.17)            |\\n| Placebo     | Treatment 3 | -0.47                   | 0.49                    | (-1.43,0.49)            | -0.31                    | 0.67                     | (-1.62,1.00)             |\\n| Placebo     | Treatment 4 | -0.52                   | 0.48                    | (-1.46,0.43)            | -0.90                    | 0.69                     | (-2.26,0.46)             |\\n| Placebo     | Treatment 5 | -0.82                   | 0.52                    | (-1.84,0.22)            | -                        | -                        | -                        |\\n| Treatment 2 | Treatment 3 | 1.34                    | 0.54                    | (0.28,2.41)             | -                        | -                        | -                        |\\n| Treatment 2 | Treatment 4 | 1.29                    | 0.52                    | (0.27,2.32)             | 1.40                     | 0.70                     | (0.03,2.77)              |\\n| Treatment 2 | Treatment 5 | 0.99                    | 0.56                    | (-0.10,2.10)            | -                        | -                        | -                        |\\n| Treatment 3 | Treatment 4 | -0.04                   | 0.32                    | (-0.68,0.59)            | 0.00                     | 0.35                     | (-0.68,0.68)             |\\n| Treatment 3 | Treatment 5 | -0.34                   | 0.38                    | (-1.10,0.41)            | -                        | -                        | -                        |\\n| Treatment 4 | Treatment 5 | -0.30                   | 0.21                    | (-0.71,0.11)            | -0.30                    | 0.21                     | (-0.71,0.11)             |  \\nA number of authors tabulate the probability that each treatment is best, which is an output available  from  Bayesian or other simulation-based approaches. This should be treated with  \\ngreat caution, however, particularly when there are many treatment alternatives. A treatment whose mean effect ranks quite low may still have a high probability of being best if there is relatively more uncertainty in its mean effect. This is misleading because for a given set of expected  (mean)  treatment  effects,  greater  uncertainty  may  flatter  a  treatment.  Differences between  treatments  in  probability  of  being  best  of  less  than  90%  cannot  be  given  much credence. A more reliable indicator is a plot of the rankings of each treatment. When there are multiple  outcomes,  for  example  remission,  relapse,  discontinuation  due  to  side  effects, 'rankograms'  for  each  treatment,  which  plot  the  ranks  on  each  outcome,  can  be  very informative. Readers are referred to Cipriani et al. 29 , where these plots first appeared, and to Ades  et  al. 30 for  a  further  application.  Salanti  et  al. 31 suggest  a  number  of  graphical presentations of results that may be useful in different circumstances.\")]"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ensemble_retriever.invoke(\"Documents about Parkinson network that are TAs\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "f3fd5b8f",
   "metadata": {},
   "outputs": [],
   "source": [
    "from pydantic import BaseModel, Field\n",
    "\n",
    "class doc_type(BaseModel):\n",
    "    doc_type: str = Field(description=\"Whether the document is a TSD (Technical Support Document) or a TA (Technical Assessment).\")\n",
    "\n",
    "llm = ChatOpenAI(model=\"gpt-4o\", temperature=0)\n",
    "\n",
    "\n",
    "structured_llm = llm.with_structured_output(doc_type)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "613845df",
   "metadata": {},
   "outputs": [],
   "source": [
    "response = structured_llm.invoke(\"TSD documents about parkinson's network\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "28847c67",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "doc_type(doc_type='TSD')"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "a0188edf",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'TSD'"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response.doc_type"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "fe3285ee",
   "metadata": {},
   "outputs": [],
   "source": [
    "retriever = vector_store.as_retriever(search_kwargs={\"k\": 5})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "c15ce9a5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(50, 'TSD')"
      ]
     },
     "execution_count": 70,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "query = \"Documents about Parkinson network\"\n",
    "doc_type = structured_llm.invoke(query).doc_type\n",
    "\n",
    "filtered_mkd_docs = [d for d in mkd_docs if d.metadata.get(\"doc_type\") == doc_type]\n",
    "len(filtered_mkd_docs), doc_type"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "d73e5bd7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "There are documents of the requested type.\n"
     ]
    }
   ],
   "source": [
    "if filtered_mkd_docs:\n",
    "    print(\"There are documents of the requested type.\")\n",
    "else:\n",
    "    print(\"There are no documents of the requested type.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "5308a776",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[VectorStoreRetriever(tags=['Chroma', 'OpenAIEmbeddings'], vectorstore=<langchain_community.vectorstores.chroma.Chroma object at 0x0000025D03C30440>, search_kwargs={'k': 5, 'filter': {'doc_type': 'TSD'}}), BM25Retriever(vectorizer=<rank_bm25.BM25Okapi object at 0x0000025DA7D17820>)]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'type': 'text', 'doc_type': 'TSD', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades'}, page_content='| 1. INTRODUCTION.......................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1. INTRODUCTION.......................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 8                                                                                           |\\n|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|\\n| 2. OVERALL ANALYTIC APPROACH TO SYNTHESIS FOR COST EFFECTIVENESS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ANALYSIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ......................................................................................... 9 |\\n| 2.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | SEPARATE MODELS FOR BASELINE NATURALHISTORY AND FOR RELATIVE TREATMENT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                             |\\n| EFFECTS .............................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | EFFECTS .............................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 9                                                                                           |\\n| 2.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | THE DECISION-MAKINGCONTEXTAND METHODOLOGY FOR EVIDENCE SYNTHESIS......                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 9                                                                                           |\\n| 2.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | ANALYTIC METHODS COMPATIBLE WITH PROBABILISTIC COST-EFFECTIVENESS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                             |\\n| ANALYSIS.........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | ANALYSIS.........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11                                                                                          |\\n| 3. DATASET FOR EVIDENCE SYNTHESIS OF RELATIVE TREATMENT EFFECTS..........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 3. DATASET FOR EVIDENCE SYNTHESIS OF RELATIVE TREATMENT EFFECTS..........................................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 11                                                                                          |\\n| 3.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | COMPARATOR SETS FOR DECISIONAND FOR SYNTHESIS ...........................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12                                                                                          |\\n| 3.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | TRIAL INCLUSION AND EXCLUSION .........................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12                                                                                          |\\n| 3.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | EXTENSION OF THE SYNTHESIS COMPARATOR SET ...................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 14                                                                                          |\\n| 3.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | RECORDING OF TREATMENTEFFECTMODIFIERS ......................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15                                                                                          |\\n| 3.5.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | DEALING WITH DISCONNECTED NETWORKS.............................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 15                                                                                          |\\n| 4. PRESENTATION OF THE EVIDENCE AND THE RESULTS OF EVIDENCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 4. PRESENTATION OF THE EVIDENCE AND THE RESULTS OF EVIDENCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                             |\\n|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16                                                                                          |\\n| SYNTHESIS...................................................................................................................... 4.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | THE EVIDENCE BASE ..............................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 16                                                                                          |\\n| 4.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | DESCRIPTION OF SYNTHESIS METHODOLOGY...........................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 17                                                                                          |\\n| 4.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | PRESENTATION OF SYNTHESIS RESULTS ..................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 18                                                                                          |\\n| 4.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | MODELDIAGNOSIS AND SELECTION ........................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20                                                                                          |\\n| 5.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | USING THE TECHNICAL SUPPORT DOCUMENTS.........................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 20                                                                                          |\\n| 6.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | REFERENCES..........................................................................................................                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22                                                                                          |\\n| TABLES AND FIGURES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | TABLES AND FIGURES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | mean                                                                                        |\\n| Table 1 Certolizumab Pegol (CZP) for Rheumatoid Arthritis: 28 number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with Placebo, and mean disease duration (in years) for patients in each trial. Blank cells indicate that the treatment was not compared in that trial. All trial arms had Methotrexate in addition to the placebo or active treatment. .....17 Table 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5....................................18 Table 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the | Table 1 Certolizumab Pegol (CZP) for Rheumatoid Arthritis: 28 number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with Placebo, and mean disease duration (in years) for patients in each trial. Blank cells indicate that the treatment was not compared in that trial. All trial arms had Methotrexate in addition to the placebo or active treatment. .....17 Table 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5....................................18 Table 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the |                                                                                             |\\n| relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta- analysis and separate pairwise meta-analyses with fixed effects..............................................................19 Figure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in                                                                                                                                                                                                                                                                                                                                                                                                                                  | relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta- analysis and separate pairwise meta-analyses with fixed effects..............................................................19 Figure 1 Treatment network where the decision and synthesis comparator sets differ. Lines represent a comparison of the connected treatments in at least one trial. Treatments relevant to the decision are in                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                             |\\n| bold. Treatment X has been added to the synthesis set because it links treatment C to the rest of the network (dashed lines)...........................................................................................................................12 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | bold. Treatment X has been added to the synthesis set because it links treatment C to the rest of the network (dashed lines)...........................................................................................................................12 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                             |\\n| Figure one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments Xand Y................................................................................................................................16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Figure one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments Xand Y................................................................................................................................16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                             |\\n| Figure 3 Parkinson network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers trials making that comparison................................................................................................................19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Figure 3 Parkinson network: each edge represents a treatment, connecting lines indicate pairs of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers trials making that comparison................................................................................................................19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | of                                                                                          |'),\n",
       " Document(metadata={'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'type': 'text', 'doc_type': 'TSD', 'title': 'Introduction to evidence synthesis for decision making'}, page_content=\"Although the parameters required  by the  CEA tend to be the absolute treatment effects of each treatment, it  is  essential that both the relative treatment effects, which are the outputs from  the  evidence  synthesis,  and  the  absolute  effects  on  which  the  CEA  is  based  are presented.  It  is  important  for  those  reviewing  and  evaluating  submissions  that  there  is absolute clarity  and  transparency  about  exactly  what  relative  efficacies  between  treatments are being assumed, and exactly what absolute effects are going forward into the CEA. This can  be  achieved  in  a  number  of  ways.  Perhaps  the  simplest  method  is  a  table  of  the  mean treatment effect with 95% Credible Intervals (CrI), of every treatment relative to placebo, or to a standard comparator. Table 2 gives an example, of the relative and absolute mean offtime reduction in patients given four dopamine agonists and Placebo as adjunct therapy for Parkinson's disease. The treatment network is presented in Figure 3 (for further details see TSD2 7 , Example 5).  \\nTable 2 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the  mean off-time reduction for the fixed effects models for the treatment effects of Treatments 2 to 5 relative to Placebo, and absolute mean off-time reduction for Placebo and treatments 2 to 5.  \\n|             |             | mean                                          | sd                                            | 95% CrI                                       |\\n|-------------|-------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|\\n| X           | Y           | Relative effects of treatment Y compared to X | Relative effects of treatment Y compared to X | Relative effects of treatment Y compared to X |\\n| Placebo     | Treatment 2 | -1.81                                         | 0.33                                          | (-2.46,-1.16)                                 |\\n| Placebo     | Treatment 3 | -0.47                                         | 0.49                                          | (-1.43,0.49)                                  |\\n| Placebo     | Treatment 4 | -0.52                                         | 0.48                                          | (-1.46,0.43)                                  |\\n| Placebo     | Treatment 5 | -0.82                                         | 0.52                                          | (-1.84,0.22)                                  |\\n|             |             | Absolute treatment effects                    | Absolute treatment effects                    | Absolute treatment effects                    |\\n| Placebo     | Placebo     | -0.73                                         | 0.22                                          | (-1.16,-0.30)                                 |\\n| Treatment 2 | Treatment 2 | -2.54                                         | 0.40                                          | (-3.32,-1.76)                                 |\\n| Treatment 3 | Treatment 3 | -1.21                                         | 0.53                                          | (-2.25,-0.15)                                 |\\n| Treatment 4 | Treatment 4 | -1.25                                         | 0.53                                          | (-2.28,-0.21)                                 |\\n| Treatment 5 | Treatment 5 | -1.55                                         | 0.57                                          | (-2.66,-0.43)                                 |  \\n<!-- image -->  \\nTreatment 3  \\nFigure  3  Parkinson  network:  each  edge  represents  a  treatment,  connecting  lines  indicate  pairs  of treatments which have been directly compared in randomised trials. The numbers on the lines indicate the numbers of trials making that comparison.  \\nAnother format (Table 3) allows investigators to contrast results of pair-wise meta-analyses with  the  results  of  a  network  synthesis.  Although  this  table  does  not  constitute  a  formal analysis of inconsistency in the network (see TSD4 21 ), if the direct estimates are very close to their  network counter-parts, there  may  be  no need to proceed with further consideration of inconsistency. Similarly, graphical displays such as forest plots which summarise the results in  the  tables  along  with  the  raw  effect  estimates  from  each  trial  informing  that  treatment comparison, can also be presented. TSD3 19 shows an example of these plots (Example 2 in the Appendix).  \\nTable 3 Parkinson example: posterior mean, standard deviation (sd) and 95% Credible interval (CrI) of the relative effect of treatment Y compared to X for all possible treatment comparisons, for the network meta-analysis and separate pairwise meta-analyses with fixed effects.  \\n|             |             | Network Meta-analysis   | Network Meta-analysis   | Network Meta-analysis   | Pairwise Meta-analyses   | Pairwise Meta-analyses   | Pairwise Meta-analyses   |\\n|-------------|-------------|-------------------------|-------------------------|-------------------------|--------------------------|--------------------------|--------------------------|\\n| X           | Y           | mean                    | sd                      | 95% CrI                 | mean                     | sd                       | 95% CrI                  |\\n| Placebo     | Treatment 2 | -1.81                   | 0.33                    | (-2.46,-1.16)           | -1.83                    | 0.34                     | (-2.49,-1.17)            |\\n| Placebo     | Treatment 3 | -0.47                   | 0.49                    | (-1.43,0.49)            | -0.31                    | 0.67                     | (-1.62,1.00)             |\\n| Placebo     | Treatment 4 | -0.52                   | 0.48                    | (-1.46,0.43)            | -0.90                    | 0.69                     | (-2.26,0.46)             |\\n| Placebo     | Treatment 5 | -0.82                   | 0.52                    | (-1.84,0.22)            | -                        | -                        | -                        |\\n| Treatment 2 | Treatment 3 | 1.34                    | 0.54                    | (0.28,2.41)             | -                        | -                        | -                        |\\n| Treatment 2 | Treatment 4 | 1.29                    | 0.52                    | (0.27,2.32)             | 1.40                     | 0.70                     | (0.03,2.77)              |\\n| Treatment 2 | Treatment 5 | 0.99                    | 0.56                    | (-0.10,2.10)            | -                        | -                        | -                        |\\n| Treatment 3 | Treatment 4 | -0.04                   | 0.32                    | (-0.68,0.59)            | 0.00                     | 0.35                     | (-0.68,0.68)             |\\n| Treatment 3 | Treatment 5 | -0.34                   | 0.38                    | (-1.10,0.41)            | -                        | -                        | -                        |\\n| Treatment 4 | Treatment 5 | -0.30                   | 0.21                    | (-0.71,0.11)            | -0.30                    | 0.21                     | (-0.71,0.11)             |  \\nA number of authors tabulate the probability that each treatment is best, which is an output available  from  Bayesian or other simulation-based approaches. This should be treated with  \\ngreat caution, however, particularly when there are many treatment alternatives. A treatment whose mean effect ranks quite low may still have a high probability of being best if there is relatively more uncertainty in its mean effect. This is misleading because for a given set of expected  (mean)  treatment  effects,  greater  uncertainty  may  flatter  a  treatment.  Differences between  treatments  in  probability  of  being  best  of  less  than  90%  cannot  be  given  much credence. A more reliable indicator is a plot of the rankings of each treatment. When there are multiple  outcomes,  for  example  remission,  relapse,  discontinuation  due  to  side  effects, 'rankograms'  for  each  treatment,  which  plot  the  ranks  on  each  outcome,  can  be  very informative. Readers are referred to Cipriani et al. 29 , where these plots first appeared, and to Ades  et  al. 30 for  a  further  application.  Salanti  et  al. 31 suggest  a  number  of  graphical presentations of results that may be useful in different circumstances.\"),\n",
       " Document(metadata={'type': 'text', 'doc_type': 'TSD', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'title': 'Introduction to evidence synthesis for decision making'}, page_content=\"1.   National  Institute  for  health  and  Clinical  Excellence.  Guide  to  the  methods  of technology appraisal (updated June 2008). 2008.\\n2.   Brennan,  A.,  Bansback,  N.,  Nixon,  R.,  Madan,  J.,  Harrison,  M.,  Watson,  K.  et  al. Modelling  the  cost  effectiveness  of  TNF-alpha  antagonists  in  the  management  of rheumatoid  arthritis:  results  from  the  British  Society  for  Rheumatology  Biologics Registry. Rheumatology 2007; 46:1345-1354.\\n3.   Woolacott, N.F., Bravo Vergel, Y., Hawkins, N., Kainth, A., Khadjesari, Z., Misso, K. et  al.  Etanercept  and  infliximab  for  the  treatment  of  psoriatic  arthritis:  a  systematic review and economic evaluation. Health Technology Assessment 2006; 10(31).\\n4.   Woolacott, N.F., Jones, L., Ford, C.A., Mather, L.C., Sowden, A.J., Song, F.J. et al. The clinical  effectiveness  and  cost-effectiveness  of  buproprion  and  nicotine  replacement therapy  for  smoking  cessation:  a  systematic  review  and  economic  evaluation. Health Technology Assessment 2002; 6(16):1-245.\\n5.   Wang, D., Connock, M., Barton, P., Fry-Smith, A., Aveyard, P., Moore, D. 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis. Health Technology Assessment 2008; 12(2).\\n6.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  5:  Evidence  synthesis  in  the  baseline  natural  history  model.  2011;  last updated April 2012; available from http://www.nicedsu.org.uk\\n7.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  2:  A  generalised  linear  modelling  framework  for  pair-wise  and  network meta-analysis of randomised controlled trials. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n8.   Eccles,  M.,  Freemantle,  N.,  Mason,  J.  Using  systematic  reviews  in  clinical  guideline development. In: Egger M., Davey Smith G., Altman D.G., eds. Systematic Reviews in Health Care: meta-analysis in context . Second ed. BMJ; London: 2001; 400-409.\\n9.   Rubin, D.B. A new perspective. In: Wachter K.W., Straf M.L., eds. The Future of Metaanalysis . Russell Sage Foundation; New York: 1990.\\n10.   Greenland,  S.  Invited  commentary:  A  critical  look  at  some  popular  meta-analytic methods. American Journal Of Epidemiology 1994; 140(3):290-296.\\n11.   Higgins, J.P.T., Green, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, Wiley, Chichester; 2008.\\n12.   Russell,  K.,  Kiddoo,  D.  The  Cochrane  library  and  nocturnal  enuresis:  an  umbrella review. Evidence-Based Child Health: a Cochrane Review Journal 2006; 1(1):5-8.  \\n13.   Wells,  G.A.,  Sultan,  S.A.,  Chen,  L.,  Khan,  M.,  Coyle,  D.  Indirect  Evidence:  Indirect Treatment Comparisons in Meta-Analysis. Cochrane Database of Systematic Reviews 2009. Ottawa, Canadian Agency for Drugs and Technologies in Health.\\n14.   Iglehart, J.K. Prioritizing comparative-effectiveness research - IOM recommendations. New England Journal of Medicine 2009; 361:325-328.\\n15.   Glasziou,  P.P.,  Irwig,  L.M.  An  evidence-based  approach  to  individualising  treatment. British Medical Journal 1995; 311:1356-1359.\\n16.   Doubilet,  P.,  Begg,  C.B.,  Weinstein,  M.C.,  Braun,  P.,  McNeill,  B.J.  Probabilistic sensitivity  analysis  using  Monte  Carlo  simulation:  a  practical  approach. Medical Decision Making 1985; 5:157-177.\\n17.   Critchfield,  G.C.,  Willard,  K.E.  Probabilistic  analysis  of  decision  trees  using  Monte Carlo simulation. Med Decis Making, MED 1986; 6:85-92.\\n18.   Dias,  S.,  Sutton,  A.J.,  Welton,  N.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document 6: Embedding evidence synthesis in probabilistic cost-effectiveness analysis: software choices. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n19.   Dias,  S.,  Sutton,  A.J.,  Welton,  N.J.,  Ades,  A.E.  NICE  DSU  Technical  Support Document  3:  Heterogeneity:  subgroups,  meta-regression,  bias  and  bias-adjustment. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n20.   Cooper,  N.J.,  Peters,  J.,  Lai,  M.C.W.,  Juni,  P.,  Wandel,  S.,  Palmer,  S.  et  al.  How valuable  are  multiple  treatment  comparison  methods  in  evidence-based  health-care evaluation? Value in Health 2011; 14:371-380.\\n21.   Dias,  S.,  Welton,  N.J.,  Sutton,  A.J.,  Caldwell,  D.M.,  Lu,  G.,  Ades,  A.E.  NICE  DSU Technical  Support  Document  4:  Inconsistency  in  networks  of  evidence  based  on randomised controlled trials. 2011; last updated April 2012; available from http://www.nicedsu.org.uk\\n22.   Welton,  N.J.,  Willis,  S.R.,  Ades,  A.E.  Synthesis  of  Survival  and  Disease  Progression Outcomes for Health Technology Assessment of Cancer Therapies. Research Synthesis Methods 2010; 1:239-257.\\n23.   Welton, N.J., Cooper, N.J., Ades, A.E., Lu, G., Sutton, A.J. Mixed  treatment comparison with multiple outcomes reported inconsistently across trials: evaluation of antivirals  for  treatment  of  influenza  A  and  B. Statistics  In  Medicine 2008;  27:56205639.\\n24.   Burch, J., Paulden, M., Conti, S., Stock, C., Corbette, M., Welton, N.J. et al. Antiviral drugs  for  the  treatment  of  influenza:  a  systematic  review  and  economic  evaluation. Health Technology Assesment 2010; 13(58):1-290.\\n25.   Batagelj,  V.,  Mrvar,  A.  Pajek  -  Program  for  Large  Network  Analysis. Connections 1998; 21(2):47-57.  \\n26.   R:  A  Language  and  Environment  for  Statistical  Computing  [  Windows.  Vienna, Austria: R Foundation for Statistical Computing; 2010.\\n27.   Salanti, G. Multiple-treatments meta-analysis of a network of interventions. http://www mtm uoi gr/ 2011;  Available from http://www.mtm.uoi.gr/\\n28.   National  Institute  for  health  and  Clinical  Excellence.  Certolizumab  pegol  for  the treatment  of  rheumatoid  arthritis.  2010;  TA186.    National  Institute  for  Health  and Clinical Excellence. NICE technology appraisal guidance.\\n29.   Cipriani, A., Furukawa, T.A., Salanti, G., Geddes, J.R., Higgins, J.P.T., Churchill, R. et al.  Comparative  efficacy  and  acceptability  of  12  new  generation  antidepressants:  a multiple-treatments meta-analysis. Lancet 2009; 373:746-758.\\n30.   Ades,  A.E.,  Mavranezouli,  I.,  Dias,  S.,  Welton,  N.J.,  Whittington,  C.,  Kendall,  T. Network meta-analysis with competing risk outcomes. Value in Health 2010; 13(8):976-983.\\n31.   Salanti, G., Ades, A.E., Ioannidis, J.P.A. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011; 64:163-171.\\n32.   Ades, A.E., Caldwell, D.M., Reken, S., Welton, N.J., Sutton, A.J., Dias, S. NICE DSU Technical  Support  Document  7:  Evidence  synthesis  of  treatment  efficacy  in  decision making: a reviewer's checklist. 2012; available from http://www.nicedsu.org.uk\"),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content=\"Although the focus of the TSDs is for situations where a connected evidence network can be constructed  from  randomised  evidence,  there  may  be  situations  like  the  one  depicted  in Figure 2 where the evidence forms two, or even more, disconnected elements. In these cases the methods described in TSD2 7 cannot be applied without further assumptions being made.  \\n<!-- image -->  \\nC  \\nFigure 2 Disconnected treatment network. Lines represent a comparison of the connected treatments in at least one trial. The network formed by treatments A, B and C is not connected to the network formed by treatments X and Y.  \\nThese assumptions must take the form of a relative treatment effect linking the two networks. For example an assumption may be made about the relative efficacy of treatment X relative to A, of treatment Y relative to A, or of treatment X relative to B, and so on. From a technical point of view a distribution for such a treatment effect can readily be inserted into a synthesis (see  methods  for  shared  parameter  models  in  TSD2 7 )  and  expert  opinion  or  observational data  can  be  used  to  inform  the  treatment  effect. The  difficulty,  of  course,  lies  in  making  a convincing case for the central estimate of the 'missing' treatment effect and assigning it a variance that appropriately reflects the  increased  uncertainty attaching to a non-randomised comparison. The increased uncertainty will affect comparisons between, but not within, the two networks.\"),\n",
       " Document(metadata={'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'doc_type': 'TSD'}, page_content='The DSU thanks Rachael Fleurence, Jeroen Jansen, Alec Miners, Jaime Peters, Mike Spencer and the team at NICE, led by Gabriel Rogers, for reviewing this document. The editor for the TSD series is Allan Wailoo.  \\nThe production of this document was funded by the National Institute for Health and Clinical Excellence  (NICE)  through  its  Decision  Support  Unit.  The  views,  and  any  errors  or omissions, expressed in this document are of the author only. NICE may take account of part or all of this document if it considers it appropriate, but it is not bound to do so.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Introduction to evidence synthesis for decision making', 'authors': 'Sofia Dias,Nicky J Welton,Alex J Sutton,AE Ades', 'doc_type': 'TSD'}, page_content='The NICE Guide to the Methods of Technology Appraisal i is a regularly updated document that provides an overview of the key principles and methods of health technology assessment and  appraisal  for  use  in  NICE  appraisals.  The  Methods  Guide  does  not  provide  detailed advice  on  how  to  implement  and  apply  the  methods  it  describes.  This  DSU  series  of Technical  Support  Documents  (TSDs)  is  intended  to  complement  the  Methods  Guide  by providing detailed information on how to implement specific methods.  \\nThe TSDs provide a review of the current state of the art in each topic area, and make clear recommendations  on  the  implementation  of  methods  and  reporting  standards  where  it  is appropriate to do so. They aim to provide assistance to all those involved in submitting or critiquing evidence as part  of  NICE  Technology  Appraisals,  whether manufacturers, assessment groups or any other stakeholder type.  \\nWe recognise that there are areas of uncertainty, controversy and rapid development. It is our intention that such areas are indicated in the TSDs. All TSDs are extensively peer reviewed prior to publication (the names of peer reviewers appear in the acknowledgements for each document).  Nevertheless,  the  responsibility  for  each  TSD  lies  with  the  authors  and  we welcome any constructive feedback on the content or suggestions for further guides.  \\nPlease be aware that whilst the DSU is funded by NICE, these documents do not constitute formal NICE guidance or policy.'),\n",
       " Document(metadata={'type': 'text', 'title': 'Embedding evidence synthesis in probabilistic cost effectiveness analysis Software choices', 'authors': 'Sofia Dias,Alex J Sutton,Nicky J Welton,AE Ades', 'doc_type': 'TSD'}, page_content='| 1. 2.                                                                                                                                                                                                                                                                                                   | INTRODUCTION....................................................................................................... EMBEDDING EVIDENCE SYNTHESIS IN PROBABILISTIC CEA....................                                                                                                               | 7 8                                                                                                                                                                                                                                                                                                     |\\n|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\\n|                                                                                                                                                                                                                                                                                                         | 2.1. BAYESIAN POSTERIOR SIMULATION: ONE-STAGE APPROACH.....................................                                                                                                                                                                                                             | 2.1. BAYESIAN POSTERIOR SIMULATION: ONE-STAGE APPROACH.....................................                                                                                                                                                                                                             |\\n| 2.2.                                                                                                                                                                                                                                                                                                    | BAYESIAN POSTERIOR SIMULATION: TWO-STAGE APPROACH ....................................                                                                                                                                                                                                                  | 9                                                                                                                                                                                                                                                                                                       |\\n| 2.3.                                                                                                                                                                                                                                                                                                    | FREQUENTIST ESTIMATION WITH MONTE CARLO SAMPLING.....................................                                                                                                                                                                                                                   | 9                                                                                                                                                                                                                                                                                                       |\\n| 2.3.1.                                                                                                                                                                                                                                                                                                  | 2.3.1.                                                                                                                                                                                                                                                                                                  | Stand-alone meta-analysis packages.............................................................. 10                                                                                                                                                                                                     |\\n| 2.3.2.                                                                                                                                                                                                                                                                                                  | 2.3.2.                                                                                                                                                                                                                                                                                                  | General statistical packages with support for meta-analysis .......................... 10                                                                                                                                                                                                               |\\n| 2.3.3.                                                                                                                                                                                                                                                                                                  | 2.3.3.                                                                                                                                                                                                                                                                                                  | Software for network meta-analysis................................................................ 10                                                                                                                                                                                                   |\\n| 2.3.4.                                                                                                                                                                                                                                                                                                  | 2.3.4.                                                                                                                                                                                                                                                                                                  | Parameterisation of treatment effects............................................................. 11                                                                                                                                                                                                   |\\n| 2.4. FREQUENTIST                                                                                                                                                                                                                                                                                        | 2.4. FREQUENTIST                                                                                                                                                                                                                                                                                        | ESTIMATION WITH BOOTSTRAPPING ................................................. 11                                                                                                                                                                                                                      |\\n| 2.5. SUMMARY OF METHODS AND RESTRICTIONS ON THEIR USE                                                                                                                                                                                                                                                   | 2.5. SUMMARY OF METHODS AND RESTRICTIONS ON THEIR USE                                                                                                                                                                                                                                                   | .................................. 12                                                                                                                                                                                                                                                                   |\\n| 3.                                                                                                                                                                                                                                                                                                      | USE OF MULTIPLE SOFTWARE PLATFORMS................................................ 12                                                                                                                                                                                                                   | USE OF MULTIPLE SOFTWARE PLATFORMS................................................ 12                                                                                                                                                                                                                   |\\n| 3.1. COMMUNICATION BETWEEN SOFTWARE                                                                                                                                                                                                                                                                     | 3.1. COMMUNICATION BETWEEN SOFTWARE                                                                                                                                                                                                                                                                     | PACKAGES................................................ 13                                                                                                                                                                                                                                             |\\n| 3.2. INTEGRATED USE OF SOFTWARE                                                                                                                                                                                                                                                                         | 3.2. INTEGRATED USE OF SOFTWARE                                                                                                                                                                                                                                                                         | PLATFORMS.......................................................... 13                                                                                                                                                                                                                                  |\\n| 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 | 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 | 4. REFERENCES.......................................................................................................... 15 APPENDIX: PARAMETERISATION OF THE BASELINE TERM IN NETWORK META-ANALYSIS MODELS.......................................................................................... 19 |\\n| TABLES                                                                                                                                                                                                                                                                                                  | TABLES                                                                                                                                                                                                                                                                                                  | TABLES                                                                                                                                                                                                                                                                                                  |\\n| Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   | Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   | Table 1 Summary of methods and their properties and restrictions...................................................................12                                                                                                                                                                   |')]"
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "retriever = vector_store.as_retriever(search_kwargs={\"k\": 5, \"filter\": {\"doc_type\": doc_type}})\n",
    "retrievers = [retriever, BM25Retriever.from_documents(filtered_mkd_docs, search_kwargs={\"k\": 5})] if filtered_mkd_docs else [retriever]\n",
    "weights = [0.5, 0.5] if filtered_mkd_docs else [1.0]\n",
    "print(retrievers)\n",
    "ensemble_retriever = EnsembleRetriever(\n",
    "    retrievers=retrievers,\n",
    "    weights=weights\n",
    ")\n",
    "ensemble_retriever.invoke(query)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f1e6eedc",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "MAR (3.13.11)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
